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Arsenic trioxide (AS2O3) is one of the arsenic compounds found in nature. For 
centuries, it has been used as a traditional Chinese Medicine for the treatment of 
arthritis, skin disorders and other maladies. Since 70，s, AS2O3 was shown to be 
effective in treating acute promyleocytic leukemia (APL) patients without severe 
toxicity. Thereafter, AS2O3 was found to induce anti-tumor effects on other 
leukemias and solid tumors through the induction of apoptosis, differentiation and 
cell cycle arrest. 
In recent years, breast cancers arouse much concern. Together with growing 
incidence all over the world, development of drug resistance to tamoxifen, the most 
commonly prescribed chemotherapeutic drug for breast cancer patients has 
highlighted the importance of developing a new chemotherapeutic drug in combating 
against breast cancer. 
Aiming at treating breast cancers, the anti-tumor effects of AS2O3 in MCF-7 
cells were studied. MCF-7 cells are estrogen responsive, which mimic breast 
cancers at early stage. 
Here, we report that AS2O3 exhibited cell survival inhibitory effects on MCF-7 
cells in a dose and time dependent manner. The IC50 of AS2O3 in inhibiting cell 
survival of MCF-7 cells were 8|liM, 1 .8 [iM, 1.2 )IM, 0 .8 JIIM and 0.5 |IM upon 1 day, 
2 days, 3 days, 4 days and 5 days treatment, respectively. While exhibiting 
cytotoxic effects on MCF-7 cells, AS2O3 did not induce any toxic effect on normal 
fibroblasts (Hs68) cell line or animal heart and liver tissues. In elucidating the 
underlying action mechanisms, AS2O3 was found to induce mitochondrial mediated 
apoptosis as evidenced by the disruption of mitochondrial membrane potential after 
treatment. Moreover, AS2O3 induced cell cycle arrest at Gi phase in MCF-7 cells, 
which may explain its growth inhibitory effects on MCF-7 cells. Further studies 
indicated that AS2O3 regulated apoptosis and cell cycle related proteins as it 
upregulated p53 protein level and downregulated bcl-2 protein level. In contrast to 
its effects on other solid tumors, AS2O3 did not enhance reactive oxygen species 
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(ROS) production. It is hypothesized that ROS may not be involved in AS2O3 
induced anti-tumor effects on MCF-7 cells. 
In addition, we have also demonstrated that AS2O3 was capable of reducing the 
cell survival of MCF-7 cells via the suppression of estrogen's growth stimulatory 
effects on MCF-7 cells. AS2O3 was shown to suppress estrogen's action through the 
regulation of estrogen stimulated estrogen receptor (ERa) signaling pathway. 
AS2O3 could down-regulate ERa m R N A and protein levels without competing with 
estrogen for ERa binding. AS2O3 also inhibited the transcription activity mediated 
by ERa signaling pathway and ultimately it downregulated c-myc protein expression 
and inhibited cell entry to S phase under estrogen's stimulation. As estrogen is a 
primary risk factor of developing breast cancer, the anti-estrogenicity exhibited by 
AS2O3 shed light on the hormonal therapy of breast cancer. 
Our study revealed that AS2O3 was more potent than tamoxifen in 
combating against MCF-7 cells. It also exhibited cell survival inhibitory effect on 
MDA-MB-231 cells, a more aggressive, estrogen independent breast cancer cell line. 
It will be of great interest in further drug development as AS2O3 mediates various 
mechanisms in treating breast cancer at both early and advanced stages. 
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線粒體膜電位下降（mitochondrial membrane potential, ATm)及阻止細胞週期循 
環系統(cell cycle arrest)而弓丨致細胞凋亡及抑制其生長。其作用機制硏究顯示， 
三氧化二砷能上調p53蛋白表達及下調bcl-2蛋白表達。相反，三氧化二砷不影 
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1.1 The Characteristics of Arsenic Trioxide (AS2O3) 
Arsenic trioxide (AS2O3) is an arsenic compound formed by covalent binding of 
arsenic and oxygen elements. It exists as odorless, tasteless and white crystals or 
powders. In traditional Chinese medicine, arsenic trioxide is called pishang (石比霜) 
(Fig 1.1). It can be purified from a naturally occurring mineral called pishi (石比石） 
which is composed of 90 % of arsenic trioxide (中醫藥發展籌備委員會，1997). 
In United States, arsenic trioxide is manufactured primarily from flue dust 
generated at copper and lead smelters [Hazardous Substances Data Bank (HSDB), 
1990]. Arsenic trioxide is mainly used for wood preservation. It is also used for 
the production of agricultural chemicals such as insecticides, herbicides, algicides 
and growth stimulants for plants and animals. Smaller amount of arsenic trioxide are 
used in glass and nonferrous alloys production. Some are used in the electronic 
industry (Rosenberg et ai, 1980). 
Arsenic is a transition element or metalloid. Pure arsenic is steel-gray-colored 
and brittle. It is abundant in earth's crust, seawater and air. Due to its metalloid 
nature, arsenic is uncommon in environment. However, arsenic is commonly found 
as compound form. It usually forms complexes with metals such as calcium 
arsenite and lead arsenite. It forms inorganic compounds with oxygen, chlorine and 
sulfur such as arsenic trioxide. It also reacts with carbon and hydrogen to give 
organic compounds (Naqvi et al., 1994). 
Arsenic trioxide is classified as arsenite among the arsenic compounds due to its 
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valence three oxidation state. In fact, arsenic exists in three different oxidation or 
valence states: 0 oxidation state (metalloid), trivalent or 3+ oxidation state (arsenite) 
and pentavalent or 5+ oxidation state (arsenate). As the arsenic element in arsenic 
trioxide exists as 3+ oxidation state, empirically, two arsenic elements covalently 
bind with three oxygen elements giving rise to AS2O3. The structure of arsenic 
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Fig 1.2 The structure of arsenic trioxide, AS4O6 (Godfrey et al” 1998). 
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1.2 The Therapeutic Applications of Arsenic Trioxide (AS2O3) 
AS2O3 has been used as therapeutic agent since century in the western world. 
The clinical trial of arsenic trioxide was first introduced by William Withering in the 
treatment of digitalis (Aronson, 1994 and Antman, 2001). Following this 
introduction, Thomas Fowler mixed AS2O3 with potassium bicarbonate to form 
Fowler's solution in curing a variety of diseases since 1865 (Kwong and Todd, 1997). 
In 1878, Fowler's solution was found to reduce the white blood cell counts in a 
patient with leucocythemia. Then this solution was used to treat chronic 
myelogenous leukemia (CML) as antileukemic agent (Antman, 2001). In the 
following years, AS2O3 was developed in the form of pastes for the treatment of skin 
and breast cancers and as the main ingredient in salvarsan for curing syphilis and 
trypanosomiasis (Aronson, 1994). 
Meanwhile in traditional Chinese medicine, AS2O3 in fact was used clinically in 
early century according to the Compendium of Materia Medica by Mr Li 
Shi-Zhen (1518-1593) (Zhang et al, 2001). This white AS2O3 was used to promote 
the healing of surgical wounds and to treat skin diseases and asthma at that time 
(Wang, 2001). It was not until 1970,s, AS2O3 was found to be effective in the 
treatment of a type of leukemia called acute promyelocytic leukemia (APL). Zhang 
Ting-Dong found that AS2O3 was the active ingredient of a Chinese remedy for the 
treatment of arthritis, skin disorders and other maladies. He then investigated the 
effects of AS2O3 on a number of cancers and found that it was most effective in 
killing APL cells. Later on, another group from Shanghai Second Medical 
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University joined in the studies and found promising effects of AS2O3 in clinical trials 
of APL patients, and the results were published internationally in 1994. Since then, 
AS2O3 has been used in clinical trial of APL patients worldwide and its mechanisms 
are examined in both in vitro and in vivo studies. 
In 1999, AS2O3 was formally approved by the State Drug Adminstration (SDA) 
in China (Zhang et al., 2001). In 2000, AS2O3 was approved by the Food and Drug 
Adminstration (FDA) to treat APL patients basing on four separate clinical trials in 
which long-lasting, high rates of complete remission of APL patients upon AS2O3 
treatment were achieved. In a trial consisting of 40 patients, 70% of complete 
remission was achieved within 2 months on average. Among theses patients, 68% 
were still alive and 58% were disease-free at a median follow up time of 16 months 
(Cohen et al, 2001). 
1.3 Acute Promyelocytic Leukemia (APL) 
Acute promyelocytic leukemia (APL) is a rare type of leukemia identified in 
1957 (de The and Chelbi-Alix, 2001 and Piazza et at., 2001). APL accounts for 
10% - 15% of all acute myeloid leukemias (AML) in adults (Soignet et al., 1998). 
Both sexes are equally suspectible to APL but children are rarely infected (Awisati 
et al., 1991). Clinically, patients of APL suffer from severe bleeding which is 
exacerbated by chemotherapy (Chen et al., 1997). 
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1.3.1 Pathologies of APL 
APL is characterized by three distinct features. Firstly, the cytologic 
morphology of APL cells shows numerous large granules and Auer rods (linear 
package of granules), sometimes group in faggots (Bennett et al., 1976). 
Accompany with the typical low white blood cell count, this feature is classified into 
the M 3 subtype in the FAB classification of A M L (Degos and Wang, 2001). 
Secondly, APL is characterized by severe hypofibrinogenopenia with high levels of 
fibrinogen or fibrin degradation products. This feature refers to as coagulopathy. 
Thirdly, the molecular pathologies of APL are associated with the reciprocal 
translocation of retinoic acid receptor a gene (RARa) on chromosome 17 to 
promyelocytic leukemia gene (PML) on chromosome 15 resulting in the fusion of 
P M L and R A R a proteins. P M L mediates apoptosis and suppress growth (Mu et al., 
1994; Koken et al., 1994 and Le Goff et al., 1998) while R A R a is responsible for 
the differentiation signal transduction (Tsai, 1993 and Labrecque, 1998). The 
resulting PML/RARa fusion protein interferes myeloid differentiation and 
antagonizes growth suppression by PML, leading to deregulated cell growth (Warrell 
et al； 1993; Borrow, 1990 and Grignani et al； 1993) 
1.3.2 All Trans Retinoic Acid (ATRA) Treatment of APL Patients 
In early times, APL patients were treated with anthracyclines. This cytotoxic 
chemotherapy achieved 70% to 85% CR but also induced severe complications and 
drug resistance in APL patients (Warrell et al., 1993 and Bernard et al., 1973). It 
was until the characterization of molecular pathologies of APL, a group from 
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Shanghai found that all trans retinoic acid (ATRA) was effective in combating 
against the disease. Clinical trials indicated C R in 85%-90% of the cases (Huang et 
al., 1988). 
In vitro studies of APL cell line, NB4，and in vivo studies have shown that 
ATRA induces relocalization of the P M L and restores the normal structure of P M L 
oncogenic domains (POD) early in the differentiation (Dyck et al., 1994; Koken et 
al., 1994 and Weis et al., 1994). It also binds to PML-RAR a specifically and 
subsequently degrades the fusion protein, leaving the wild type R A R a intact within 
12 hours of treatment at a concentration of 0.1|liM (Raelson et al., 1996 and Yoshida 
et al., 1996). Consequently, the signal transduction pathway mediated by R A R is 
restored. Since R A R a mediated signal pathway regulates the genes transcription, 
which are involved in myeloid differentiation, the action of R A R a thus induces the 
differentiation of APL cells. 
Nevertheless, ATRA treatment shows improvement in coagulopathy and high 
complete remission in APL patients (Huang et al., 1988), adverse effects are also 
observed. Hyperleukocytosis is developed during second and third weeks of 
treatment. It is attributed to the activation of leukocytes (Castaigne et al., 1990). 
Together with other syndromes such as respiratory distress, pleural effusions, weight 
gain, fever and occasionally renal failure, these adverse effects are collectively called 
‘retinoic acid syndrome'. In addition, secondary ATRA resistance occurs in all 
patients upon ATRA treatment. APL patients under ATRA treatment usually 
relapse within 6 months and become refractory to the treatment for 6-12 months 
(Degos and Wang, 2001). 
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1.3.3 Clinical Trials of Arsenic Trioxide f AS2O3�on APL Patients 
The side effects of ATRA treatment prompt researchers to modify the treatment, 
meanwhile, Chinese researchers have demonstrated AS2O3 to be effective in treating 
APL as mentioned in section 1.3. The first clinical trial was conducted in China by 
a group from the First Hospital affiliated with the Harbin Medical University in 1971. 
Since then frequent clinical trials have been performed to assess the effectiveness of 
AS2O3 in APL treatment. The clinical trials focusing on APL are summarized in 
Table 1.1 
Complete 
Year Compound No. of Patients remission rate References 
m  
1992 Ming 1 32 85.5 Sun et al, 1992 
1995 Composite Indigo 60 98 辽^， 
^ ^ ^ Zhaj 二 < 
liii^ ^ ； She二“,.， 
5 ； H ^ " . ， 
1998 一 AS2O3 — 98 87.1 “ Ma et aL, 
1999 — AS2O3 — 11 72.7 “ Niu et al, 
1999 — AS2O3 — 47 85.1 Niu et al, 1999 
1999 — AS2O3 — 100 84.9 Uxetal, 1999 
^ m ^ Zha溫 o;“/.， 
^ ^ Zha器 or,•， 




In general, AS2O3 achieved complete remission rate (CR) of 57-98% in both de 
novo and relapsed APL patients. Moreover, patients receiving arsenic trioxide 
treatment had improved disseminated intravascular coagulation (DIG), 
hyperfibrinolysis and bleeding symptoms (Shen et al., 1997 and Guo et al., 1999). 
Besides APL patients, AS2O3 was also administrated intravenously in patients 
with different cancers. Therapeutic effects were observed in CML, lymphoma, 
esophageal cancer and APL. 
1.3.4 In Vitro and In Vivo Studies of Arsenic Trioxide (AS2O3) in the 
Treatment of APL 
The effective treatment of AS2O3 on APL patients encouraged the elucidation of 
its action mechanisms. Over 10 years, numerous studies have been performed in 
investigating the action mechanisms of arsenic trioxide on APL. These in vitro 
studies were done by using NB4 cells, an APL cell line with chromosome 
translocation t(15;17) from a relapsed APL patient (Lanotte et al., 1991). Some 
studies made use of primary APL cell culture and fresh APL cells from the APL 
patients. In vivo studies, mouse model or transgenic mice were used. In NB4 cells, 
AS2O3 was shown to exert dose-dependent dual effects. At low concentration, 
0.1-0.5|liM, AS2O3 induces differentiation while at high concentration, 0.5-2|^M, it 
induces apoptosis (Chen et al., 1997). 
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1.3.4.1 Induction of Apoptosis 
Studies in NB4 cells have shown that AS2O3 induces apoptosis at concentrations 
of 1-2|liM, as indicated by the formation of apoptotic bodies morphologically, namely 
the appearance of D N A fragmentation on gel electrophoresis and apoptotic peak in 
flow cytometry. Further studies have found that apoptotic induction is mediated by 
downregulation of bcl-2 messenger ribonucleic acid (mRNA) and protein expression, 
modulation of the PML-RARa/PML protein through targeting P M L onto nuclear 
body (NB) and inducing degradation (Chen et al., 1996 and Zhu et al” 1997), 
activation of caspase 3, caspase 8 (Kitamura et al., 2000) and reactive oxygen 
species (ROS) production (Huang, 1999 and Dai et al., 1999), disruption of early 
mitochondrial membrane potential (Chen et al., 1998 and Shao et al., 1998). 
1.3.4.2 Induction of Cell Differentiation 
When NB4 cells were treated with low concentrations of AS2O3 (0.1-0.25|iM) 
over 10 days, condensed chromatin, smaller nuclei, decreased nuclei were observed. 
Cytoplasm ratio and appearance of granules in the cytoplasm were also observed 
(Chen et al., 1996). Further investigation shows the upregulation of CD52 and 
BFl-1, downregulatoin of RARa, and synergistic effects in regulation of protein 
kinase CB-1, and small ubiquitin-related modifier 1 (SUMO-1) (Cai et al., 2000). 
Recent findings show that AS2O3 induces acetylation of hi stones 3,4 resulting in 
transcriptional activation of downstream genes for differentiation (Wang, 2001). 
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1.3.5 General Toxicity and Side Effects of Arsenic Trioxide (AS2O3) on APL 
Patients 
For centuries, arsenic trioxide was considered as a poison. However, in the 
clinical trials on APL patients, no significant myelosuppression was observed. The 
side effects were tolerable and or disappeared rapidly with symptomatic treatment 
(Chen et al； 1996, 1997; Shen et al” 1997 and Soignet et al., 1998). 
1.4 Effects of Arsenic Trioxide (AS2O3) on Other Primary Cancer 
Cells and Cancer Cell Lines 
The therapeutic efficacy of AS2O3 in APL patients and the studies on APL cell 
line, NB4, have prompted the investigation of AS2O3 in other cell lines and further 
elucidation of the mechanisms in mediating these effects. 
AS2O3 induces apoptosis in numerous cell lines. In gastric cancer cell lines, 
AGS and MKN-28, AS2O3 increases p53 protein expression, activated caspase 3 and 
thus degradation of poly (ADP-ribose) polymerase (PARP) (Jiang et al., 2001). In 
neuroblastoma cell lines, SK-N-BE, IMR-32, SMS-MSN and SH-SY5Y，AS2O3 
decreases protein expression of bcl-2 and stimulates the activation of caspase 3 (Ora 
et al., 2000). In B cell leukemia cell lines, AS2O3 activates caspase activities and 
downregulates bcl-2 protein expression (Yukihiro et al, 1998). In primary 
malignant lymphoma cells, ovarian cell lines CI80-13S, OVCAR, G G and JAM and 
cervical cancer cell line, HeLa, AS2O3 increases cell population in sub-Gl phase and 
Page 12 
CHAPTER 1 
induces apoptotic features such as condensed chromatin, nuclear fragmentation 
(Zhang and Nie, 2001 and Du and Ho, 2001). Recently, we have found that 
AS2O3 elicits anti-tumor effects on human hepatoma cells. AS2O3 induces apoptosis 
in HepG2 cells upon 5 days treatment through the activation of caspase 3 and 
independent of mitochondria (Siu et al., 2002). 
Besides, AS2O3 also regulates cell cycle progression of several cell lines. For 
head and neck cancer cell line PCI-1, 2 |aM AS2O3 induces G2/M arrest by increasing 
p21 protein expression, decreasing the cdc2 and cyclin B1 protein expressions, 
decreasing cdc2 kinase activity and enhancing the binding of p21 with cdc2 (Seol, 
1999). AS2O3 also induces Gi/M growth arrest in promonocytic U937 cells through 
the upregulation of cyclin B and cyclin B-dependent kinase (Park, 2001). 
In addition, AS2O3 induces cell death via other signaling pathways. For 
example, in treating U937 cells with AS2O3, cellular ERKl and ERX2 were 
inactivated while JNK and p38 were activated. AS2O3 was reported to mediate its 
effect by producing Ca〗. dependent superoxides (Iwama, 2001). 
To date, little is known about the effect of AS2O3 on human breast cancer. In fact, 
public concern and awareness about breast cancer have been heightened recently 
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1.5 Epidemiology of Breast Cancer 
In recent years, cancer is the major cause of death in the female of Hong Kong 
according to the statistics provided by the Hong Kong Cancer Registry in 2000. 
Over 1700 new cases were reported and one in every 24 females is infected with 
breast cancer. In fact, the incidence rate of breast cancer in females is kept rising 
over the past ten years. As indicated in Fig 1.3, the incidence rate per 100000 
females was increased from 39.2 in 1990 to 52.2 in 1999. Meanwhile, the mortality 
rate per 100000 females was just slightly increased from 10.0 in 1990 to 11.5 in 1999. 
It may be due to the advanced development of breast cancer diagnosis and treatment 
over the last decade. 
In fact, breast cancer is a common cancer of women in the world. United 
States has the highest crude and age-standardized breast cancer incidence rates in the 
world. In the States, breast cancer is the most common cancer among women, 
nearly 1 of every 3 cancers diagnosed in American women is breast cancer. It is the 
second leading cause of cancer deaths in women, with approximately 40,000 women 
died of this cancer in 2001. Approximately 192,000 new cases of invasive breast 
cancer were diagnosed in 2001 among American women. 
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Fig 1.3 The incidence rate of breast cancer per 100000 females (Hong Kong 
Cancer Registry). 
The majority of breast cancer patients in Hong Kong are aged over 40 as over 
90% of incidence rate per 100000 females were estimated in 1995-1999 (Table 1.2). 
Moreover, there was a higher increase in the cases of breast cancer in age groups 




Age interval Average Age Average 
(yrs) distribution incidence * Distribution mortality ** 
Below 30 1.40% 14 ^ 
30-39 15.30% 
4 0 ^ 28.10% 877 20.0% 1^3 
5 0 ^ 16.80% 17.4% 
6 0 ^ 17% ^ 18.8% 28 
70 or above 21.40% 132.2 34.7% ^ 
* Average annual age-specific incidence rate per 100,000 in 
1993-97 
** Average annual age-specific mortality rate per 100,000 in 
1995-99 
Table 1.2 Age distributions of breast cancer patients and the average incidence 
and mortality in Hong Kong (Hong Kong Cancer Registry). 
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Fig 1.4 Age specific rates in different periods of breast cancer patients in 
Hong Kong (Hong Kong Cancer Registry). 
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1.6 Classification of Breast Cancer 
Breast cancer is classified into two classes: non-invasive and invasive breast 
cancers. Non-invasive breast cancer cells confine themselves in the milk ducts 
(Ductal carcinoma in situ) or milk lobules (Lobular carcinoma in situ). They will 
not spread or invade to the surrounding breast tissues and other parts of the body. 
Invasive breast cancer is more malignant and serious. They spread to the surrounding 
normal breast tissues and other parts of the body through the bloodstream and 
lymphatic system. For breast cancer cells develop in the milk duct, they are called 
invasive ductal carcinoma (IDC) while those develop in the milk glands are called 
invasive lobular carcinoma (LLC) (littp://www, breastcancer.org). 
1.7 Etiology of Breast Cancer 
Like other cancers, breast cancer is resulted from the uncontrolled growth of 
normal breast cells. In normal breast cells, cell proliferation and apoptosis are of 
well controlled and balanced. Upon the stimulation of exogenous or endogenous 
carcinogens, the genetic state of normal breast cells is altered. This leads to defects 
in cellular processes such as cell cycle, D N A repair and results in the upregulation of 
cell proliferation and downregulation of apoptosis. Consequently, the number of 
breast cells expands in a dysregulation manner (Parton et al., 2001). 
At present, the cause of breast cancer is still unclear. There are a number of 
potential risk factors for breast cancer as shown in Table 1.3. Some of the risk 
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factors can be controlled but some cannot, nevertheless, 70% of women diagnosed 
with breast cancer have no known risk factors. 
Potential Risk Factors 
Relationship 
for Breast Cancer 
Age The older the women, the greater the risk 
Higher risk for women with a first-degree relative 
having breast cancer. 5-10% of cases result 
Family History of Breast Cancer 
from inherited mutations in breast susceptibility 
genes such as BRCA 1 & BRCA 2 
Estrogen and progesterone are stimulant of 
Hormonal Factors 
breast cancer 
Early menarche, late menopause increase 
Personal Factors 
exposure to estrogen and PG and thus the risk 
Alcohol consumption, postmenopausal obesity 
Lifestyle Factors 
and lack of exercise increase the risk, 
Table 1.3 Summary of known risk factors for breast cancer. 
1.8 Hormones and Breast Cancer 
Female hormone estrogens play an essential role in the growth and 
differentiation of wide variety of normal tissues such as female reproductive tracts, 
skeletal system and mammary glands (Laron et aL, 1989, Purohit et al., 1992 and 
White et al., 1996). 
Over the past years, both in vitro and in vivo studies provided support for the 
role of estrogens in the development of breast cancer. Estrogens were found to be 
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the primary stimulant of the growth of breast cancer (Henderson et al., 1982 and 
Lippman et al., 1976). In vivo studies have demonstrated that estrogens can induce 
and promote primary mammary tumors and inoculated MCF-7 cells in rodents and 
mice (Soule and McGrath, 1980; Shafie and Grantham, 1981; Huseby et al., 1984; 
Brunner et al., 1989 and Kyprianou et al., 1991). Reverse effects were shown upon 
removal of the ovaries and administration of anitestrogenic drugs or estrogen 
synthesis inhibitors (Nadi et al, 1995). Clinical trials have also demonstrated that 
approximately one-third of women with metatastic breast cancer responds positively 
to estrogen ablation and the antiestrogenic therapy (Kyprianou et al., 1991 and 
Fabian et al, 1994). 
The roles of hormones other than estrogens are still under investigation. It has 
been shown that progesterone is also a primary mitogen of breast cancer (Braunsberg 
et al., 1986 and Molinolo et al., 1987). In rodent models, progestin was found to be 
able to support the initial development and growth of breast cancer cells (Welsch, 
1985; Jabara et al； 1973). There may also be a close correlation of androgens and 
breast cancer as androgens can be converted into estrogens via the action of 
aromatase in breast tissue (Brodie and Njar, 2000 and Dimitrakakis et al., 2002). 
The action mechanisms of estrogens on breast cancer involve both promotion of 
cell proliferation and prevention of apoptosis (Kyprianou et al” 1991). 
Estrogens increases the cell proliferation rate by recruiting non-cycling cells into 
the cell cycle, shortening the overall cell cycle time through the reduction of the 
length 
of Gi phase and promoting cell entry to S phase (Brunner et al., 1989 and Clarke 
Page 19 
CHAPTER 1 
et al； 1997). Estrogen dependent breast cancer cells MCF-7 innoculated in 
ovariectomized female athymic null mice regressed 50% by two weeks after estrogen 
removal and further studies indicated the induction of apoptosis in the cells 
(Kyprianou et al., 1991 and Wang and Phang, 1995). Estrogens were found to 
promote resistance of chemotherapeutic drugs on MCF-7 cells by upregulation of 
Bcl-2 m R N A and protein levels which is an antiapoptotic protein (Teixeira et al., 
1995). Similar study has also shown the inhibition of paclitaxel or ultraviolet (UV) 
radiation induced apoptosis by estrogens through the inhibition of JNK activity, in 
turn bcl-2 and bcl-xl phosphorylation and caspase 9 activation and ultimately 
apoptosis induction. 
1.9 Estrogen Receptors (ER) 
Estrogens are lipophilic and they enter cells and nucleus by diffusing through the 
plasma and nuclear membranes. In the cytosol and nucleus, estrogens bind 
specifically to receptors called estrogen receptor (ER) with high affinity. The action 
of estrogens is mediated through ER. ERs are members of the nuclear receptor 
superfamily for steroid and thyroid hormones, vitamin D, retinoids and prostanoids 
(Altucci and Gronemeyer, 200land Olefsky, 2001). Two ER are identified, 
estrogen receptor a (ERa) and estrogen receptor p (ERP), with molecular weight 
66,182 Dalton and 55,000 Dalton respectively (Levenson and Jordan, 1999 and 
Katzenellenbogen et al., 2000). ERp was only identified in 1996, studies are still 
undertaken in fully understanding its role plays in breast tumorgensis (Kuiper et al., 
1996 and Katzenellenbogen and Korach, 1997). At the onset of breast cancer, 
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46%-77% of breast cancers are ERa positive (Dicksen and Lippman, 1995). Thus, 
ERa expression in human breast tumors is important prognostic indicator and 
markers to the responsiveness of endocrine therapies. The studies of regulation of 
ERa and the respective signaling pathway will unravel the proliferation stimulatory 
effects of estrogens on breast cancer and thus shed light on the development of 
strategies in treating breast cancer. 
1.9.1 Structures of Estrogen Receptors (ER) 
B y structural studies, E R a and E R p show similar functional organization in 
varying degrees of homology as shown (Fig 1.5). 
AF1 DNAI Llgand/AF-2 
ERa A/B I C iDl E iF 
1 180 263 302 552595 
ERP N \ r； i i 
��.1 1*44 S^ feao 
N | I I Z I I D I I B I I I > 
Fig 1.5 Schematics of the human estrogen receptor alpha (ERa) and human 
receptor beta (ERp) (Katzenellenbogen et al., 2000). 
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Both proteins have modular structure that characterizes the nuclear receptor 
superfamily: six function domains designated A-F. The structural domains are 
defined according to the functions in the regions. The activation of estrogen target 
genes mediated by ER requires the interaction of several domains, they can be 
classified into ligand dependent pathway and ligand independent pathway (Levenson 
and Jordan, 1999 and Katzenellenbogen et al., 2000). 
1.9.2 Estrogen Receptors (ER) Mediated Signaling Pathways 
1.9.2.1 Ligand Dependent Pathway 
Ligand dependent pathway requires the binding of ligands and ER resulting in 
the formation of ligand-ER-complex and conformational change of ER. ER 
complex then binds to specific D N A response elements called estrogen response 
element (EREs) in the promotor regions of estrogen response genes. The binding 
may be facilitated by cofactor proteins such as SRC-1, AIBl, GRJPl etc. through the 
stabilization of the formation of transcription preinitiation complex and disruption of 
chromatin at the ERE. The transcriptional activation of these genes is mediated by 
activation functional domains AFl and AF2, located in the N terminus and the 
ligand-binding domain of ER respectively (Hall et al., 2001) (Fig 1.6). 
1.9.2.2 Ligand-Independent Pathway 
In the absence of estrogens, other signaling pathways can activate ER. They 
include growth factors such as epidermal growth factor (EGF) and insulin-like 
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growth factor-1 (IGF-1), regulators of the general cellular phosphorylation state such 
as protein kinase A (PKA), cytokines or neurotransmitters and cell cycle regulators. 
Growth factors cross link with ER signaling pathway via mitogen activated 
phosphate kinase (MAPK) and p 21. The mechanisms are still unclear but studies 
have found that both pathways may be dependent on each other synergistically to 
give biological response and they involve the phosphorylation of ERa (Robinson and 
Cobb, 1997 and Kato et al., 1998). 
1.9.2.3 Estrogen Response Element (ERE)-Independent Pathway 
Both ER a and ER p modulate gene expression without directly binding to DNA. 
Both ER can interact with the fos/jun transcription factor complex on API pathway 
via interactions with the pi60 family of coactivators (Kushner et al., 2000). 
Estrogens inhibit the cytokine IL-6 expression by complexing with ERa and in turn 
interact with c-rel subunit of the NFkB complex. In addition, ER a is found to 
interact with the Sp 1 transcription factor and activate the transcription of the retinoic 
acid receptor a 1 (RAR-1) gene (Sun et a., 1998). 
1.9.2.4 Non-Genomic Pathway 
Concurrent studies have shown that cell surface ER and membrane-coupled 
tyrosine kinase pathways are linked and estrogen can activate the M A P K signaling 
pathway in a variety of cell types. For example, in osteoblasts and osteoclasts, 
estrogens exhibit protective effect by activating M A P K pathway, which is involved 
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Fig 1.6 The action mechanisms of estrogens and estrogen receptor signaling 
pathways (Hall et al； 2001). 
Page 24 
CHAPTER 1 
1.9.3 Estrogen Receptors (ER) Regulated Gene Expression 
Growing studies are made to investigate estrogen target genes so as to unravel 
the molecular mechanisms by which estrogen elicits its both normal and pathological 
actions (Schuchard et al； 1993, Charpentier et al., 2000 and Gmvberger et al., 2001). 
Estrogen responsive genes may have ERE or contain promoter sequences that differ 
from the consensus palindromic ERE of the Xenopus vitellogenin A2 gene. Some of 
estrogen target genes are shown in Table 1.4 
Family of genes Estrogen target genes Regulation  
^ ^ Upregulation of m R N A 
Proto-Oncogenes c-myc ^ 
^ Upregulation of m R N A 
C-IOS 1 1 
level  
. Upregulation of m R N A 
^ level 
. . Heat shock protein 27 Upregulation in gene 
1163.1 snocK proteins . 
expression  
Heat shock protein 60Upregulation in gene  
expression  
Heat shock protein 70 Upregulation in gene 
family expression  
Heat shock protein 90Upregulation in gene  
expression  
Heat shock protein 20 Upregulation in gene 
family expression  
Cell cycle related genes Cyclin D1 Up regulation in gene  
expression  
Cyclin B1 Upregulation in gene  
expression  
P27 Kip 1 Upregulation in gene  
expression  
Table 1.4 Estrogens regulated target genes (adapted from April et al” 2000). 
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1.10 Current Therapy of Breast Cancer 
The complete recovery rate of breast cancer can be as high as 70-80%. Breast 
cancer cells can be removed by surgery. Patients may receive chemotherapy by 
taking anti-cancer drugs to shrink the tumor or after to reduce the chances of 
recurrence. Patients may receive radiation therapy to destroy the cancer cells by 
high energy x-rays. 
1.10.1 Hormonal Therapy (Anti-Estrogenicity) 
As discussed in section 1.8，female hormone estrogens are the growth stimulator 
of estrogen dependent breast cancer. So, the treatment of breast cancer mainly 
focuses on the removal of this stimulator and thus the growth inhibition of breast 
cancer cells. This is called hormonal therapy, endocrine therapy or anti-estrogen 
therapy. The most common drug used currently based on this therapy is anti-estrogen, 
Tamoxifen (Clarke et al” 2001). 
1.10.1.1 Tamoxifen 
Tamoxifen has been used for 30 years in the treatment of breast cancer. It is 
most effective in the breast cancer with ER. As it works by blocking estrogen from 
binding to ER and preventing the growth stimulation of estrogen on cancer cells. 
Clinical treatment in breast cancer patients has indicated that it reduces the incidence 
of cancer recurrence and delay the occurrence of breast cancer. Besides, other 
benefits are also observed. Based on the structure of tamoxifen, other analogs are 
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developed. Fig 1.7 shows the structure of tamoxifen and its analog (Macgregor and 
Jordan, 1998). 
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Fig 1.7 The structures of tamoxifen and its analogs. 
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1.10.1.2 Other Pure Anti-Estrogens 
In evidence of the partial estrogen agonistic activity of tamoxifen towards 
tumors, pure anti-estrogens are developed which exhibit estrogen antagonistic effects 
only on breast cancers. ICI 164,384 and ICI 182,780 are two pure estrogens that 
produce greater potency and affinity for the estrogen receptor. Other compounds 
are developed later on improving the bioavailability and biological activity of these 
compounds. They include R U 58668，EM-149 (Macgregor and Jordan, 1998). The 
structures of ICI 164380, ICI 182,780, R U 58668 and EM-139 are shown in Fig 1.8. 
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Fig 1.8 The structures of pure anti-estrogens for breast cancer treatment. 
Page 28 
CHAPTER 1 
1.10.2 Regulation of Estrogen Receptors (ER) and Transcription 
Coregulators 
Estrogens mediate growth stimulatory effects by regulation of target genes 
expression with the recruitment of coregulators. These proteins may be 
coactivators or corepressors, interacting with nuclear receptors in either a ligand 
dependent or ligand independent manner. Targeting at these coregulators can alter 
the estrogens regulated gene expression and in turn the growth of breast cancer 
(Bevan an Parker, 1999). 
1.10.3 Apoptosis Induction 
Recently, induction of apoptosis becomes another important mechanism in the 
chemotherapy of cancers (Makin and Dive, 2001). In recent years, the studies of 
growth inhibition of breast cancer have revealed that induction of apoptosis is one or 
only one of the action mechanisms. Anti-hormone chemotherapeutic drugs such as 
tamoxifen, ICI 182780 were also found to induce apoptosis in breast cancer in 
accompany with the anti-estrogenic effects (Ellis et al., 1997). 
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1.11 Aims of study 
In the present study, the anti-tumor effects of AS2O3 on human breast cancer 
cells were investigated. Human breast adenomacarcinoma cell lines, MCF-7 cells 
and MDA-MB-231 cells were examined as cellular models for AS2O3 treatment. In 
addition, the action mechanisms mediating the anti-tumor effects were evaluated. 
Several action mechanisms were studied which are found commonly involved in the 
chemotherapy of solid tumors or cancer cell lines. Here, the study mainly focused on 
cell death apoptotic pathway and the estrogen receptor dependent signaling pathway. 
Other mechanisms such as cell cycle regulation, free radicals induction were also 
studied. 
To explore the anti-tumor effects of AS2O3 on breast cancer cells, a range of 
concentrations were first studied. Then, AS2O3 in concentrations below 2|iM were 
focused to elucidate the action mechanisms in mediating the anti-tumor effect on 
MCF-7 cells. Clinical trial of AS2O3 at a dose of 10 mg/day in treating APL patients 
have showed high complete remission rate with manageable side effects. At this 
dosage, the plasma concentrations of APL patients were ranged between O.SjuiM and 
2|aM (Shen et al., 1997). So, AS2O3 in 2|liM is considered as clinically achievable 
concentration. In vitro studies with this concentration range in APL cell line, NB4, 
and other cancer cell lines have demonstrated anti-tumor effects induced by AS2O3 
(Chen et al., 1996; Yukihiro et al., 1998; Dia et al., 1999; Barchowsky et al., 1999; 
Zhu et al., 1999; Mahieux et al” 2001; and Siu et al., 2002). This concentration 
range is believed to be a safe concentration for clinical trials after preclinical studies 
(Du and Ho, 2001). 
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This thesis is constructed of 9 chapters. In chapter 1, background of arsenic 
trioxide and current information of breast cancer are introduced. In chapter 2, the 
materials and methods used in this research are given. In chapter 3, chapter 4, 
chapter 5, chapter 6 and chapter 7, the results of study are presented. In chapter 8, a 
discussion regarding the results obtained in the study is given. In chapter 9, general 








2.1.1 Cell Lines and Culture Media 
2.1.1.1 Cell Lines 
MCF-7 and M D A - M B 231 cell lines were purchased from American Type 
Culture Collection (ATCC, Rockville, M D , USA). They are routinely maintained in 
Roswell Park Memorial Institute tissue culture medium 1640 (RPMI 1640 medium) 
(Invitrogen, USA) supplemented with 10 % (v/v) fetal bovine serum (FBS) 
(Invitrogen, USA) and 1 % antibiotics (v/v), penicillin/streptomycin (10000 units/ml) 
(Invitrogen, USA) (complete medium) at 37。C in a humidified atmosphere of 5% 
carbon dioxide. Cells were cultured in 150cm culture flask (Wako) and were 
subculutured twice a week. Medium was discarded, cells were washed once with PBS 
and were trypsinized with 1.5ml trypsin-EDTA (0.25% trypsin, I m M EDTA) by 
incubating at 2>TC for 3 minutes. Complete medium was added to stop trypsinization. 
The cell suspension was centrifuged at 200x g for 5 minutes. The cell pellet was 
resuspended in complete medium. Cells were seeded at a density of 2 x 10^ cells in 
25ml complete medium per flask. 
For all experiments, cells were grown in an 'experimental medium', defined 
as phenol red-free RPMI-1640 supplemented with 10% dextran coated charcoal 
stripped fetal calf serum (Hyclone, USA) and 1 % antibiotics (v/v), 
penicillin/streptomycin (10000 units/ml) and 25mM HEPES. Experiments were 
begun with pre-treatment of cells in experimental medium for 2 days, based on studies 
showing that phenol red has estrogenic activity and its presence could mask the effects 
of added estrogen (Beithois, et al., 1986). 
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Hs 68 cell line was purchased from American Type Culture Collection (ATCC， 
Rockville, M D , USA). They are maintained in Dulbecco's modified Eagle's medium 
(Invitrogen, USA) supplemented with 10 %(v/v) fetal bovine serum (FBS) (Invitrogen, 
USA) and 1 % antibiotics (v/v), penicillin/streptomycin (10000 units/ml) (Invitrogen, 
USA) (complete medium) at 37°C in a humidified atmosphere of 5% carbon dioxide. 
Cells were cultured in 150cm culture flask (Wako) and were subcultured once a week 
following same procedures as other cell lines. 
2.1.1.2 Culture Media 
RPMI 1640 medium powder was purchased from Invitrogen. For the preparation, 
the RPMI 1640 powder with phenol red, L-glutamine and 0.5mM HEPES was 
dissolved in 1 litre of distilled water. It was supplemented with 24 m M sodium 
bicarbonate by adding 2 grams of sodium bicarbonate into 1 litre of medium. The pH 
of the medium was adjusted to 7.2. 
For the experimental medium, phenol red-free R P M I 1640 medium (p-RPMI 
1640) was used. It is purchased from Sigma Chemical Company as powder form. 
Powder phenol red-free R P M I was dissolved in 1 litre of distilled water and 
supplemented with 2 4 m M sodium bicarbonate by dissolving 2 grams of sodium 
bicarbonate in the medium. As phenol red is absence in the medium, it is colourless 
and 2 5 m M H E P E S was added in each litre of medium for pH stabilization (Good et al., 
1966). The final pH of medium was kept at 7.2. 
Prior to usage, R P M I 1640 medium and phenol red-free R P M I 1640 medium were 
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sterilized by filtration with bottle-top filter (Millipore) under sterile condition. 
The filtered media were stored at 4°C. 
In all culture experiments, 10% fetal bovine serum and 1 % antibiotics 
penicillin-streptomycin were added. 
2.1.2 Chemicals 
Arsenic trioxide (AS2O3) was purchased from Sigma Chemical Company. It is 
prepared by dissolving powder AS2O3 in boiled phosphate buffered saline (PBS) in 
lOmM. Boiling is continued until AS2O3 powder is completely dissolved. Distilled 
water was added to compensate the loss of water vapour during boiling. The stock 
solution is sterilized by using 0.22|liM filter (Milipore) and stored at Aliquots of 
I m M are prepared for in vitro studies, which is further diluted to working 
concentrations with culture medium. 
17(3 Estradiol (‘cyclodextrin，encapsulated) was purchased from Sigma 
Chemical Company. Stock solution of 50|aM was prepared by dissolving in distilled 
water and sterilized with 0.22|iM filter (Milipore). It was stored at -20''C. Working 
concentrations were prepared with culture medium for in vitro culture. 
Tamoxifen was purchased from Sigma Chemical Company. Stock solution of 
lOjaM was freshly prepared by dissolving in absolute ethanol and sterilized with 
0.22|LIM filter (Milipore). Working solutions with various concentrations was 
prepared with culture medium for in vitro culture. 
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Paclitaxel was purchased from Sigma Chemical Company. Stock solution 
of I m M was freshly prepared by dissolving in absolute ethanol and sterilized with 
0.22|LIM filter (Milipore). Working solutions with various concentrations was 
prepared with culture medium for in vitro culture. 
N-acetyl-L-cysteine (NAC) was purchased from Sigma Chemical Company. 
Stock solution of 200mM was freshly prepared by dissolving in PBS. It was sterilized 
with 0.22|iM filter before use. Working solutions with various concentrations were 
prepared by culture medium. 
2.1.3 Reagents and Buffers 
Phosphate buffered saline (PBS) was prepared by dissolving 136mM NaCl， 
2.7mM KCl，1.5mM KH2PO4 and 8 m M Na2P04 in distilled water (dHzO). The pH of 
PBS was adjusted to 7.4 and was autoclaved to make it sterile. It was stored at 
2.1.3.1 Reagents for MTT Assay 
Tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma) was dissolved in PBS at concentration of 5mg/ml. The 
solution was filtered by a 0.22|Lxm Millipore filter and stored at 4°C in dark. 
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2.1.3.2 Reagents for�methvl-^Hl Thymidine Incorporation to DNA 
Hisafe 2 Liquid Scintillation Cocktail was purchased from Perkinelmer. 
[methyl-^H] Thymidine was purchased from Amersham Biosciences with total 
activity of 5mCi. 
2.1.3.3 Reagents for Trypan Blue Exclusion Assay 
Trypan blue solution (0.4%) was purchased from Sigma Chemical Company. It 
was stored at room temperature and used directly without prior dilution. 
2.1.3.4 Reagents and Buffers for Western Blot Analysis 
Lysis buffer for total protein extraction was composed of 2% (w/v) SDS，10% 
glycerol (v/v) and 0.625M Tris-HCl (pH 6.8). Buffer was stored at room temperature. 
lOx SDS Running buffer was composed of 25mM Tris base, 192 m M glycin and 
0.1% (w/v) SDS and stored at room temperature. 
4x Lower Gel Buffer was composed of 1.5M Tris base and 14mM sodium 
dodecyl sulfate (SDS). Buffer was adjusted to pH 8.8 with HCl and stored at room 
temperature. 
6x Upper Gel Buffer was composed of 0.5M Tris base and 14mM sodium 
dodecyl sulfate (SDS). Buffer was adjusted to pH 6.8 and stored at room temperature. 
2x SDS Loading Buffer was composed of 2% (w/v) SDS, 10% (w/v) sucrose, 
0.002% bromophenol blue and 62.5 m M Tris. Buffer was adjusted to pH 6.4 by HCl 
and stored at 4°C. 5% (v/v) 2-mercaptoethanol was added prior to usage. 
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Electroblot Transfer Buffer was composed of 2 5 m M Tris base, 192mM glucine 
and 15% (v/v) methanol and stored at room temperature. 
TBS-Tween-20 (TBS-T) was composed of lOmM Tris base, 0.15M NaCl and 
0.1% (v/v) Tween-20. The pH was adjusted to 8. lOx stock solution was prepared and 
stored at 4°C. Prior to use, lOx solution is diluted 10 fold to Ix as working 
concentration. 0.1% Tween-20 was added in the working solution and kept at room 
temperature. 
10% Resolving gel buffer was composed of 5.34ml 30 % acrylamide / 
bis-acrylamide solution (Sigma Chemical company), 4ml 4x lower gel buffer, 80jil 
10% ammonium persulfate (APS), 18.6|li1 N，N, N,, N‘-tetramethyl-ethylene diamine 
(TEMED, Bio-Rad) and 6.56 ml distilled water. 
15% Revolving gel buffer was composed of 8.1ml 30 % acrylamide / 
bis-acrylamide solution (Sigma Chemical company), 4ml 4 X lower gel buffer, 80)al 
10% ammonium persulfate (APS), 18.6 [i\ N, N, N’，N'-tetramethyl-ethylene diamine 
(TEMED, Bio-Rad) and 3.8ml distilled water. 
10% (w/v) ammonium persulfate (APS) was purchased from Sigma Chemical 
Company. It was prepared by dissolving Ig of ammonium persulfate powder in 10ml 
distilled water. It was stored at -20°C. 
4.5 % stacking gel buffer was composed of 0.6ml 30% 
acrylamide/bis-acrylamide solution (Sigma Chemical Company), 1ml 4 X upper gel 
buffer, 30^ 11 10% ammonium persulfate (APS), 5.3 |il T E M E D (Bio-Rad) and 2.4 ml 
distilled water. 
BSA protein standard (2 mg/ml) was prepared by dissolving 0.02g bovine 




B C A protein assay reagent was composed of reagent A and regent B in the ratio 
of 50:1. Reagent A (Bicinchoninic Acid Solution) was purchased from Sigma 
Chemical Company and reagent B was prepared dissolving 4 % CuS04*5H20 (v/v) in 
dH20. They were kept at room temperature. 
Commassie Blue staining solution for staining protein was prepared by 
composing acetic acid, methanol and distilled water in the ratio of 1:3:10 and 
supplemented with 0.05 % (w/v) commassie brilliant blue R-250. The staining 
solution was stored at room temperature. 
De-staining solution for removing commassie brilliant blue R-250 was 
prepared by composing 40 % (v/v) methanol and 10 % (v/v) acetic acid. The de-stain 
solution was stored at room temperature. 
E C L Western blotting detection reagents were purchased from Amersham 
Biosciences. They were stored at 4°C. 
Rainbow™ coloured protein molecular weight markers were purchased from 
Amersham Biosciences. The high molecular weight range covers from 14.3kDa to 
222kDa. Aliquots were stored at -20T. 
Antibodies for western blot analysis. The primary antibodies used were 
anti-ERa (Oncogene, 1:500，recognize 66kDa protein), anti-c-myc (BD Pharmingen, 
1:500, recognize 62kDa protein), anti-bcl-2 (Santa Cruz Biotechnology Inc, 1:500, 
recognize 26kDa protein), anti-p53 (Santa Cruz Biotechnology Inc, 1:500, recognize 
53kDa protein). Secondary antibody, HRP-Goat Anti-mouse conjugate, was 
purchased from Zymed Laboratories Inc, 1:500 against ERa, bcl-2 and c-myc and 
1:1000 against p53. 
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2.1.3.5 Reagents and Buffers for Flow Cytometry 
Dehydrated dimethyl sulfoxide (DMSO) was used for solution preparation of 
dyes for flow cytometry. It was prepared by incubating molecular sieves in D M S O 
solution overnight and then kept at room temperature. 
5,5',6,6'-tetrachloro-l,l'3,3'-tetraethylbenzimidazolcarboyanine iodide 
(JC-1) was purchased from Molecular Probes. Stock solution of lOmM was prepared 
by dissolving in dimethyl sulfoxide (DMSO). 
Hydroethidine (HE) was purchased from Molecular Probes. Stock solution of 
lOmM was prepared by dissolving in D M S O and stocked at -20°C. 
Propidium iodide (PI) was purchased from Sigma Chemical Company. Stock 
solution of 2mg/ ml was prepared by dissolving in PBS and stored at 
RNase A was purchased from Sigma Chemical Company. It was prepared by 
dissolving in dHiO in lOmg/ml. 
Digitonin was purchased from Sigma Chemical Company. It was dissolved in 
dHiO to a stock concentration 20mg/ml. The stock solution was stored in 4 
Valinomycin was purchased from Sigma Chemical Company. It was dissolved in 
dHiO to a stock concentration of ImM. It was stored at -20 
2.1.3.6 Reagents and Buffers for Reverse Transcription Polymerase Chain 
Reaction (RT-PCR) 
TRIzol Reagent was purchased from Invitrogen, USA. It was stored at 4°C. 
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Taq Polymerase was purchased from Amersham Biosciences and stored 
at-20°C. 
Superscript™ First Strand Synthesis System for RT-PCR was purchased 
from Invitrogen, USA. It was stored at —20°C. 
RT-PCR loading dye (6x) was composed of 0.25% (w/v) bromophenol blue, 
0.25% (w/v) xylen cyanol FF and 40% (w/v) sucrose. 
DEPC-dHiO was prepared by adding 1ml ofDEPC (diethyl pyrocarbonate) in IL 
distilled H2O. DEPC-dHiO was mixed and autoclaved. Stock solution was liquated 
and stored at room temperature. 
Tris-Acetate (TAE) buffer was prepared in 5Ox which is composed of 242g Tris 
base, 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA. Buffer was adjusted to pH 
8.0 and stored at room temperature. 
One Hundred Base-Pair DNA Marker was prepared by mixing 1 jiil of 1 jug/ul of 
100 base pair D N A marker (Amersham Biosciences) and 5\x\ autoclaved distilled 
water and 4|LI1 D N A loading dye (6x). 
Ethidium Bromide was purchased from Pharmacia Biotechnology. Stock 
solution was prepared by dissolving lOmg in 1ml dH20 and stored at 4°C wrapped in 
aluminum foil.. 
Agarose was purchased from Sigma Chemical Company. Solution was prepared 
by dissolving 1.0% (w/v) in TAE buffer for R N A and D N A analysis. 
2.3.1.7 Reagents for Transfection and Luciferase Reporter Assay 
FuGene™ 6 transfection reagent was purchased from Roche Diagnostics 
Corporation. It was stored at -20°C. 
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Dual-Luciferase Reporter Assay System, Renilla Luciferase Assay System, 
basic pGL3 basic vector, pGL3 control vector were purchased from Promega. They 
were stored at -20°C. 
Luciferae Assay Reagent II was prepared by resuspending lyophilized luciferase 
assay substrate in 10ml of the assay buffer 11. 
Stop & Glo Reagent was prepared by resuspending dried Stop & Glo substrate in 
200|LI1 Stop & Glo substrate solvent. The reagent was aliquated and stocked at -20°C. 1 
volume of stock solution was further diluted with 50 volume of Stop & Glo buffer 
upon assay. 
Ix Passive Lysis Buffer was freshly prepared by adding 1 volume of 5x Passive 
Lysis Buffer (provided in Dual-Luciferase Reporter Assay System) to 4 volumes of 
dEhO. 
2.1.3.8 Reagents and Buffers for In Vivo Studies 
Saline was prepared by dissolving 0.9 % of NaCl (w/v) dHaO. It was stored at 
40c. 
Pentobarbital in 25mg/ml was prepared by dissolving in PBS and stored at 4°C. 
2.2 Methods 
2.2.1 In Vitro Studies 
2.2.1.1 Cell Treatment 
Exponentially growing MCF-7 cells were incubated with AS2O3 for long term 
treatment. Prior to the assays, unless specified, cells were incubated with phenol 
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red-free RPMI 1640 supplemented with 10% dextran coated charcoal fetal calf serum 
(experimental medium) for 2 days and then the medium was discarded and AS2O3 was 
added with fresh experimental medium for 24, 48 and 72 hours. 
2.2.1.2 Drug Preparation 
The stock solution of AS2O3 was prepared by dissolving AS2O3 powder in PBS at a 
concentration of lOmM. Then the solution was boiled at 100°C until complete 
dissolution. Additional distilled water was added to bring the evaporated solution to 
the final volume (Sin et al., 2002). 
2.2.1.3 MTT Assay 
MCF-7 cells and MDA-MB-231 cells were seeded at 1 x lO"^  cells/well in 1 00|LI1 of 
experimental medium in 96-well flat bottom microliter plate and incubated at 37°C, 
5% CO2 incubator for 48 hours. After treatment, suspension medium was removed. 
Cells were treated with a range of concentrations of AS2O3 or other drugs in fresh 
experimental medium. Untreated control was prepared by treating cells in 
experimental medium only. After treatment, suspension medium was removed and 
cells were washed once with cold PBS. Then 30jal M T T solution was added to each 
well and incubated at 2>TC for 2-4 hours. Viable cells will reduce the soluble 
tetrazolium salt to give purple precipitate. lOO^ il D M S O solvent was added to each 
well and further incubated for 15 minutes at ?>TC. The plate was mixed gently for 2-3 
minutes on the microtitre plate shaker. Optical density at 540nm were measured with 
ELISA plate reader when the formazan was fully dissolved 
Samples were tested in > 3 (n>3) in each plate. Percentage survival of each 
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sample was mean 士 standard deviation (S.D.). Percentage survival was defined as 
follows: 
% Survival = 100 % x (O.D. test sample / O.D. control) 
2.2.1.4 Trypan Blue Exclusion Assay 
Cells were seeded at3 x 10^  cells/well in 6-well plate in 3ml experimental medium. 
After 2 days incubation, suspension medium was removed and drugs at different 
concentrations were added with fresh experimental medium. The plate was incubated 
for experimental treatment period at 37。C. Floating cells together with trypsinized 
adhesive cells were collected. 10|il of cell suspension was mixed with lOfil trypan 
blue solution (Sigma Chemical Company). 10|il mixture was transferred to 
hemacytometer. Viable cells (unstained cells) were counted for viable cell number 
assessment while dead cells (blue colored stained cells) were counted for cytotoxicity 
assessment. Each square of the hemacytometer represents a total volume of O.lmm^. 
Icm^ is approximately equivalent to 1ml, the cell concentration per ml was calculated 
as follows: 
Cells per ml=average count per squared x dilution factor (=2) x 
% Control = 100% x (treated cells/ml)/(control cells/ml) 
% Viability = 100% x (viable treated cells/ml)/(total treated cells/ml) 
% Cytotoxicity = 100% x (dead treated cells/ml)/(total treated cells/ml) 
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2.2.1.5 fmethyl-^HI Thymidine Incorporation into DNA 
Cells were seeded at 1 x cells/well in lOOjiil experimental medium in 96-well 
plate and incubated at ？)TC, 5% CO2 incubator for 2 days. The medium was removed 
and drugs in various concentrations were added to each well in lOOjil fresh 
experimental medium. Controls were prepared by adding experimental medium only. 
After treatment, 0.5|il [methyl-^H] thymidine solution was added in 20jLil experimental 
medium to each well. The plate was further incubated at 37 for 6 hours. The plate 
was placed at -20°C overnight. After thawing the frozen cell suspension to solution 
form, the cell suspension was transferred to filter paper by using cell harvester. Each 
well was washed several times with dH20 to ensure complete transfer of cell 
suspension. The nucleic acids in cells were trapped on the filter paper. After drying 
the filter paper overnight, the filter papers corresponding to different wells were 
transferred to separate scintillation vials for radioactivity counting with 2ml 
scintillation cocktail. The percentage [methyl-^H] thymidine incorporation was 
calculated as follow: 
% [methyl-^H] thymidine incorporation = 
100% X [(cmp of treated samples)/ (cpm of control samples)] 
2.2.1.6 Detection of DNA Fragmentation 
To determine D N A fragmentation after treatment, Cell Death Detection 
ELISAPlus was used (Roche). Cells were seeded at 1 x cells/well in lOOjal 
experimental medium in 96-well plate and incubated at 37°C, 5% CO2 incubator for 2 
days. The medium was discarded and various concentrations of drugs were added in 
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lOOjLil experimental medium and further incubated for 24, 48 and 72 hours. Each 
treatment was assessed in triplicate. After treatment, the plate was centrifuged at 200x 
g for 10 minutes. The incubation medium was transferred to a new plate that was 
assessed later to determine the amount of D N A fragments in medium. The cells in the 
wells were lysed in 200|LI1 lysis buffer for 30 minutes at room temperature. The cell 
lysate was collected by centrifugation at 200x g for 10 minutes. 20|LI1 of cell lysate, 
20of incubation medium, was transferred in triplicate wells of the 
streptavidin-coated microtiter plate. Background control (Incubation buffer) and 
positive control of same volume were added in triplicate to separate wells. 80|LI1 of 
immunoreagents (4|LI1 anti-histone-biotin, 4|LI1 anti-DNA-POD and 72jLil incubation 
buffer) was transferred to each well and incubated with gentle shaking at 300 
revolution per minute for 2 hours at room temperature. After incubation, the solution 
was discarded. Each well was rinsed with 250-300|il incubation buffer for three times. 
100|j1 guaiacol, 2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) 
solution was added to each well and incubated on plate shaker at 250ipm for color 
development. The absorbance was measured at 405nm against 490nm. Cellular 
proteins in each treatment were extracted from separate wells of the same treatment in 
the same experiment. The amount of proteins in each treatment was determined by 
B C A method. Enrichment factor was calculated after normalization of protein amount 
in each treatment. The enrichment factor was calculated as followed: 
O.D. of the sample (incubation medium/cell lysate) / mg protein 
O.D. of the untreated control / mg protein 
The enrichment factor of untreated control was defined as 1. 
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2.2.1.7 ERa Competitive Binding Assay 
The ability of ERa binding was assessed by using Estrogen-R(a) competitor 
screening kit (Wako) according to the procedures suggested in manual. Various 
concentrations of AS2O3, tamoxifen, paclitaxel and 17p estradiol were prepared. 20|LI1 
of drugs were mixed with 114^1 of reaction solution provided in a 96-well plate. Each 
sample was prepared in triplicate wells. For negative control, solvents were added 
instead. The reaction mixture were mixed and transferred to the supplied ERa coated 
microplate. The plate was incubated for 2 hours at room temperature. Then, the 
reaction mixture was discarded and each well was washed with 200jLil of Ix washing 
buffer for 5 times. The plate was shaken in a plate shaker while washing. Ix washing 
buffer was prepared by adding 9 volumes of dH20 to lOx stock buffer. The washing 
solution was completely discarded. 100|LI1 of assay solution was added to each well 
and fluorescence intensity was measured at excitation 485nm and emission 535nm by 
fluorescent plate reader (FLUOStar, B M G Biotechnologies). The specific binding 
was calculated as: 
Specific Estradiol _ (O.D. of treated samples / O.D. of solvent 
Binding (% Control) control) x 100 % 
The specific binding to ERa of solvent control was expressed as 100% 
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2.2.1.8 Cell Cycle Analysis by Flow Cytometry with Propidium Iodide (PI) 
Staining 
Cells at 3 X 10^  cells/well were seeded in 3ml experimental medium in 6-well 
plate and incubated at 37。C，5% CO2 incubator for 2 days. The medium was removed 
and drugs in various concentrations were added to each well in 3 ml fresh experimental 
medium. Controls were prepared by adding experimental medium only. After 
treatment, both floating and trypsinized adherent cells were collected, washed with 
phosphate-buffered saline twice, and fixed with 70% ethanol for at least 30 minutes. 
After fixation, cells were washed with PBS and stained with PI solution (2mg/ml), 
RNase A (lOmg/ml) and 400^1 PBS for 30 min at 37。C under subdued light. Stained 
cells were analyzed using FACSort flow cytometer (Becton Dickinson). With 
‘CellQuest, program, the cell population was targeted by forward light scatter (FSC) 
and side scatter (SSC). The fluorescence signal of PI was collected at channels of 
FL-2. The percentages of D N A content at different phases of cell cycle were analyzed 
with Modfit software. 
2.2.1.9 Cell Cycle Analysis by Flow Cytometry with Annexin V-PI Staining 
Cells at 3 X 10^  cells/well were seeded in 3ml experimental medium in 6-well 
plate and incubated at 37。C, 5% CO2 incubator for 2 days. The medium was removed 
and drugs in various concentrations were added to each well in 3ml fresh experimental 
medium. Controls were prepared by adding experimental medium only. After 
treatment, both floating and trypsinized adherent cells were collected by centrifugation 
at 250x g for 5 minutes and then washed with serum and phenol red free RPMI 
medium twice. Cells of each sample were counted with hemacytometer. The number 
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of cells in each sample was adjusted to 5 x 10^  cells. Cells were pelleted and incubated 
in lOOjLil Annexin V Incubation Reagent (Trevigen) containing 10|il lOx binding 
buffer, lOjil propidium iodide (PI), 2|LI1 Annexin V-Conjugate and 78|LI1 dHiO for 15 
minutes in the dark at room temperature. After incubation, 400|LI1 of Ix binding buffer 
(prepared by diluting 40|LI1 lOx binding buffer with 360|il dHiO) was added to each 
sample. Stained cells were analyzed using FACSort flow cytometer (Becton 
Dickinson). With 'CellQuest' program, the cell population was targeted by forward 
light scatter (FSC) and side scatter (SSC). The fluorescence signal of Annexin 
V-Conjugate and PI were collected at channels of FL-1 and FL-3 respectively. Data 
were analyzed by Winmdi 2.8. 
2.2.1.10 Cell Cycle Analysis by Flow Cytometry with TC-1 Staining 
Cells at 3 x 10^  cells/well were seed in 6-well plate with 3ml experimental 
medium for treatment. After treatment, both floating and trypsinized adherent cells 
were collected by centrifugation at 25Ox g for 5 minutes and then washed with serum 
and phenol red free RPMI medium twice. Cells of each sample were counted with 
hemacytometer. The number of cells in each sample was adjusted to 3 x 10^  cells. 
Cells were pelleted and resuspended in 400|j.l serum and phenol red free RPMI. 100|LI1 
of JC-1 staining solution in 50jaM was added to cell suspension and incubated for 15 
minutes at 3TC in the dark. Stained cells were analyzed using FACSort flow 
cytometer (Becton Dickinson). With 'CellQuest' program, the cell population was 
targeted by forward light scatter (FSC) and side scatter (SSC). The fluorescence signal 
of JC-1 was collected at channels of FL-2. Data were analyzed by Winmdi 2.8. 
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2.2.1.11 Cell Cycle Analysis by Flow Cytometry with Hydroethidine (HE) 
Staining 
Cells at 3 X 10^  cells/well in 3ml experimental medium in 6-well plate and 
incubated at 37。C, 5% CO2 incubator for 2 days. The medium was removed and drugs 
in various concentrations were added to each well in 3ml fresh experimental medium. 
Controls were prepared by adding experimental medium only. After treatment, both 
floating and trypsinized adherent cells were collected by centrifugation at 250x g for 5 
minutes and then washed with serum and phenol red free RPMI medium twice. Cells 
of each sample were counted with hemacytometer. The number of cells in each 
sample was adjusted to 3 x 10^  cells. Cells were pelleted and resupended in 400(il 
serum and phenol red free RPMI. lOOjil of HE staining solution in lOmM was added 
to cell suspension and incubated for 15 minutes at 37°C in the dark. Stained cells were 
analyzed using FACSort flow cytometer (Becton Dickinson). With 'CellQuest' 
program, the cell population was targeted by forward light scatter (FSC) and side 
scatter (SSC). The fluorescence signal of HE was collected at channels of FL-1. Data 
were analyzed by Winmdi 2.8. 
2.2.1.12 Western Blot Analysis of Proteins 
Total protein extraction 
Cells were seeded at 1 x 10^  cells/well in 10ml experimental medium in 100mm 
culture dish and incubated at 37°C, 5% CO2 incubator for 2 days. The medium was 
removed and drugs in various concentrations were added to each well in 10 ml fresh 
experimental medium. Controls were prepared by adding experimental medium only. 
Page 50 
CHAPTER 1 
After various time treatments, both floating and trypsinized adherent cells were 
collected by centrifiigation at 250x g for 5 minutes. The pellet was washed with cold 
PBS twice and resuspended in 100- 200)^ 1 protein lysis buffer according to the size of 
pellet. The lysate was left on ice for 1 hour for cell lysis. After boiling for 15 minutes, 
the supernatant was then collected by centrifiigation at 12000x g for 20 minutes. 
Aliquotes were prepared for later use and stored at -20°C. 
Determination of protein concentration 
Protein concentration of sample was measured by B C A protein assay. Ijiil of 
sample was mixed with 198|LI1 of assay reagent in round bottom 96-well plates. A 
standard curve was made by preparing a set of known standard protein samples. They 
were prepared by mixing dHiO to BSA protein stock (2mg/ml). Each sample was 
measured in triplicate. The plate was incubated at T^TC for 30 minutes and the 
absorbance of each sample was measured by a microplate reader (Model 3550, 
BIO-RAD) at wavelength 540nm. A standard curve was made by plotting absorbance 
against standard protein concentration (Fig 2.1). The protein concentration of sample 
was determined from the standard curve. The volume of protein samples used for each 
SDS electrophoresis was calculated from the concentrations. Equal amount of protein 
(30|Lig to 50|ag) was used for each sample. 
SDS polyacrylamide gel electrophoresis 
Prior to gel electrophoresis, protein samples of calculated volume were mixed 
with SDS loading buffer and then p mercaptoethanol (5% v/v). Meanwhile, SDS page 
electrophoresis apparatus (Mini-protean III Electrophoresis Cell, BIO-RAD) was set 
up according to the instructions provided. For bcl-2 protein analysis, 15% resolving 
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gel was used. For c-myc, p53 and ERa proteins analysis, 10 % resolving gels were 
used respectively. 4% stacking gel was used for all the detection. The samples were 
boiled in loading buffer for 5-10 minutes before loading. For each gel, a protein 
molecular marker was loaded to the same gel to indicate the molecular weights of 
separated proteins. Electrophoresis was performed with a constant voltage of 120V at 
room temperature for each gel until the proteins were resolved as indicated from the 
marker. 
Electroblotting 
3 pieces of 3 m m chromatography paper (Whatman) were soaked in electroblot 
transfer buffer and transferred to a semi-dry transfer cell (Trans-Blot SD semi-dry 
transfer cell, BIO-RAD). 0.45|im polyvinylidene fluoride (PVDF) transfer membrane 
(Immobilon-P, Millipore) were soaked in absolute methanol and then electroblot 
transfer buffer and put on the top of the filter papers. On its top, the SDS gel with 
separated proteins was put and then covered with another three pieces of filter paper 
wet with electroblotting buffer. Electroblotting was performed at 150mA for 20 
minutes to 60 minutes depending on the protein detected. 
After electroblotting, the SDS gel was stained by commassie blue staining 
solution for 1 day with gently shaking and then de-stanied with de-staining solution for 
30 minutes. 
Probing of proteins with antibodies 
After electroblotting, the PVDF transfer membrane was soaked in 10% non-fat 
milk overnight at 4°C or 2 hours at room temperature. Then it was rinsed two times 
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with TBS-T and washed while rotating with TBS-T for 15 minutes for three times. 
Then the membrane was incubated with primary antibody in 10% non-fat milk in 
TBS-T for 2 hours at room temperature with gentle rotation. Then the membrane was 
rinsed once with TBS-T and washed four times while rotating for 15 minutes each. It 
was incubated with secondary antibody in 10% non-fat milk in TBS-T for 1 hour at 
room temperature with gentle rotation. 
Enhanced chemiluminescence (ECL) assay 
The membrane was incubated with ECL Reagents (reagent 1 and reagent 2 mixed 
in ratio 1:1) for 2 minutes and then wrapped with a wrapping paper. It was transferred 
to a autoradiography cassette (Hypercassette, Amersham Biosciences) with a Super 
R X X-ray film (Fuji) on the top and exposed for various time courses. The films were 
processed in a X ray film processor (M35 X-OMAT, Kodak). The band intensity was 
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Figure 2.1 A standard curve for determination of protein concentrations. 
The protein concentration for a sample was determined by B C A method. The equation, 
y = 0.039x + 0.016 was obtained from which the concentrations of protein samples 
were determined. The y value of equation represented the mean O.D. of protein sample 
and the x value represented the concentrations of protein of samples, r^  represented the 




2.2.1.13 Assessment of the Transcriptional Activity of ERa 
Preparation of DNA plasmids 
In each experiment, three plasmids were transfected. ERE containing vector was 
constructed by insertion of a single stranded ERE oligonucleotide into pGL3 basic 
vector at Nhe I site upstream of the luciferase gene (technical support by Chan YW). 
The sequence of ERE oligonucleotide was constructed according to the previous 
report (Sathya et al., 1997). 
The sequence is: 
5,-CCAGGTCAGAGTGACCTGAGCTAAAATAACACATTCAG-3, 
pGL3-control vector was used as a positive control which emitted strong 
luminance upon activation. Successful transfection can be indicated from the 
luminance. pGL3-basic vector was used as negative control that is lack of promoter 
and enhancer sequences. The luminance measured represented the background 
intensity of substrate reagents. Renilla luciferase reporter plasmid was prepared to act 
as internal control for determination of transfection efficiency. 
Co-transfection 
Cells were seeded at 5 x cells/well in 0.5ml experimental medium in 24-well 
plate and incubated at 37。C, 5% CO2 incubator for 2 days until confluence at 
40%-60%. Four wells were prepared for each treatment. 50|al experimental medium 
without serum supplement was transferred to microtube in which 2 ERE luciferase 
reporter plasmid, 2 control plasmids, 1 |li1 Renilla luciferase reporter plasmids, A\i\ 
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Fugene 6 transfection reagent were added. The mixture was incubated at room 
temperature for 30 minutes. After incubation, the medium in 24 well plates was 
discarded and 50)11 transfection reagent mixture was transferred to each well. The 
cells were incubated with transfection mixture for 6 hours at 37°C. The mixture was 
discarded and drugs in various concentrations were added and incubated with cells for 
various time intervals. 
Luciferase assay 
After treatment, the medium was discarded and the cells were washed with PBS 
twice. The cells were lysed in 100|LI1 IX Passive Lysis Buffer. The plate was shake for 
15 minutes to ensure complete lysis. 20\x\ lysate was transferred to a flow tube. To 
determine the luminescence of Firefly Luciferase, 50jil Luciferase Assay Reagent II 
was added to the sample and mixed gently, then the luminescence was measured in 
luminometer (Lumat LB 950). Following the first measurement, 50}il Stop & Glo 
Reagent was added to the measured sample. After gentle mixing, the luminescence 
emitted from Renilla Luciferease was measured again. The luminescence of ERE 
luciferase measured is proportional to the luciferase activity of ERa complex upon 
treatment. The luminescence of Renilla luciferase is proportional to transfected cells. 
Normalized luciferase luminescence is calculated as follow: 
Normalized Luminescence (Firefly Luciferase) 
Luciferase = 





Normalized Luciferase _ x 100 % 
Activity (% Control) Normalized Luciferase 
Luminescence (Untreated 
Control) 
Normalized luciferase activity of untreated control was expressed as 100%. 
3.2.1.14 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RNA extraction 
R N A was isolated using the TRIZOL reagent according to the procedures 
suggested. Cells were seeded at 3 x 10^  cells/well in 3 ml experimental medium in 
6-well plate and incubated at 37°C, 5% CO2 incubator for 2 days. Cells were treated 
with lOnM 17p estradiol, 2|LIM AS2O3 and co-treated with both for 24 and 48 hours. 
Untreated control was prepared by incubating with experimental medium only. Each 
sample was seeded in triplicate wells. After treatment, medium was discarded and the 
cells in each well were lysed in 1 ml TRIZOL reagent. The cell lysate was pipetted up 
and down and incubated at room temperature for 5 minutes. The lysate from each well 
was transferred to separate microtube. 0.2 ml chloroform was added to each sample 
and shaken by vigorously for 15 seconds. Samples were incubated for 2-3 minutes at 
room temperature and then centrifuged at llOOOx g for 15 minutes at 4°C. After 
centrifugation, 3 layers of liquid were observed. The upper colourless layer containing 
R N A was carefully transferred to a new microtube without disturbing the other two 
layers in which D N A and protein were contained. 800ml isopropanol was added to 
each microtube containing approximately 450|il R N A solution and incubated at -20°C 
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for 30 minutes. Samples were pelleted by centrifugation at llOOOx g for 10 minutes at 
4°C. 1ml of 75% ethanol was added to rinse the samples and then discarded. The 
R N A pellet was dried briefly for 5 minutes at room temperature. 20)il ofDEPC-dHiO 
was added and transferred to other tubes of the same treatment. Samples were 
incubated at 60。C for 10 minutes. R N A sample was stored at -80。C until cDNA was 
synthesized by reverse transcription. Before the transcription, the R N A concentration 
in each sample was measured by reading absorbance at 260nm and 280nm by using 
UV-visible spectrophotometer (Shimadzu, model UV- 1602). 1 jil of R N A sample was 
mixed with 499|il DEPC-dH20 in a quartz curette. The concentration of R N A (|ag/|il) 
was calculated by (O.D.26ox40) / (1/500 x 1000) (Ausubel et al., 1990). Purity of the 
R N A extract was reflected from the value of O.D. 260/280 greater than 1.6. 3)ig of R N A 
samples was mixed with D N A loading dye and loaded to 1% agarose gel stained with 
eithidium bromide for agarose gel electrophoresis to ensure intact R N A was extracted. 
cDNA synthesis 
cDNA was synthesized using Superscript ™ First-Strand Synthesis System. All 
the reagents were incubated on ice and briefly centrifuge before use. R N A samples of 
5[ig were mixed in 0.5 ml microtube with Ijil lOmM dNTP mix, 1 jiil 01igo(dT)i2-i8 
(0.5|Lig/)^l) in DEPC-dHiO to final volume of lOj^il. The samples were incubated at 
65°C for 5 minutes and then placed on ice for at least 1 minute. A reaction mixture 
composed of l^il RNase inhibitor, 2[i\ lOx RT buffer, 2[i\ DTT (O.IM), 4jLil MgCl2 
(25mM) was added to each sample and mixed gently. The samples were incubated at 
42°C for 2 minutes. l|il of Superscript RT (reverse transcriptase) were added and 
incubated for 50 minutes at 42。C and then 15 minutes at 70。C the mixture was chilled 
on ice. Finally, l|il RNase H was added and further incubated for 20 minutes at TTC. 
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The cDNA samples were stored at -20°C until use. 
Polymerase chain reaction (PCR) 
In the experiment, the gene expression of ERa was studied. So PCR was 
performed with ERa primers of size 490bp. The sequence of primers were as follows 
(Cullen et a/., 2001): 
Forward, 5, CAG GGG T G A A G T G G G GTC TGC TC 3, 
Backward, 5' ATG C G G A A C C G A GAT GAT GTA G C 3’ 
As an internal control, PCR with primers specific for glyceraldehydes phosphate 
dehydrogenase (GADPH) was carried out and the PCR product was 400 bp and the 
sequence are designed as followed: 
Forward, 5’ A C A C A GTC CAT GCC ATC A C 3’ 
Backward, 5' TCC A C C A C C CTG TTG CTG TA 3’ 
cDNA was mixed with 5[i\ lOX PCR buffer, 5|il dNTP mix (2mM), 5|al reverse 
primer, 5\i\ forward primer, 0.5|il Taq Polymerase and DEPC-dH20 to a final volume 





Conditions | i Number | ： Number 
Temperature； Time ； Temperature： Time ； 
I i of Cycles i of Cycles 
Initial 
940c 5min 1 9rC 2 min 1 
denaturation 
Denaturation 95°C 1 min 94°C ' 1 min ' 
Annealing 1 min 30 6 0 ^ 0.5 min 30 
Elongation 1 min ' 1 min 
Final 
72°C 10 min 1 72T 5 min 1 
Elongation 
Table 2.1 The PGR conditions of amplification of ERa and GADPH cDNA 
strands. 
The PCR products were stored at -20°C. 10|LI1 of samples were mixed with 2)^ 1 6x 
loading dye and electrophoresed in 1% agarose gel electrophoresis. A 100 bp D N A 
marker was loaded to indicate the molecular sizes of the PCR products. The band 
intensities of PCR products were analyzed by ImageQuant program. 
2.2.2 In Vivo Studies 
In vivo experiments were performed to investigate the effect of AS2O3 on the 
normal tissues of animals (nude mice). 
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2.2.2.1 Animal Models 
Nude mice of 6-8 weeks old were used as animal models. They were bred in 
Laboratory Animal Services Center of the Chinese University of Hong Kong. They 
were housed in cages with filter on top for ventilation. They were fed with autoclaved 
tap water and animal diet. As they were deficient of immune system, treatments were 
carried out in pathogen free hood. 
2.2.2.2 Treatment Schedules 
6-8 weeks old nude mice were divided into three groups (8 nude mice per group). 
The three groups are: (i) normal group (without treatment) (ii) saline group (negative 
control), (iii) treatment group (5mg/kg AS2O3). 
5mg/kg AS2O3 was injected to nude mice of average 30g. In view of the previous 
clinical studies of arsenic trioxide injection intravenously to ALP patients at a dosage 
of 0.16mg/kg for 28-40 days, the higher dosage adopted in the present study ensure the 
therapeutic effects of AS2O3 without toxicity on normal tissues (Shen et al., 1997and 
Niu et al., 1999). AS2O3 solution was prepared by dilution of stock (lOmM) with 
saline. Saline and AS2O3 in 0.2ml were injected intravenously thorough the vein in 
mouse tails. The whole treatment was carried out for 3 weeks. Three injections were 
made per week in alternative days. 
2.2.2.3 Sacrifice of Nude Mice 
After the last injection, mice were sacrificed on next day. Mice were anesthetized 
by intra-peritoneal (i.p.) injection of 0.1ml pentobarbital. Blood was collected with a 
25G syringe (rinsed with heparin solution prior to use) from hearts immediately. It 
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was transferred to 1.5 ml microtube and then centrifUged at 200x g for 15 minutes at 
4°C. Plasma was separated from red blood cells. The plasma was transferred to a new 
microtube for enzyme assays. 
2.2.2.4 Enzymatic Assays 
Four enzymatic assays were performed to assess the effect of AS2O3 on normal 
tissues, namely liver and heart, of nude mice. Sigma Diagnostic Kits were used for all 
the assays. Procedures in the assays were performed according to the instructions 
provided in the kits. Prior to the assays, lyophilized regents were reconstituted and 
wanned to the experimental temperature (if necessary). 
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2.2.2.4.1 Aspartate Transaminase (AST) 
1 ml AST reagent was transferred to a cuvet and warmed to 3TC. 0.1 ml plasma 
sample was added and incubated for 60 seconds. Initial reading was read and recorded 
at 340nm versus dH^O as reference. The cuvet was kept at 2>TC cuvet compartment 
and absorbance was read for 120 seconds at 30-second intervals to check the linearity 
of the reaction rate. 
Statistical calculations 
AST activity was calculated as follows: 
dA per minute x TV x 1000 
AST (U/L)= 
6.22 X LP X SV 
where: 
dA per min = Change in absorbance per minute at 340nm 
TV = Total volume (1.1ml) 
SV = Sample volume (0.1ml) 
6.22 二 Millimolar absorptivity of N A D H at 340nm 
LP = Lightpath (1 cm) 
1000 = Conversion of units per ml to units per liter 
dA per minute x TV x 1000 
AST (U/L)= 
6.22 X LP X SV 
二 dA per minute x 1768 
One unit of activity was defined as the amount of enzyme that produced one 
micromole of N A D per minute under the conditions of the assay procedure. 
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2.2.2.4.2 Alanine Transaminase (ALT) 
1ml ALT reagent was transferred to a cuvet and warmed to 37°C. 0.1 ml plasma 
sample was added and incubated for 60 seconds. Initial reading was read and recorded 
at 340nm versus dHiO as reference. The cuvet was kept at liTC cuvet compartment 
and absorbance was for 120 seconds at 30-second intervals to check the linearity of the 
reaction rate. 
Statistical calculations 
ALT activity was calculated as follows: 
dA per minute x TV x 1000 
ALT (U/L)= 
6.22 X LP X SV 
dA per min = Change in absorbance per minute at 340nm 
TV = Total volume (1.1ml) 
SV == Sample volume (0.1ml) 
6.22 = Millimolar absorptivity ofNADH at 340nm 
LP = Lightpath (1 cm) 
1000 = Conversion of units per ml to units per liter 
dA per minute x 1.1 x 1000 
ALT (U/L) 二  
6.22 X 1.0x0.1 
ALT (U/L) - dA per minute X 1768 
One unit of activity was defined as the amount of enzyme that produced one 
micromole of N A D per minute under the conditions of the assay procedure. 
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2.2.2.4.3 Creatine Kinase (CK) 
1ml C K reagent was transferred to a cuvet and warmed to 37°C. 0.02 ml plasma 
sample was added and incubated for 180 seconds. Initial reading was read and 
recorded at 340nm versus dHsO as reference. The cuvet was kept at 30°C cuvet 
compartment and absorbance was read for 120 seconds at 30-second intervals to check 
the linearity of the reaction rate. 
Statistical calculations 
CK activity was calculated as follows: 
dA per minute x 1.1 x 1000 
C K (U/L)= 
6.22 X 1.0x0.1 
where: 
dA per min = Change in absorbance per minute at 340nm 
TV = Total volume (ml) 
SV = Sample volume 
6.22 = Millimolar absorptivity ofNADH at 340nm 
LP 二 Lightpath 
1000 = Conversion of units per ml to units per liter 
dA per minute x 1.02 x 1000 
C K (U/L)= 
6.22 X 1.0x0.02 
= d A per minute x 8200 
One unit of activity was defined as the amount of enzyme that produced one 
micromole of N A D per minute under the conditions of the assay procedure. 
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2.2.Z4.4 Lactate Dehydrogenase (LDH) 
1ml LDH reagent w as transferred lo a cuvci and wanned to 37X. 0.05 ml plasma 
sample was added and incubalcd for 30 scconds Initial reading was read and rccordcd 
at 340nm versus (JH:0 as rcfcrcncc. The cuvci uas kept al cuvci com pan ni cm 
and absorhancc u as for 1 20 sccunds at 30-sccorul i n t e rva l .� t u chcck ihc linearity of the 
rtracUon rate. 
Statistical calculation s 
LDH activity n-as culculatcJ u\ folio��'�: 
dA per niiiuiic \ 1 0： \ |(mmj 
LDII (1' L) — “ 
6 22 \ 丨 n \ 0 0： 
\v here 
dA per m m Chai^ gc in absorb.incc per "川uilc a!、“"nm 
'I Io{.il rc.iciior\ muturc \oluinc I 1 <»《mil 
S\' Sample M>lufnc (<"»《mh 
h 22 \tillnm»!.ir .ibsorptiMt) o{ \ \1)|| al，“"nm 
I V I ightp.iih i 1 an) 
11MM) t t n n c f M o n u n i t s p e r n i l u m t s p e r l i t e r 
i! \ pcf imnuic \ I •” \ 
1 I)|i (I I I — — " " " ~ " - - 1 一 ~ - ~ ~ — — 
心：\ 1 «» \ “ <»《 
J \ pc? nun \ ‘、、 
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Data were expressed as the mean values 土 S.D. in different experiments. All the 
experiments were performed at least in triplicate. Significance was claimed only at 




Effects of Arsenic Trioxide (AS2O3) On 





In this research, in vitro assay systems were employed in evaluating the 
potential anti-tumor effects of AS2O3 on MCF-7 cells. MCF-7 cells were cultured 
as a monolayer when exposing to pharmaceutical dose of AS2O3. As AS2O3 was 
approved by F D A in treating APL patients, the majority of research on AS2O3 were 
conducted at the clinical achievable concentration which is equivalent to 2jLiM in in 
vitro system. At this dosage, therapeutic effect is achieved with clinical tolerable side 
effects. Nevertheless, a range of concentrations of AS2O3 was used firstly in 
assessing the effect of AS2O3 on cell proliferation of MCF-7 cells. By M T T assay, 
the effect of cell survival of AS2O3 on MCF-7 cells was assessed. By pulse exposure 
to [methyl- H] thymidine, the effect of cell proliferation of MCF-7 cells upon AS2O3 
treatment was assessed. From these two viability assays, effective dosages of 
AS2O3 and its relationship with duration of exposure were determined. Next, trypan 
blue exclusion assay was adopted in assessing the cytotoxicity and cell survival of 
AS2O3 at a concentration range below 2fiM. Based on these results, the action 
mechanisms of AS2O3 induced anti-tumor effects on MCF-7 cells will be further 
studied at a range of concentrations upon the most effective treatment duration. 
In the second part of this chapter, the anti-tumor effects of AS2O3 on MCF-7 
cells were studied in comparison to tamoxifen. Tamoxifen, a nonsteroidal 
antiestrogen, is the most commonly used therapeutic drug in the chemotherapy of 
breast cancer patients (Macgregor and Jordan, 1998). Recently, tamoxifen is found 
to be resistant upon long-term treatment (Clarke et al, 2001). So, comparison of 
their cell survival inhibitory effects on MCF-7 cells will be useful in assessing the 
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possibility of clinical application of AS2O3 as chemotherapeutic drug on human 
breast cancer cells. 
3.2 Effect of AS2O3 on Cell Survival of MCF-7 cells by MTT 
Assay 
M T T (thiasolyl blue) is converted from yellow coloured salt to purple coloured 
formazan by active mitochondrial dehydrogenases present in the mitochondria of 
viable cells. So, the colorimetrical analysis of the purple formazan formed in AS2O3 
treated or untreated cells will indicate the percentage of cell survival of MCF-7 cells 
upon treatment. 
Figure 3.1 shows the dose and time response curves of AS2O3 on the cell 
viability of MCF-7 cells. MCF-7 cells were incubated with a range of 
concentrations of AS2O3 for 24, 48, 72, 96 and 120 hours. The curves indicate the 
reduction of cell viability of AS2O3 on MCF-7 cells at increasing concentrations and 
longer treatment duration. The IC50 (i.e. the drug concentration exposed to cells at 
which cell viability is inhibited by 50%) of AS2O3 on MCF-7 cells are 
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Fig 3.1 Cell survival of MCF-7 cells upon AS2O3 treatment for various time 
courses. 
MCF-7 cells at 1 x cells/well were seeded in 96-well plate. Cells were treated 
with different concentrations (0-32^M) of AS2O3 for 24, 48, 72, 96 and 120 hours. 
The percentage of cell survival was measured by M T T assay. Data are presented as 
means 土 SD for 6 replicate measurements. The % survival is expressed relative to 
untreated control that is 100 percent. 
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3.3 Cytotoxicity of AS2O3 on MCF-7 Cells by Trypan Blue 
Exclusion Assay 
Trypan blue exclusion assay is performed based on the principle that only dead 
cells are permeable to trypan blue, whereas viable cells are impermeable to it. By 
this assay, the degree of AS2O3 induced cell death on MCF-7 cells can be studied. 
From the results obtained by performing M T T assay and [methyl-^H] thymidine 
incorporation into DNA, at the concentrations below 2|LIM, which is equivalent to 
the clinically achievable concentration of AS2O3, the inhibition was 50% or more of 
cell viability and growth of MCF-7 cells upon 48 and 72 hours treatment. So, 
MCF-7 cells were treated with AS2O3 at concentrations below 2[iM for these two 
time durations and 24 hours treatment. 
The effect of AS2O3 on the cell viability was studied by counting the trypan 
blue non-stained cells. The percentage of viability was calculated and shown in 
Fig 3.2. The result indicates the percentage of viable cells upon AS2O3 treatment 
at various AS2O3 concentrations and treatment intervals. The inhibitory effect was 
dose and time dependent. No apparent decrease of cell viability was observed at 
various concentrations of AS2O3 in cells treated with the drug for 24 hours. When 
treated with 2|LIM of AS2O3, the viability was reduced to less than 50% upon 72 
hours treatment. 
Apart from the cell viability, results from Fig 3.3 also demonstrates that AS2O3 
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can induce direct cytotoxic effect on MCF-7 cells. The cytotoxicity was assessed 
by the percentage of trypan blue stained dead cells. Upon 24 hours treatment, the 
percentage was below 10% for all concentrations. The percentage at each 
concentration increased as time treatment increased to 72 hours. At 2[iM of 
AS2O3, the percentages were 3.81%, 22.17% and 47.35% upon 24, 48 and 72 hours 
respectively. The percentage of cytotoxicity was dose dependent as evidenced by 
the result that higher concentrations of AS2O3 induced higher percentage of 
cytotoxicity in treated MCF-7 cells. 
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Fig 3.2 Cell viability of MCF-7 cells upon AS2O3 treatment for various time 
courses. 
MCF-7 cells at 3 x 10^  cells/well were seeded in 6-well plate. Cells were treated 
with various concentrations (0-2|liM) of AS2O3 for 24，48 and 72 hours. The viable 
cells, which were not stained by trypan blue, were counted after treatment under light 
microscope. Data are presented as means 士 S.D. of triplicate experiments. The 
percentage of viability was expressed relative to the control (expressed as 100%) of 
the corresponding time treatment. (*p < 0.005) 
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Fig 3.3 Cytotoxicity of MCF-7 cells upon AS2O3 treatment for various time 
courses. 
MCF-7 cells at 3 x 10^  cells/well were seeded in 6-well plate. Cells were treated 
with various concentrations (0-2jiM) of AS2O3 for 24, 48 and 72 hours. Trypan 
blue stained dead cells were counted after treatment under light microscope. Data 
are presented as means 士 S.D. of triplicate experiments. The percentage of 
viability is expressed relative to the control (expressed as 100%) of the 
corresponding time treatment. (*p <0.05) 
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3.4 Effect of AS2O3 on DNA Synthesis and Cell Proliferation of 
MCF-7 cells by�methyl-SHI Thymidine Incorporation into DNA 
Thymidine is one of the nucleotides essential for the synthesis of D N A for cell 
division. Incorporation of thymidine indicates the active D N A synthesis and thus 
cell proliferation. Tritium labeled thymidine allows us to detect the thymidine 
incorporation into the cells during drug treatment, which reflects the effect of drug 
on the D N A synthesis and proliferation of the cells. In this section, this method was 
adopted to assess the D N A synthesis and cell proliferation inhibitory effects of 
AS2O3 on MCF-7 cells. 
MCF-7 cells were incubated with a range of concentrations of AS2O3 for 24, 48 
and 72 hours. Fig 3.4 shows the percentages of [methyl-^H] thymidine 
incorporation into MCF-7 cells after 24, 48 and 72 hours treatment. When 
incubated with high concentrations of AS2O3 (above 8 jiiM), over 50% reduction of 
[methyl-^H] thymidine incorporation was observed starting from 24 hours 
incubation. The inhibition increased with time treatment. When incubated with 
low concentrations of AS2O3 (below 2|aM) for 24 and 48 hours, no significant 
inhibition was observed in comparison to the untreated control. When the 
incubation was increased to 72 hours, over 50% of inhibition was observed. 
In addition, a dose dependent inhibition of thymidine incorporation was 
observed in a wide range of concentrations (0.125 |liM to 32 |jM). This result 
indicates the inhibition of new D N A synthesis and cell proliferation of MCF-7 cells 
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upon AS2O3 treatment. AS2O3 in clinical achievable concentration, namely 2\xM, 
inhibits 50 % of cell proliferation of MCF-7 cells upon 72 hours treatment. 
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Fig 3.4 Effect of AS2O3 on DNA synthesis and cell proliferation of MCF-7 cells 
upon various time courses. 
MCF-7 cells at 1 x cells/well were seeded in 96-well plate. Cells were treated 
with various concentrations (0-32|iM) of AS2O3 for A) 24 hours, B) 48 hours, C) 72 
hours. 0.5|LiCi/well of was pulsed to the cells for 6 hours. Cells were then 
harvested by cell harvester and the [methyl-^ H] thymidine incorporated into D N A 
was measured by scintillator. Data are presented as means 士 SD for 6 replicate 
experiments. The percentage is expressed relative to untreated control that is 100 
percent. (* p < 0.05) 
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3.5 Comparison of Cytotoxicity of AS2O3 on MCF-7 Cells with 
that of Tamoxifen 
By M T T assay, the cytotoxicty of tamoxifen on MCF-7 cells was first 
determined. To compare with AS2O3, a range of concentrations of tamoxifen was 
tested. The result is shown in Fig 3.5. The cell viability of MCF-7 cells upon 
AS2O3 treatment was dose and time dependent. When comparing to the effects of 
AS2O3, tamoxifen was less potent than AS2O3. The IC50 of tamoxifen on MCF-7 cells 
was 8 |liM but that of AS2O3 was 1.8 [iM upon 48 hours treatment. Table 3.1 shows 
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Fig 3.5 Cell Survival of MCF-7 cells upon tamoxifen treatment for various 
time courses. 
MCF-7 cells at 1x1 O^ cells/ well were seeded in 96-well plate. Cells were treated 
with different concentrations (O-lOOjiM) of tamoxifen for 24, 48, 72 hours. The 
percentage of cell survival was measured by M T T assay. Data are presented as 
means 土SD for 6 replicate measurements. The % survival is expressed relative 






24 hours 48 hours 72 hours 
AS2O3 (|iM) 8 1.8 , 1.2 
Tamoxifen 
17 8 4 
( _ 
Table 3.1 Comparison of cytotoxicity of AS2O3 and tamoxifen on MCF-7 cells 
upon various time treatments in terms of IC50. 
MCF-7 cells at 1 x cells/well were seeded in 96-well plate. Cells were treated 
with different concentrations of AS2O3 and tamoxifen for 24, 48, 72 hours. The 
percentage of cell survival was measured by M T T assay. The IC50, the 
concentration at which 50% survival of MCF-7 cells was obtained, of AS2O3 and 




In this section, the anti-tumor effect of AS2O3 on MCF-7 cells was studied. From 
M T T assay, the values of IC50 of AS2O3 upon 24, 48，72, 96 and 120 hours treatment 
were 8 )iM 1.8 \iM, 1.2 ^ iM, 0.8 iiM and 0.25jiM respectively (Fig 3.1). The cell 
viability inhibiting effect was dose and time dependent. By trypan blue exclusion 
assay, the percentages of cell viability of MCF-7 cells were 96.07%, 76.59% and 
49.86% upon 2|LIM AS2O3 treatment for the same time points (Fig 3.2). These 
percentages were deviated from those obtained by M T T assay, this may be accounted 
for the loss of both viable and dead cells during sample preparation. AS2O3 was 
found to induce direct cytotoxic effect on MCF-7 cells. AS2O3 was shown to induce 
nearly 3.81%, 22.47% and 47.35% of direct cytotoxic effect on MCF-7 cells upon 24, 
48 and 72 hours treatment respectively (Fig 3.3). AS2O3 was also shown to possess 
growth inhibitory effect on MCF-7 cells. In addition, there was a reduction of D N A 
synthesis and cell proliferation upon treatment for 24 hours with high concentration 
of AS2O3. At concentration of 2|LIM, AS2O3 inhibited D N A synthesis and cell 
proliferation upon 72 hours treatment (Fig 3.4). The results have demonstrated that 
AS2O3 induces cytotoxic and growth inhibitory effects on MCF-7 cells in dose and 
dependent manner. 
Comparing with tamoxifen, the most commonly prescribed chemotherapeutic 
drug in treating breast cancer patients, AS2O3 was more potent in inhibiting the cell 
viability of MCF-7 cells. This was supported from the finding that the IC50 of 
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According to studies of genesis and development of human breast cancer, 
estrogens, 17p estradiol (E2), the major biologically active circulating estrogen, are 
potent stimulants in growth and development of breast cancer cells in early stage 
(Lippman et al., 1976; Soule and McGrath, 1980; Henderson et al, 1982). 
Approximate 95-97% of breast cancers in early stage are estrogen sensitive and 
classified as hormone-responsive breast cancer cells (Pasqualini and Chetrite, 2001). 
During reproductive life of female, estrogen is continuously produced in ovary. After 
menopause, ovarian function is destmcted. However, tissular concentrations of 
estrone (Ei), derived primarily from adrenal androstenedione, will also supply 
estrogen to female. Continuous estrogen supply contributes to stimulation of breast 
cancer genesis in high risk group or cancer progression in breast cancer patients. 
Therefore, therapeutic drug of breast cancer capable of estrogen withdrawal from 
breast cancer cells will be one of promising approaches in combating against breast 
cancer. 
The capability of AS2O3 on estrogen withdrawal from MCF-7 cell line, a 
hormone responsive breast cancer cell line, was studied in this research. The study 
was conducted by assessing the capability of AS2O3 in blocking the growth 
stimulation of MCF-7 cells. 
The growth kinetics was assessed by several methods. Various concentrations 
of estrogen was incubated with MCF-7 cells to assess its effect on MCF-7 cells. In 
addition, MCF-7 cells were incubated with estrogen simultaneously with AS2O3 to 
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observe any alteration induced by AS2O3 on MCF-7 cells as compared to estrogen 
treatment alone. In every experiment, a control without any treatment was included 
to assess the basal growth parameter of MCF-7 cells. 
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4.2 Effect of 17B Estradiol on Cell Viability of MCF-7 Cells by 
MTT Assay 
Numerous studies have been conducted in correlating the concentrations of 
estrogens and potency of its growth stimulation in breast cancer in in vitro system, 
animal models and clinical trials. However, different results were obtained. So, 
different concentrations were used in further studies regarding estrogen's action on 
breast cancer. Summarized from these studies, the physiological level of estrogen is 
roughly between lO'^^M to 10'^  M at which growth stimulatory effect was observed. 
Estrogen concentrations above 10"^  M is considered to be pharmacological 
concentrations at which tumor growth can be inhibited (Umans et al., 1984; Fabian et 
al., 1994; Saeki et al., 1991; lacobelli et al., 1984; Lippman et al., 1976). 
So, prior to the experiments, the growth stimulatory effects of 17p estradiol on 
MCF-7 cells in a range of concentrations were determined by M T T assay. The % 
survival of MCF-7 cells increased upon incubation with 0.1 n M to 500nM 17p 
estradiol (Fig 4.1) with respect to untreated control. Within 24 hours incubation, no 
obvious survival stimulation was observed. It was until 48 hours incubation, 
estrogen induced % survival from 100% in untreated control to maximum 137 % in 
lOnM 17P estradiol treatment. Increasing time incubation to 72 hours, the % 
survival further was increased. At this time period, lOnM 17p estradiol attained the 
maximum survival stimulation to 165% with respect to untreated control. 
On the other hand, lOOOnM 17(3 estradiol reduced cell survival, as % survival 
was 75% to 49% of untreated control after 24 to 72 hours treatment respectively. 
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Fig 4.1 Cell survival of MCF-7 cells upon l ip estradiol treatment for various 
time courses. 
Cells at 1 X 104 cells/ well were seeded in 96-well plate. Cells were treated with 
different concentrations (O-lOOOnM) of 17p estradiol for 24, 48, 72 hours. The 
percentage of cell survival was measured by M T T assay. Data are presented as 
means 土 SD for 6 replicate measurements. The % survival is expressed relative to 
untreated control that is 100 percent (* p<0.05). 
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4.3 Effect of AS2O3 and 17B Estradiol on Cell Survival of MCF-7 
Cells by MTT Assay 
To assess the effect of AS2O3 on 17p estradiol treated MCF-7 cells, MCF-7 
cells were incubated with AS2O3 and 17p estradiol simultaneously. From the result 
obtained in Fig 4.1, lOnM of 17p estradiol was found to have maximum growth 
stimulatory effect on MCF-7 cells upon 24, 48 and 72 hours. As it was reported to 
be physiological level in some studies, lOnM of 17p estradiol was used in all the 
experiments in assessing the effects of AS2O3 on 17p estradiol stimulated MCF-7 
cells. 
From Fig 4.2, lOnM of 17p estradiol was found to exhibit growth stimulatory 
effect on MCF-7 cells as indicated by the increase in 65% survival. When treated 
together with AS2O3, the % survival of MCF-7 cells was reduced as compared to 17(3 
estradiol treatment alone. The reduction was dose and time dependent. For 
concentrations between 0.25 to 0.5 |liM, AS2O3 did not reduce % survival. At 
concentration of 2|iM, 25% reduction of survival was induced after 24 hours 
treatment, it maximized after 72 hours treatment to 52 % as compared to untreated 
control. 
The IC50 of AS2O3 alone, 17p estradiol and AS2O3 on growth survival of MCF-7 
cells were shown in Table 4.1. The IC50 of AS2O3 incubated with 17p estradiol was 
higher as compared to AS2O3 alone for both 24 and 48 hours treatment. It became 
lower than that in the presence of 17p estradiol after 72 hours treatment. At that 
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time, 2|iM of AS2O3 could inhibit 52% of MCF-7 cells and also in the presence of 
17p estradiol that was shown to stimulate growth survival (Fig 4.2). 
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Fig 4.2 Effect of AS2O3 on cell survival of MCF-7 cells treated with lOnM 17p 
estradiol. 
Cells at 1 X 104 cells/well were seeded in 96-well plate. Cells were treated with 
lOnM 17(3 estradiol alone(E) and various concentrations (0.25-2^M) of AS2O3 
simultaneously with lOnM 17p estradiol (E) for 24, 48, 72 hours. Cells without any 
treatment was used as negative control for comparison (CTL). The percentage of 
cell survival was measured by M T T assay. Data are presented as means 土SD for 
6 replicate measurements. The % survival is expressed relative to untreated control 




Dmg Treatment Time Incubation 
AS2O3 (2 ^ iM) 
24 hours 48 hours 72 hours 
Treatment 
MCF-7 cells 8 1.8 1.2 
17P Estradiol 
stimulated >2 >2 2 
MCF-7 cells 
Table 4.1 I C 5 0 of AS2O3 on MCF-7 cells treated with or without lOnM 17p 
estradiol. 
Cells at 1 X 104 cells/well were seeded in 96-well plate. Cells were treated with 
various concentrations (0-32|aM) of AS2O3 alone and various concentrations 
(0.25-2|LIM) of AS2O3 simultaneously with lOnM 17(3 estradiol for 24, 48, 72 hours. 
Cells without any treatment was used as negative control for comparison. The IC50, 
the concentration of AS2O3 at which 50% cell survival was obtained, of AS2O3 




4.4 Cytotoxicity of AS2O3 on 17B Estradiol Stimulated MCF-7 
Cells by Cell Number Counting with Hemacytometer 
MCF-7 cells were treated with various concentrations (0.5|iM-2.0|aM) of AS2O3 
with or without lOnM 17p estradiol, viable cells were counted. When incubating 
together with AS2O3, growth stimulation was reduced (Fig 4.3). At concentrations 
of 0.5|aM, the reduction of growth stimulation was apparent but the effect of lOnM 
17P estradiol on the stimulation of cell growth of MCF-7 cells remained as the curve 
represented by 0.5fiM treatment remained above that of control. As the 
concentrations increased to 2|liM, the reduction of growth stimulation was so 
significant that the % cell number of MCF-7 cells was inhibited by 31% and 58% (i.e. 
69.0 0/0 and 42.3% of control) over 48 and 72 hours treatment respectively. It is 
supported by the curve representing 2jiM AS2O3 treatment in Fig 4.3 that becomes 
slope downward starting from 24 hours treatment and finally below that of the 
control beyond 48 hours treatment. 
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Fig 4.3 The percentage cell viability of MCF-7 cells upon lOnM 17p Estradiol 
alone and AS2O3 and 17p estradiol treatments for various time courses. 
MCF-7 cells at 3 x 10^  cells/well were seeded in 6-well plate. Cells were treated 
with various concentrations (0-2|aM) of AS2O3 for 24, 48 and 72 hours. Viable cells, 
trypan blue unstained dead cells were counted after treatment under light microscope. 
Data are presented as means 士 S.D. of triplicate experiments. It is expressed as the 
percentage of viability relative to the control (expressed as 100%) of the 
corresponding time treatment (* p<0.05 as relative to control while # p<0.05 as 
relative to 17(3 estradiol). 
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4.5 Growth Inhibitory Effect of AS2O3 on 17B Estradiol 
Stimulated MCF-7 Cells by fmethvl-SHl Thymidine 
Incorporation into DNA 
Then, the effect of AS2O3 on the D N A synthesis of lOnM 17p estradiol 
stimulated MCF-7 cells was assessed. MCF-7 cells were incubated with lOnM 17(3 
estradiol treatment, various concentrations of AS2O3 and lOnM 17p estradiol 
simultaneously with AS2O3. As indicated in Fig 4.4, relative to untreated control, 
lOnM 17(3 estradiol increased the [methyl-^H] thymidine incorporation into the D N A 
of MCF-7 cells upon 24 hours treatment to 135% of control. Longer time treatment 
to 48 hours did not increase the incorporation but a further increase in treatment to 72 
hours increased the % incorporation to 178% of control. Thus, lOnM 17p estradiol 
increased D N A synthesis of MCF-7 cells. 
When treating MCF-7 cells with lOnM 17p estradiol simultaneously with 0.25 
|iM and 0.5 |iM AS2O3，the % incorporation is higher than that of untreated control. 
AS2O3 at concentration above l|iM also reduced the % incorporation compared to 
lOnM 17(3 estradiol which was even lower than the control. The reduction in % 
incorporation was dose and time dependent. 2|iM AS2O3 after 72 hours treatment 
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Fig 4.4 Effect of AS2O3 on DNA synthesis and cell proliferation of lOnM 17p 
Estradiol stimulated MCF-7 cells upon various time treatment. 
MCF-7 cells at 1 x cells/well were seeded in 96-well plate. Cells were treated 
with various concentrations (0-2|aM) of AS2O3 simultaneously with lOnM 17p 
estradiol (E) for 24，48 and 72 hours. Cells without any treatment (CTL) and 
treated with lOnM 17p estradiol (E) were used for comparison. 0.5jaCi/well of 
[methyl-^ H] thymidine was pulsed to cells for 6 hours. Cells were then harvested 
by cell harvester and incorporated into D N A was measured by scintillator. Data are 
presented as means 士 SD for 3 replicate experiments. The percentage is expressed 
relative to untreated control that is 100 percent (* p<0.05 as relative to control while 
# p<0.05 as relative to 17(3 estradiol). 
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4.6 Effect of AS2O3 on Cell Survival of Hormone Independent 
Breast Cancer Cell Line. MDA-MB-231 
During the early stage of breast cancer，the cancer cells are estrogen responsive 
due to the presence of estrogen receptors. Nevertheless, estrogen responsive breast 
cancer cells will become independent and estrogen receptors negative at their later 
stage. At this stage, the cancer cells are more aggressive and classified as advanced 
stage. 
In the previous section, AS2O3 was demonstrated to block the growth 
stimulatory action of 17(3 estradiol in MCF-7 cells. It is reasonable to assume that 
AS2O3 will then show no effect on estrogen independent breast cancer cells. 
In this section, the effect of AS2O3 on cell survival of a hormone independent 
breast cancer cell line, MDA-MB-231, was studied. The dose and time responsive 
curves of MDA-MB-231 cells to a range of AS2O3 treatment were plotted in Fig 4.5. 
It is obvious that AS2O3 inhibits the cell survival of MDA-MB-231 cells in dose and 
time dependent manner. For concentrations below 2|iM of AS2O3, grow inhibitory 
effects were also shown. This also implies that AS2O3 exhibits inhibitory effect on 
both estrogen responsive and non-responsive breast canccr cells. 
To compare the cell survival inhibiting effects of AS2O3 in MCF-7 cells and 
MDA-MB-231 cells, IC50 after various time treatments was obtained and shown in 
Table 4.2. The IC50 of AS2O3 in MDA-MB-231 cells upon 24’ 48’ 72, 96 and 120 
hours were found to be 17jiM, 7}iM, 4.8|aM. 3.4fiM and 2.1 \iM respectively. 
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Higher IC50 of AS2O3 was obtained in MDA-MB-231 cells as compared with MCF-7 
cells. This implies that, higher concentrations of AS2O3 are required to induce 50% 
growth inhibition in MDA-MB-231 cells than that of MCF-7 cells. In other words, 
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Fig 4.5 Cell survival of MDA-MB-231 cells upon AS2O3 treatment for various 
time courses. 
MDA-MB-231 cells at 1x1 O* cells/well were seeded in 96-well plate. Cells were 
treated with different concentrations (0-32i^M) of AS2O3 for 24, 48, 72, 96 and 120 
hours. The percentage of cell survival was measured by M T T assay. Data are 
presented as means 土 SD for 6 replicate measurements. The % survival is 
expressed relative to untreated control that is 100 percent. 
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IC 50 of Arsenic trioxide (|iM) Breast Cancer Cell Lines  
Time Treatment (Hours) MCF-7 MPA-MB-231 
24 8 17 
48 1.8 — 7 
72 1.2 4.8 
96 0.8 3.4 
m 0.5 2.1 
Table 4.2 Comparison of I C 5 0 of AS2O3 in MCF-7 cells and MDA-MB-231 cells 
upon various time treatments. 
MCF-7 cells and MDA-MB-231 cells at 1 x lO"^  cells/well were seeded in 96-well 
plate. Cells were treated with various concentrations (0-32|aM) of AS2O3 for 24, 48， 
72, 96 and 120 hours. Cells without any treatment was used as negative control for 
comparison. The IC50, the concentration of AS2O3 at which 50% cell survival was 
obtained, of AS2O3 treatment on MCF-7 cells were compared with those of AS2O3 




lOnM 17P estradiol stimulated the cell survival of MCF-7 cells by 62% (Fig 4.1). 
When treated with various concentrations of AS2O3, simultaneously, the cell survival 
and growth stimulatory effects were reduced at different extents depending on the 
concentration of AS2O3 and time treatment duration. 
In assessing cell viability by M T T assay, the % cell survival of MCF-7 cells over 
72 hours treatment was stimulated by lOnM 17p estradiol to 160% of control. It 
was reduced to 46% of control upon incubation with 2|LIM AS2O3 simultaneously. 
Within 48 hours treatment period, IC50 of AS2O3 in treating MCF-7 cells was lower 
than that in the presence of lOnM 17p estradiol (Fig 4.2). Over longer treatment 
period, i.e. 72 hours, IC50 of AS2O3 was 1.8|LIM and 2|LIM in the treatment without and 
with lOnM 17(3 estradiol respectively (Table 4.1). 
When determine the viable cell numbers of MCF-7 cells after treatments with 
AS2O3 alone or simultaneously with lOnM 17p estradiol, a reduced % cell number 
was shown in 2\iM AS2O3 treatment over 72 hours treatment period by 58 % at 
maximum (Fig 4.3). 
For D N A synthesis of MCF-7 cells, lOnM 17p estradiol showed a significant 
stimulatory effect to 178% of untreated control，whereas the stimulatory effect was 
reduced by 2fiM AS2O3 with maximum reduction to 40% of control upon 72 hours 
treatment (Fig 4.4). 
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When treating with hormone unresponsive cells, MDA-MB-231 cells, various 
concentrations of AS2O3 could induce cell survival inhibitory effect. The IC50 of 
AS2O3 treatment on MDA-MB-231 cells upon 24, 48, 72, 96 and 120 hours were 
17|IM, 7 | IM, 4.8|IM, 3.4|AM and 2 .1| l iM respectively (Fig 4.5). Nevertheless, the 
IC50 of AS2O3 treatment on MDA-MB-231 cells were higher than those on MCF-7 
cells, indicating that AS2O3 is more effective in inhibiting the growth of MCF-7 cells 
(Table 4.2). 
The above results suggests that AS2O3 at a concentration of 2 j l i m or below 
induce growth inhibitory effects not only in MCF-7 cells (discussed in chapter 3) but 
also in MCF-7 cells supplied with lOnM 17p estradiol. As 17p estradiol is a 
growth stimulant of MCF-7 cells, it can thus be concluded that 2|liM AS2O3 is 
capable of blocking estrogen from stimulating MCF-7 cells in cell survival and 
proliferation. Further study with MDA-MB-231 cells suggest that AS2O3, in fact, is 
not only capable of estrogen withdrawal but may also trigger other mechanisms in 




Effects of Arsenic Trioxide 
(AS2O3) on Normal Cells 
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5 . 1 I n t r o d u c t i o n 
AS2O3 was considered as toxic substance. Acute high doses or chronic exposure 
can lead to diverse manifestations of poisoning such as human carcinogenesis (Zhao et 
al., 1997). On the basis of theory of “toxic against toxic" in traditional Chinese 
• th 
medicine, AS2O3 was used as therapeutic agents extensively since early 15 century. 
Later on, clinical trials of AS2O3 on the treatment of acute promyelocytic leukemia did 
show side effects such as hyperleukocytosis. In general, the toxicities associated with 
AS2O3 therapy are well identified, when monitored and treated appropriately, they are 
manageable. 
Owing to the fact that AS2O3 therapy is safe for administration in patients with 
appropriate guidelines, its efficacy in the treatment of acute promyelocytic leukemia 
(APL) patients secures the approval by FDA for the treatment of this disease. 
Although extensive evidence indicates that AS2O3 is harmless to patients and 
clinically achievable dose. 2[IM is defined and used extensively in most preclinical 
studies, the toxic effect of AS2O3 on normal cells re-examined in accompany with the 
studies of its effect of tumor cells. It is to ensure that the dose used in this study was 
harmless to normal cells. 
The toxicity of AS2O3 was examined by assessing the survival of normal cells 
after exposure to AS2O3. In in vitro studies, the cytotoxicity effect in normal cell line, 
HS 68 cells, was assessed. In in vivo studies, nude mice were used as animal model. 
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5 . 2 E f f e c t o f AS2O3 o n N o r m a l H u m a n F i b r o b l a s t C e l l L i n e . H s 68 
The effects of AS2O3 on normal tissues were assessed by using a human fibroblast 
cell line, Hs 68, which was derived from human male foreskin tissues. 
Hs 68 cells were incubated with a range of concentrations of AS2O3 including 
those found effective in inhibiting the survival of MCF-7 cells. The percentage 
survival of AS2O3 on Hs 68 was plotted in Fig 5.1. As expected, survival of Hs 68 cells 
was inhibited at very high concentrations of AS2O3, above 10|liM. Exposure to 
concentrations above 10)iM inhibited cell survival by 20% to 50%, with greater 
inhibition upon higher concentration and longer time exposure. At lower 
concentrations, below 5[iM, most cells were viable and less than 20% of cells survival 
was inhibited. 2|iM of AS2O3, which would also be the concentration used in other 
studies, showed no inhibition on cell survival, indicating that AS2O3 at 2)aM was not 
cytotoxic to normal Hs 68 cells. The result suggests that the concentration of AS2O3 in 
inducing cytotoxic effect on MCF-7 cells is not cytotoxic to normal cell line, Hs 68. 
So, the cytotoxicity of AS2O3 at concentration below 2jaM is selective to MCF-7 cells. 
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Fig 5.1 Effects of AS2O3 on the cell survival of human normal fibroblast, Hs 68 
cells upon 24 to 120 hours exposure. 
Hs 68 at 1 X cells/well were seeded in 96-well plate. MCF-7 cells were incubated 
with various concentrations of AS2O3 for 24,48,72,96 and 120 hours. The percentage 
cell survival of Hs 68 was determined by M T T assay. Data are means 土 S D for 6 
replicate wells. The experiment is repeated at least 3 times. The % survival is 
presented relative to untreated control that is 100 percent. 
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5 . 3 E f f e c t s o f AS2O3 o n t h e N o r m a l C e l l s o f N u d e M i c e 
In normal cells, enzymes are present which catalyze cellular processes so as to 
maintain the normal functions of physiological processes within the cells. These 
enzymes may be tissue specific, localizing in one specific tissue and performing 
specific function(s). Any damage to this tissue will cause the release of specific 
enzymes. Tissue specific enzymes act as good indicators of tissue damage. 
Measurement of tissue specific enzymes thus enables the detection of damage of the 
corresponding tissues. 
Based on this principle, the effects of AS2O3 on normal cells are assessed by 
measurement of tissue specific enzymes. 5mg/kg AS2O3 was administrated 
intravenously into nude mice for three weeks. After the treatment period, blood was 
collected from heart and the tissue specific enzymes in serum were measured by 
spectrophotometrical method. Four enzymes level were measured in the present study: 
aspartate dehydrogenase (AST), alanine dehydrogenase (ALT), creatine kinase (CK), 
lactate dehydrogenase (LDH). 
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5.3.1 Effect of AS2O3 on Aspartate Transaminase (AST) Activity of Nude 
Mice 
AST localizes in liver, heart and skeletal at highest concentrations than other 
tissues in the body. The high activity of AST in serum will mainly be contributed by 
those releasing from liver. So, elevated level indicates liver damages. 
Measurement of AST is performed based on the principle that AST catalyzes the 
transfer of the amino group of aspartate to oxoglutarate. Oxalacetate formed will 
oxidize N A D H to oxidized form, N A D . The light emitted was measured and the 
enzyme activity was calculated. 
AST 
Aspartate 




Pyuvate + NADH ^ Malate +NAD 
The enzyme activity of AST in sera of mice from untreated control, saline 
treatment and AS2O3 treatment is shown in Fig 5.2. It is obvious that no apparent 
difference of AST levels in sera of mice of was observed in all treatment groups. 
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Fig 5.2 Effect of AS2O3 on aspartate transaminase (AST) activity of nude mice. 
5mg/kg in 0.2ml of AS2O3 was injected intravenously into nude mice for 3 weeks. 
After treatment, plasma was collected and serum AST activity was measured to assess 
the effect of AS2O3 on liver tissues of treated mice. Normal mice without any 
treatment and mice injected with saline were used as control for comparison. Data 
shown is obtained from a single representative experiment. The result was confirmed 




5.3.2 Effect of AS2O3 on Alanine Transaminase (ALT) Activity of Nude Mice 
Alanine transaminase (ALT) localizes in liver, kidney and heart at the highest 
concentrations among tissues in body. In general, elevated ALT level in serum 
indicates liver damage such as hepatitis, intrahepatic cholestasis etc. 
ALT level is measured basing on its catalytic property of the enzyme in 
transferring an amino group from alanine to oxoglutarate to yield pyruvate. Pyruvate 
in turn oxidizes N A D H to N A D . Measurement of N A D absorbance over reaction time 
could determine the activity of ALT. 
ALT 
•, . ‘ Pyruvate + L-Glutamate 
Alan ine • 
Latate 
Dehydrogenase 
Pyuvate + NADH ^ Lactate +NAD 
As seen in Fig 5.3, there is no marked change in ALT activity in sera of mice upon 
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Fig 5.3 Effect of AS2O3 on alanine transaminase (ALT) activity of nude mice. 
5mg/kg in 0.2 ml of AS2O3 was injected intravenously into nude mice for 3 weeks. 
After treatment, plasma was collected and serum ALT activity was measured to assess 
the effect of AS2O3 on liver tissues of treated mice. Normal mice without any 
treatment and mice injected with saline were used as control for comparison. Data 
shown is obtained from a single representative experiment. The result was confirmed 




5.3.3 Effect of AS2O3 on Creatine Kinase (CK) Activity of Nude Mice 
Creatine kinase (CK) located in skeletal muscle, heart muscle and brain 
tissue. Serum C K is usually used to detect myocardial infarction and muscle 
diseases such as muscular dystrophy and viral myositis . 
In the presence of creatine phosphate and adenosine phosphate (ADP), C K 
catalyzes the conversion of a phosphate group from creatine phosphate to A D R The 
ATP molecule formed transfers the phosphate group to glucose, yielding 
glucose-6-phosphate. Afterwards, G-6-P transfers the phosphate group to N A D . The 
reduced form N A D H was measured spectrophotometrically. 
C K 
Cteatine phosphate + ADP ^ Creatine + ATP 
H K 
ATP + Glucose ^ ADP + Glucose-6-phospahte 
G-6-PDH 
Glucose-6-phosphate + NAD ^ 6-PG + NADH 
The C K activity in sera of mice of after different treatments is plotted in Fig 5.4. 
The serum C K activity measured after AS2O3 treatment is comparable to that of control 
without treatment or treated with saline. 
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Fig 5.4 Effect of AS2O3 on creatine kinase (CK) activity of nude mice. 
5mg/kg in 0.2ml of AS2O3 was injected intravenously into nude mice for 3 weeks. 
After treatment, plasma was collected and serum C K activity was measured to assess 
the effect of AS2O3 on heart tissues of treated mice. Normal mice without any 
treatment and mice injected with saline were used as control for comparison. Data 
shown is obtained from a single representative experiment. The result was confirmed 




5.3.4 Effect of AS2O3 on Lactate Dehydrogenase (LDH) Activity of Nude 
Mice 
Lactate dehydrogenase (LDH) is composed of 5 different enzymes located 
in different tissues including heart, kidney, brain, erythrocytes, liver and skeletal 
muscles. High level of serum L D H is usually associated with heart disease such as 
myocardial infaraction. So, measurement of change in L D H activity of sera in mcie 
after AS2O3 treatment was performed to assess the effect of AS2O3 on heart tissue of the 
host. 
Measurement of L D H is based on the reaction shown below. L D H catalyzes the 
reduction of N A D to N A D H by oxidizing lactate to pyruvate. The rate of change of 
N A D H formation indicated the enzyme activity. 
LDH 
Lactate + NAD ^ Pyruvate + NADH + H+ 
In Fig 5.5, a histogram is plotted showing the L D H activities in sera of mice upon 
different treatments. Comparing with untreated control or saline treatment, AS2O3 
treatment shows no significant elevation in L D H activity in the sera of the mice. 
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Fig 5.5 Effect of AS2O3 on lactate dehydrogenase (LDH) activity of nude mice. 
5mg/kg of AS2O3 was injected intravenously into nude mice for 3 weeks. After 
treatment, plasma was collected and serum AST activity was measured to assess the 
effect of AS2O3 on heart tissues of treated mice. Normal mice without any treatment 
and mice injected with saline were used as control for comparison. Data shown is 
obtained from a representative experiment. The result was confirmed by three 




5 . 4 S u m m a r y 
The effects of AS2O3 on normal tissues were studied in this chapter. 
In vitro study, 2|aM AS2O3 did not reduce % survival of normal cells line, human 
fibroblasts Hs68 cells, upon 5 days incubation. In vivo study with animal models also 
showed no significant elevation of specific tissue enzymes, AST, ALT, C K and LDH, 
after 3 weeks treatment of AS2O3 at a dosage equivalent to 2 )aM. This suggests that 
AS2O3 treatment does not cause significant damage on animal tissues 
In conclusion, AS2O3 does not inhibit cell survival normal cells or damage to 
tissue cells at a concentration, 2|aM, which is clinically achievable concentrations 




Action Mechanisms Underlying 
the Survival Inhibitory Effects of 
Arsenic Trioxide (AS2O3) on MCF漏7 Cells 
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6 . 1 I n t r o d u c t i o n 
In Chapter 3, AS2O3 was shown to induce cytotoxic and growth inhibitory effects 
in MCF-7 cells. The mechanisms underlying the cytotoxic effects may be associated 
with necrosis or apoptosis. 
Necrosis and apoptosis are two distinct modes of cell death (Schedin et al., 1996; 
Hengartner 2000). They are pivotal in maintaining normal human cellular functions. 
Dysregulation of cell death processes results in pathological diseases. Over the past 
decade, cancer researches and cell death researches have revealed that deficient 
apoptosis is associated with cancer. Numerous studies demonstrated that the induction 
of apoptosis by anticancer drugs in tumors and proposed the practical therapeutic 
applications of apoptosis for the treatment of cancers (Kam and Ferch, 2000; Forlenza 
and Baum, 2000; Nicholson et al., 2000). 
Indeed, apoptosis is closely associated with both normal mammary breast tissues 
and breast cancers. Growing studies have demonstrated that the induction of cytotoxic 
effects induced through apoptosis in both breast cancer cell lines and animal models. 
In addition, necrosis is also found to be responsible for the anti-tumor effects in breast 
cancer cells. 
In this research, the mode of cell death mediating the cytotoxic property of AS2O3 
was investigated. Apoptosis and necrosis can be differentiated based on differences in 
morphological, biochemical and molecular changes that occur within the dying cells. 
Based on these features, various assay methods were adopted which revealed the mode 
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of cell death involved in MCF-7 cells (Willingham 1999). 
First, D N A Fragmentation determination, Annexin V staining were performed to 
diffentiate the mode of cell death. Secondly, cell cycle distribution of MCF-7 cells 
after treatment was analyzed to assess whether regulation of cell cycle progression is 
involved in the action mechanisms. Thirdly, we would go in dept to unravel the 
underlying cellular processes regulated by AS2O3 in triggering the ultimate cytotoxic 
and growth inhibiting effects in MCF-7 cells. These cellular processes involved 
alteration of mitochomdrial membrane potential, regulation of oncogens expression 
and activation of free radicals production. 
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6.2 D e t e c t i o n o f A p o p t o s i s 
6.2.1 Detection of DNA Fragmentation 
D N A fragmentation is a hallmark feature of apoptosis. In most cells undergoing 
apoptosis, activated endonuclease cleaves double strand D N A in the linker regions 
between nucleosomes and produce D N A fragments of approximately 185 bp. The 
D N A fragments are analyzed by agarose gel electrophoresis. However, in epithelial 
cells including breast cancer cells, intemucleosomal D N A fragments of 180 bp cannot 
be detected. Indeed, high molecular weight fragments of size between 50 and 300 kilo 
base pair (kb) are formed upon apoptosis (Bertrand et al., 1991; Oberhammer et al., 
1993). 
In this research, D N A fragmentation was measured after treatment of MCF-7 
cells with AS2O3 to see whether apoptosis was induced upon the treatment. Cell Death 
Detection ELISA Plus allows the detection of D N A fragments together with the 
detection of necrosis. For necrotic cells，cell swelling occurs and the cell membrane 
will be disrupted leading to the release of cellular materials to culture medium. The 
random sized D N A fragments resulted from necrosis can be detected by analyzing the 
supernatant of the culture medium after treatment. For apoptotic cells, D N A 
fragments including high molecular weight D N A fragments remain in the cell 
cytoplasm, which can only be detected after the disruption of cell membrane by cell 
lysis. MCF-7 cells were incubated with AS2O3 for 24，48 and 72 hours incubation 
medium was then collected and the remaining adherent cells were lysed by lysis buffer. 
The medium and cell lysate were analyzed separately by ELISA. When incubating 
with biotin labeled monoclonal mouse antibodies (anti-histone-biotin) and peroxidase 
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conjugated monoclonal mouse antibody (anti-DNA-POD), the D N A fragments in the 
samples were attached to the streptavidin-coated microtiter plate as a complex 
(anti-histone-biotin — D N A fragments - anti-DNA-POD). The amount of complex 
was proportional to the amount of D N A fragments. After washing off unbound 
immunoreagents, ABTS substrates were added. Peroxidase conjugated in the D N A 
complex catalyzed the conversion of ABTS to green products, which was analyzed 
photometrically by the ELISA plate reader. The absorbance measured was directly 
proportional to the amount of D N A fragments. After adjustment of equal protein 
content of sample, D N A fragmentation was determined (Fig 6.1). 
D N A fragmentation resulted from apoptotic MCF-7 cells was shown in Fig 6.2. 
Upon higher concentrations of AS2O3 and longer time treatment greater D N A 
fragments was detected. D N A fragmentation was significantly induced by 2 folds as 
compared with untreated control after 72 hours treatment with 1)LIM AS2O3. 
Comparable result was observed in treatment with 2|LIM AS2O3 after shorter time 
incubation, namely 48 hours. Further incubation with 2jiM AS2O3 to 72 hours further 
enhanced D N A fragmentation to 3.5 folds as compared to untreated control. 
When analyzing D N A fragmentation of incubation medium, no significant 
increase in D N A fragments was induced by various concentrations of AS2O3 at all 
incubation time as compared to the untreated control. Fig 6.3 demonstrated the factors 
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Fig 6.1 The principle of DNA fragmentation detection by cell death detection 
ELISAP丨us assay kit. 
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Fig 6.2 Detection of DNA fragmentation in the cytoplasm of MCF-7 cells upon 
AS2O3 treatment for various time courses. 
Cells at 1 X 104 cells/well was seeded in 96-well plate. After treatment for 24, 48 and 
72 hours with various concentrations (0.25-2.0|LIM) of AS2O3, the cells were lysed and 
incubated with immunoreagents for 2 hours. D N A fragmentation in cell lysate was 
measured spectrophotomically by microplate reader at 405nm wavelength against 
490nm reference wavelength. Data are the means 士 SD for 5 separate experiments. 
D N A fragmentation is expressed as the factor of D N A fragmentation which represents 
the fold of D N A fragments induced in treated samples after protein normalization as 
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Fig 6.3 Detection of DNA fragmentation in the incubation medium of MCF-7 
cells upon AS2O3 treatment for various time courses. 
Cells at 1 X 104 cells/well was seeded in 96-well plate. After treatment for 24, 48 and 
72 hours with various concentrations (0.25-2.0|^M) of AS2O3, the incubation medium 
and cell lysate were incubated with immunoreagents for 2 hours. D N A fragmentation 
was measured spectrophotomically by microplate reader at 405nm wavelength against 
490nm reference wavelength. Data are the means 士 SD for 5 separate experiments. 
Data is expressed as absorbance per milligram of protein in each sample (p<0.05). 
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6.2.2 Phosphatidvlserine (PS) Externalization Detected by Flow Cytometry 
with Annexin V-PI Staining 
6.2.2.1 The Principle 
Phosphatidylserine (PS) is located exclusively in the inner leaflet of the 
plasma membrane of untreated cells. Upon the initiation of apoptosis, phospholipid 
asymmetry of the plasma membrane is lost (Fadok et al； 1992; Koopman et al., 1994). 
PS translocates to outer leaflet which acts as an indicator of early apoptosis. 
PS in the outer leaflet of cell membranes is detected by staining with 
Annexin V and analyzed by FACSort flow cytometer using CellQuest programmme. 
AnnexinV is a dye binds to negatively charged phospholipids, i.e. PS. Upon 
excitation, green fluorescent light is emitted. The fluorescent intensity is 
proportional to the amount of PS on the outer leaflet of cell membrane and thus the 
extent of apoptosis undergone. 
Since translocation of PS also occurs in necrotic cells, the fluorescence emitted by 
Annexin V staining also indicates the presence of necrotic cells. To differentiate 
apoptosis from necrosis, PI is used to stain cells in combination with Annexin V. PI is 
charged fluorochrome excluded by the intact membranes of live cells. During early 
apoptosis, the cell membrane is intact and it becomes disrupted finally as shrinkage 
and blebbing occurs. On the other hand, swelling and loss of cell membrane integrity 
occur in cells undergoing necrosis. Thus, PI is permeable to and stains cells 
undergoing necrosis and late apoptosis but not early apoptosis. 
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Data are presented as dot plot in which fluorescent light emitted by PI is 
plotted against fluorescent light emitted by Annexin V. A typical dot plot is shown in 
Fig 6.4. The dot plot is divided into four quadrants: The intensities of fluorescent light 
emitted by Annexin V increases in the direction to right of x axis while that emitted by 
PI increases in the upward direction of y-axis. For cells without any treatment, dots 
localize in the lower right quadrant indicating the minimum staining by Annexin V 
and PI and thus neither apoptosis nor necrosis occurs in this cell population (Annexin 
V-/PI- cells). For cells undergoing early apoptosis, dots localized in the lower left 
quadrants due to high fluorescent intensity emitted by Annexin V but low intensity 
from PI (Annexin V+/PI- cells). For cells undergoing late apoptosis or necrosis, high 
fluorescent intensities emitted by Annexin V and PI result in the dots accumulation in 
the upper right quadrant (Annexin V+/PI+ cells) (Fig 6.4). In every experiments, 
digitionin was used as positive control. Digitonin is a chemical which can disrupt the 
membrane integrity resulting in the exposure of PS to Annexin V and exposure of 
cellular nucleic acids to PL Thus, the cell population will accumulate in the upper 
right quadrant, representing the condition of late apoptosis and necrosis. 
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Fig 6.4 A typical dot plot showing cell populations in different 
quadrants. 
6.2.2.2 PS Externalization upon AS2O3 Treatment 
After treatment for 24,48 and 72 hours, MCF-7 cells were collected by adding the 
floating cells to the adherent cells. In each time incubation, an untreated control was 
prepared which acted as a reference for comparison. As shown in Fig 6.5, the majority 
of cells were localized in the lower left quadrant after 24 hours treatment indicating the 
presence of viable cells without apoptotic or necrotic stimulation. As the time 
treatment was increased to 48 hours, cells were observed in both lower and upper left 
quadrants, with greater proportion in the former, indicating the presence of both 
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apoptotic and necrotic cells respectively. Upon treatment for 72 hours, increase in 
concentrations of AS2O3 increased percentages of cells in both quadrants. 
Simultaneously, a decrease in percentages of cells in lower left quadrants of both time 
treatments was observed. There was a shift of cells from lower left quadrant to lower 
and upper right quadrants. 
When comparing the % of apoptotic cells induced by AS2O3 with the untreated 
control, 0.7 fold to 3 folds increases were observed upon 1|liM AS2O3 treatment for 24 
to 72 hours, respectively. Whereas, 2 folds to four folds increases were observed upon 
2|iM AS2O3 for the same time treatments, respectively. To sum up, the % of apoptotic 
cells induced by AS2O3 was dose and time dependent (Table 6.1 and Fig 6.6). 
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Table 6.1 Comparison of % apoptotic cells and % necrotic cells induced in 
MCF-7 cells treated with various concentrations of AS2O3 for 24, 48 and 72 
hours. 
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Fig 6.6 Dose and time response curves of % apoptotic cells detected in MCF-7 
cells upon AS2O3 treatment for 24,48 and 72 hours. 
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6 . 3 A n a l y s i s o f C e l l C y c l e D i s t r i b u t i o n o f M C F - 7 c e l l s 
6.3.1 The Principle 
After treatment, MCF-7 cells were permeablized by fixation with 70% ethanol 
and then stained by PI (propidium iodide). PI is a fluorochrome that intercalates 
non-specifically in the double helix of D N A . Upon excitation by laser beam emitted 
by the FACSort at 488nm, red light is emitted and detected by FL2 fluorescent detector. 
Data is presented as the number of events. The intensity of fluorescence is proportional 
to the amount of PI dye bound on D N A helix and thus the D N A contents of untreated 
or treated MCF-7 cells. Data is analyzed and presented as one dimensional histogram. 
A typical histogram of D N A content distribution of untreated MCF-7 cells is shown in 
Fig 6.7. The number of events (i.e. number of cells) is plotted against the intensity of 
fluorescence. From the histogram, the percentage of cells undergoing apoptosis and in 
each phase of the cell cycle can be determined by the data analysis by ModFit LT. 
During apoptosis, cellular D N A is degraded by activated endonuclease. The 
reduced D N A content was extracted by ethanol extraction resulting in reduced 
fluorescent intensity that is recognized as sub- Gi peak below Gi peak in the histogram. 
The percentage of apoptotic cells can then be detected from the percentage of sub- Gi 
peak. 
Apart from detection of apoptosis, analysis of cellular D N A content of MCF-7 
cells after treatment enables the assessment of the effect of AS2O3 on the cell cycle of 
MCF-7 cells. As cells progress through cell cycle for the proliferation, the D N A 
content increases and lead to increase in fluorescence. From the histogram (Fig 6.7)， 
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two D N A peaks, Giand G2/M, are shown with a plateau in between them (S phase). 
Gi phase is the period of cell after the completion of mitosis and before the replication 
of D N A , cells at this phase have diploid D N A . Gi/M phase is the period of cell in 
which D N A replication is completed and awaiting for the onset of mitosis. As D N A 
content is doubled, the fluorescent intensity of cells at Gi/M phase is double that of at 
Gi phase. In transiting from Gi to G2/M phase, new D N A synthesis is taken place in S 
phase resulting in increasing D N A content and fluorescent intensity. 
6.3.2 Regulation of Cell Cycle Distribution of MCF-7 cells upon AS2O3 
Treatment 
By comparing the percentages of cell cycle phases of MCF-7 cells without 
treatment and those after AS2O3 treatment, the regulation of AS2O3 on cell cycle 
progression of MCF-7 cells was studied. 
Fig 6.8 shows the cell cycle distribution of MCF-7 cells after treatment with 1 ^ M 
and 2 jiM of AS2O3 for 24, 48 and 72 hours. Sub- Gi populations increased upon 
treatment with higher concentrations of AS2O3 throughout the experimental time frame. 
With respect to % sub- Gi peak of control, greater increase was observed upon longer 
time treatment (Fig 6.9). Thus, it implies that AS2O3 elicits cytotoxic effect on MCF-7 
cells which results in the formation of D N A of low molecular weights. However, this 
effect may be either through the induction of apoptosis or necrosis. Detection of other 
features was needed to perform for further confirmation. 
Apart from induction of sub-Gi peak, AS2O3 was also shown to regulate cell cycle 
distribution of MCF-7 cells. In exponentially growing MCF-7 cells, the % of cells 
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Gi/M phases were apparently the same despite the concentration and time treatment. 
However, there was an increase in the Gi phase and a decrease in S phase in all treated 
samples with respect to the untreated control. The change of phase distribution was 
most significant upon 2|iM of AS2O3 treatment for 72 hours. After treatment, the 
percentages of cells in Gi, S and G2/M phases of untreated MCF-7 cells were changed 
from 47.76, 24.48 and 27.17 respectively to 67.53, 9.26 and 23.21 in cells treated with 
2)iM AS2O3. There was an apparent cell accumulation at Gi phase (41 %), significant 
decrease in S phase fraction (62%) and a slight decline in G2/M fraction (14.6%). 
Thus, AS2O3 induced a shift of cells partly from G2/M phase and mostly from S phase 
to Gi phase of cell cycle (Fig 6.8). The % of cells in Gi, S and G2/M phases after 2 |iM 
AS2O3 treatment for the considered time frame are plotted in Fig 6.10. It shows the 
increase in % Gi phase, a decrease in % G2/M phase. The % S phase remains the same 
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Fig 6.7 A typical histogram showing cell cycle distribution of MCF-7 cells. 
The histogram is plotted of events (cell number) against FL2-A (PI intensity). Gi 
phase and Gi/M phase are represented by two peaks with higher and narrower for Gi 
phase. S phase is the phase in between Gi and G2/M phase, at which D N A and protein 
synthesis actively takes place in preparation for mitosis. 
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Fig 6.8 Effects of l^iM and AS2O3 on cell cycle distribution of MCF-7 cells 
after 24,48 and 72 hours treatments. 
Cells at 3 X LO'^ cells/well were seeded in 6-well plates. After treatment with 1|liM and 
2|LIM AS2O3 for 24, 48 and 72 hours, the cells were harvested and fixed in 70% ethanol 
overnight. The cells were stained with PI solution at 3TC for 30 mins. The 
populations of cells in Gi, S, G2+M and sub-Gi phases were determined by FACSort 
flow cytometer and analysed by Modfit LT. Cell populations are expressed as 
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Fig 6.9 Change in % apoptotic cells upon AS2O3 treatment for 72 hours. 
Cells at 3 X LO'^ cells/well were seeded in 6-well plates. After treatment with 1 |LIM and 
2|LIM AS2O3 for 24，48 and 72 hours, the cells were harvested and fixed in 70% ethanol 
overnight. The cells were stained with PI solution at 37°C for 30 mins. The 
populations of apoptotic cells were determined by FACSort flow cytometer and 
analysed by Modfit LT. Data are expressed as the percentages relative to untreated 
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Fig 6.10 Change in % distribution of cell cycle phases in MCF-7 cells upon 2|iM 
AS2O3 treatment for 72 hours. 
Cells at 3 X 10'^ cells/well were seeded in 6-well plates. After treatment with 2|LIM 
AS2O3 for 24, 48 and 72 hours, the cells were harvested and fixed in 70% ethanol 
overnight. The cells were stained with PI solution at 37。C for 30 mins. The 
populations of cells in Gi phase, S phase and G2/M phase were determined by 
FACSort flow cytometer and analysed by Modfit LT. Data are expressed as the 
percentages relative to untreated control at the corresponding time treatment with 
control expressed as 100%. 
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6 . 4 T h e A c t i o n M e c h a n i s m s U n d e r l y i n g AS2O3 i n d u c e d 
A p o p t o s i s o r C e l l C y c l e A r r e s t 
6.4.1 Effect of AS2O3 on Mitochondrial Membrane Potential of MCF-7 Cells 
In the previous sections, AS2O3 was shown to induce cytotoxic cell death through 
the initiation of apoptosis instead of necrosis. In fact, apoptosis is a process consisting 
of stages. The stimulation of death signals trigger cells to execute the processes 
through one or more pathways which ultimately converge to manifest apoptosis as 
shown as D N A fragmentation, PS exposure etc. In this section, the involvement of 
mitochondrial in trigger AS2O3 induced apoptosis in MCF-7 cells was studied. 
During early apoptosis, the mitochondria permeability transition pores (FTP) 
opens resulting in the free distribution of ions between both sides of the membrane. 
As a consequence, the mitochondrial transmembrane potential is disrupted (ABm) 
(Green and Reed, 1998). The collapse of mitochondrial transmembrane potential can 
be detected by flow cytometry with JC-1 staining. JC-1 is a fluorochrome that emitted 
fluorescence upon excitation. At low membrane potentials, JC-1 exists as monomer 
and emits green fluorescence. At high membrane potentials, JC-1 forms dimmer 
(J-aggregates) and emits red fluorescence. By measuring emitted green and red 
fluorescent intensities, the state of mitochondrial transmembrane potential can be 
detected. 
Results are plotted in density plot of red fluorescent intensity (FL3) against green 
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fluorescent intensity (FLl). For untreated control, the cell population was adjusted to 
localize in the middle left quadrant. In facing a disruption of mitochondrial 
transmembrane potential after treatment, the cell population will shift to lower right 
quadrant. Since at low membrane potential, JC-1 exists as monomer causing increase 
in green fluorescent intensity (FLl) while JC-1 in the form of dimmer will decrease 
resulting in decrease in red fluorescent intensity (FLl). As consequence, the cell 
population will move downward towards to right. 
With respect to the untreated control, treatment with both 1 juM and l^xM AS2O3 
induced a shift of cell population to right after both 48 hours and 72 hours treatment. 
The increment is directly proportional to the concentrations of AS2O3 (Fig 6.11). 
Greater increase in the % of cells relative to control was observed upon 72 hours 
treatment than that of 48 hours treatment. This implies that the induction of change in 
mitochondrial transmembrane potential is time dependent. Valinomycin is a 
potassium ionophore that hyperpolarizes mitochrondrial membrane potential. It 
lowers the potential and causes a shift of cell population to downward to right. It thus 
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6.4.2. Regulation of Free Oxidative Species (ROS) Production in MCF-7 
Cells upon AS2Q3 Treatment 
In the previous section, AS2O3 was shown to trigger apoptosis through the 
disruption of mitochondrial transmembrane potential. Studies of the involvement of 
free oxidative species (ROS) in apoptosis induction indicated the release of superoxide 
from mitochondria after membrane collapse. The inhibition of superoxide generation 
prevents the activation of apoptosis (Hockenbery et al., 1993). 
6.4.2.1 Analysis of Superoxide Production in MCF-7 Cells upon AS2O3 
Treatment by Flow Cytometry with Hydroethidine (HE) Staining 
The change in cellular ROS in MCF-7 cells after AS2O3 treatment was measured 
by flow cytometry with hydroethidine (HE) staining. In the presence of superoxide, 
blue fluorescence emitting H E is oxidized to ethidium bromide and intercalates with 
cellular D N A . When exited during analysis, red fluorescence is emitted with intensity 
proportional to the amount of ethidium bromide and superoxide presence in treated or 
untreated cells. So, after treatment with various concentrations of AS2O3 over 48 and 
72 hours, treated samples together with untreated control were stained with HE. 
Results are analyzed in histogram of events plotted against fluorescence intensity 
(FLl). Elevation of superoxide will result in histogram move to right. As shown in 
histograms, Fig 6.12, no obvious shift of histograms to right after treatment with 
0.5-2|LIM AS2O3 for 48 and 72 hours were observed with respect to untreated control. 
Positive control was performed by incubating MCF-7 cells with valinomycin. 
Valinomycin disrupts mitochondrial membrane potential and causes release of 
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superoxide to cytosol. Thus the fluorescence intensity after treatment increased and 
showed in histogram as moving to right. The result suggests that 0.25|IM to 2|LIM 
AS2O3 do not induce superoxide production during treatment in MCF-7 cells. 
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Fig 6.12 Detection of superoxide production in MCF-7 cells upon AS2O3 
treatment for 48 and 72 hours. 
Cells at 3 X cells/well were seeded in 6-well plates. After treatment for 48 hours 
(Fig 6.12A) and 72 hours (Fig 6.12B), the cells were harvested. 3x10^ cells/sample 
were stained with H E at 3TC for 30 mins. The H E intensity was determined by 
FACSort flow cytometer and analyzed by Modfit LT. Histograms in black, dark blue, 
purple, pale blue and yellow represent untreated control and treatment with AS2O3 in 
0.25|iM, 0.5|dM, liaM and respectively. Dark brown histogram represents 
positive control, which was prepared by treating valinomycin with MCF-7 cells over 
same treatment period as those of AS2O3. 
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6.4.2.2 Effect of AS2O3 on Cell Survival of MCF-7 Cells Co-treated with 
N-Acteyl-L-Cysteine (NAC) by MTT assay 
To determine if free radicals involve in AS2O3 induced survival inhibitory effect 
on MCF-7 cells, MCF-7 cells were treated with AS2O3 in combination with an 
antioxidant, N-acteyl-L-cysteine (NAC). 
Upon treatment for 72 hours together with 10 m M N A C , 0.5-2jaM of AS2O3 
induced comparable survival inhibitory effect in MCF-7 cells as compared to 
treatment with AS2O3 alone in same concentrations (Fig 6.13). 2jj.M AS2O3 inhibited 
0/0 survival of MCF-7 cells to 75%. 2|iM AS2O3 co-treatment with N A C induced 
inhibition by 70%. The survival inhibition in MCF-7 cells was not reduced by the 
addition of antioxidant. It may be possible that free radicals are not mediators of 
AS2O3 induced survival inhibition in MCF-7 cells. 
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Fig 6.13 The % survival of MCF-7 cells upon AS2O3 treatment alone or with 
lOmM N-acetyl-L-cysteine (NAC) over 72 hours incubation. 
Cells at 1 X 104 cells/well were seeded in 96-well plates. After treatment with various 
concentrations (0.5-2|iM) of AS2O3 simultaneously with lOmM N A C for 72 hours, % 
cell survival was determined by M T T assay. Data are means 士 SD of six wells of three 
independent experiments. Data are expressed as % survival relative to control that is 
100 percent (p<0.05). 
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6.4.3 Regulation of Bcl-2 Protein Level in MCF-7 Cells upon AS2O3 
Treatment 
Bcl-2 is a member of bcl-2 family, which encodes pro-oncogene proteins. 
Extensive studies demonstrated that bcl-2 acts as a negative regulator of apoptosis. Its 
potency in inhibiting apoptosis is determined by the expression level of another family 
member, bax. High bcl-2/bax ratio will suppress apoptosis whereas low bcl-2/bax 
ratio will trigger apoptosis induction (Adams and Cory, 1998). 
In the present study, bcl-2 protein level in MCF-7 cells upon AS2O3 treatment was 
determined. After the first 24 hours treatment, no significant alternation in the protein 
level was induced by 2|LIM AS2O3. After longer time treatment, 48 hours, 2|LIM AS2O3 
induced a decrease in the protein level by approximately 30% relative to control. This 
data reveals that AS2O3 downregulates bcl-2 protein expression in MCF-7 cells at 2jLiM 
after 48 hours treatment (Fig 6.14). 
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Fig 6.14 Regulation of bcl-2 protein level in MCF-7 cells upon 2|iM AS2O3 
treatment for 24 and 48 hours. 
MCF-7 cells were treated with 2[IM AS2O3. After 24 and 48 hours, cellular proteins 
were extracted. Equal amounts of protein samples were resolved by SDS-PAGE and 
probed with aiiti-bcl-2 antibody. Figure A, a representative Western blot of three 
independent experiments. Fig B, Relative protein expression level of different 
samples after quantification. Data are means of the three experiments 士 SD and 
expressed relative to control that is expressed as 100 (*p<0.05). 
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6.4.4 Regulation of on p53 Protein Level in MCF-7 Cells upon AS2O3 
Treatment 
p53 tumor suppressor protein playa a crucial role in many cellular functions such 
as cell proliferation. Loss of its function contributes to over 50% of all tumors 
(Hollstein et al., 1991 and Deng et al., 1994). After expression, p53 binds to specific 
D N A sequences as a transcriptional regulator. It then regulates the gene expression of 
other proteins such as Bax (Miyashita and Reed, 1995), p21/Wafl/Clipl (Cartel and 
Tyner et al., 1999) etc. These genes in turn functions in a variety of cellular processes. 
Numerous studies have associated breast cancer with p53. Wild type p53 
protein is overexpressed in ER positive breast cancer cells including MCF-7 cells 
while mutated p53 proteins are overexpressed in ER-negative breast cancer cells 
(Liossi et al., 2001). As p53 is a regulator of cell growth, it may be possible that 
regulation of p53 is involved in AS2O3 induced ER signaling pathway inactivation and 
growth suppression in MCF-7 cells. 
Comparing to untreated control, 2|LIM AS2O3 upregulated p53 protein level in 
MCF-7 cells over 50% after 48 hours treatment. It further upregulated the protein 
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Fig 6.15 Regulation of p53 protein level in MCF-7 cells upon 2\iM AS2O3 
treatment for 24 and 48 hours. 
MCF-7 cells were treated with 2|iM AS2O3. After 24 and 48 hours, cellular proteins 
were extracted. Equal amounts of protein samples were resolved by SDS-PAGE and 
probed with anti-p53 antibody. Figure A, a representative western blot of three 
independent experiments. Fig B, relative protein expression level of different samples 
after quantification. Data are means of the three experiments 士 SD and expressed 
relative to control that is expressed as 100 (p<0.05). 
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6 . 5 S u m m a r y 
In summary, AS2O3 induced apoptotic effect in MCF-7 cells as evidenced by 
the presence of D N A fragmentation (Fig 6.2), PS extemalization by Annexin V 
staining (Fig 6.3) and formation of sub-Gl peak in cell cycle distribution analysis (Fig 
6.8). In general, these effects were observed in dose and time dependent maimer with 
maximum effect induced by 2|LIM AS2O3 after 72 hours treatment. Upon the same 
concentration and time treatment, AS2O3 induced Gi arrest in cell cycle distribution 
analysis. The increase in Gi peak was compensated by the decrease of cell populations 
in S phase and G2/M phase (Fig 6.10). 
Further studies of action mechanisms mediating the apoptotsis and cell cycle 
arrest, 2|LIM AS2O3 induced collapse in mitochondrial membrane potential (Fig 6.11) 
and downregulation of bcl-2 protein expression (Fig 6.14) and upregulation of p53 
protein expression (Fig 6.15). In contrast, AS2O3 did not induce free radicals 
(superoxide) production during treatment in MCF-7 cells (Fig 6.12) and co-treatment 
with N A C did not oppose the growth inhibitory effect of AS2O3 on MCF-7 cells upon 
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7 . 1 I n t r o d u c t i o n 
In chapter 4, AS2O3 was found to be capable of blocking estrogen's action in 
MCF-7 cells as evidenced by its ability to induce significant cell survival inhibition 
in estrogen stimulated cells. In an attempt to unravel the action mechanisms 
induced by AS2O3, the action mechanisms mediating estrogen's growth stimulatory 
effects were studied. 
Estrogen mediates its action on breast cancer cells by several mechanisms as 
discussed in section 1.9.2. These mechanisms may be ER dependent or ER 
independent. The present study will mainly focus on the studies concerning ER 
dependent pathway. 
By western blot analysis, reverse transcription-polymerase chain reaction 
(RT-PCR), ER competitive binding assay and luciferase reporter system, the effects 
of AS2O3 on ER mediated signaling pathway were studied at four levels: (1) 
regulation of estrogen binding to estrogen receptor; (2) regulation of ERa expression 
at both transcription and translation levels; (3) regulation of ERa -DNA interaction 
in the nucleus and (4) regulation of protein level of estrogen target gene. 
Lastly, the ultimate effects of this regulation on growth inhibition of MCF-7 
cells were determined by studying cell cycle distribution of MCF-7 cells. 
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7 . 2 E f f e c t o f AS2O3 o n E s t r o g e n B i n d i n g t o E s t r o g e n R e c e p t o r 
g ( E R a � b y E R a C o m p e t i t i v e B i n d i n g A s s a y 
Estrogen receptor (ER) is well understood to participate in mediating estrogens' 
actions in MCF-7 cells. In the presence of estrogens, estrogen receptor complexes 
with its ligands at the ligand binding domain. Subsequently, a series of molecular 
events are initiated resulting in growth stimulation. To interfere with the effects of 
estrogen in MCF-7 cells, blocking of estrogen binding to ER is one of the 
approaches. 
In assessing the competitive binding capacity of AS2O3 on ERa, a estrogen-R(a) 
competitor screening kit was employed. It functions through reactions based on the 
competition of fluorescence labeled estrogen and tested substances to ERa. The 
principle is illustrated in Fig 7.1. Human recombinant ERa was coated in 
microplates. When incubating samples with fluorescence labeled estrogen, they 
may compete with estrogen to the binding sites on ERa. The binding will continue 
until dynamic equilibrium was attained. After removal of unbounded substances or 
fluorescence labeled estrogen, the retained estrogen was determined by measuring 
the fluorescent intensity. A control of fluorescence labeled estrogen alone is 
prepared to act as positive control. For competitive antagonist, they will bind to 
ERa, leaving less binding sites to fluorescence labeled estrogen. As a result, low 
fluorescent intensity can be measured. On the other hand, if the substance does not 
compete with estrogen for the binding sites, fluorescence labeled estrogen will bind 
to ERa and retained in the microplate. Excitation of the sample mixture will emit 
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high fluorescent intensity. The extent of binding depends on the capability of 
substance in competing with estrogen that is correlated to the affinity of that 
substance to ERa. 
The specific estradiol binding after incubation with a various concentrations of 
17p estradiol, AS2O3, tamoxifen and paclitaxel is shown in Fig 7.2. 17p estradiol in 
concentrations of 0.1 n M to 200nM reduced the specific estradiol binding 
dramatically in concentration dependent manner. Concentrations above 200nM 
completely prevented binding of fluorescent estradiol to ERa. The estradiol 
binding remained high in the presence of paclitaxel indicating that it did not compete 
with estradiol for ERa binding. The result was consistent to the fact that paclitaxel 
inhibited breast cancer survival through mechanisms other than ERa signaling. 
When incubating with tamoxifen in concentrations above 0.25|liM, which is an 
antiestrogen, the estradiol binding was reduced and over 50%. As expected, 
tamoxifen competed with 17p estradiol for ERa binding. Compared with AS2O3, 
estradiol binding remained high in concentrations below 2\IM, higher concentrations 
did not increase the ability of AS2O3 in competing with estradiol for ERa binding. 
This result suggests that AS2O3 does not compete with 17p estradiol for ERa binding. 
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Fig 7.2 The competitive binding abilities of 17p estradiol, AS2O3, tamoxifen and 
paclitaxol to ERa. 
Various concentrations of 17(3 estradiol, AS2O3, tamoxifen and paclitaxel were 
incubated in ELISA plate for 2 hours. After washing for several times, the assay 
reagent was added to assess the binding of fluorescent labeled 17p estradiol to the 
ERa binding site. Data shown is representative of three separate experiments in 
each of which triplicate wells were assayed. Error bars are SD of triplicate wells. 
The wells incubated with solvents only are considered as untreated control, whose 
fluorescent intensity is expressed as 100 percent. 
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7 . 3 R e g u l a t i o n o f E s t r o g e n R e c e p t o r a ( E R a ) m R N A L e v e l u p o n 
AS2O3 T r e a t m e n t b y R T - P C R 
As ERa is the important mediator of estrogen stimulated signaling pathway, the 
alternation of ERa level in MCF-7 cells during AS2O3 exposure may contribute to 
the interference exerted by AS2O3 on the pathway. In this sense, the effect of AS2O3 
on ERa R N A level was examined. 
Total R N A samples from the untreated control and MCF-7 cells treated with 
2[iM AS2O3 alone or simultaneously with 17p estradiol were isolated and then 
converted to cDNA strands by reverse transcription. By performing polymerase 
chain reaction (PCR), limited amount of cDNA strands were amplified to a great 
amount that can be analyzed as band intensities in agarose gel electrophoresis. 
Band intensity comparison thus allows the qualitative comparison of R N A amount 
extracted from different samples. After reverse transcription, there might be a 
slight deviation of total cDNA amount among samples. To ensure equal amount of 
total cDNA of all the samples was used for comparison, the cDNA level of a house 
keeping gene, GADPH, was examined first prior to each comparison of sample 
cDNA. G A D P H was chosen as its R N A expression is not affected by any treatment. 
The equal band intensities of G A D P H cDNA products (400 bp) are shown in Fig 
7.3A indicated the equal amount of cDNA used for all the samples. Regarding to 
ERa m R N A measurement, specific ERa primers under a specific condition were 
used to perform RT-PCR according to a study reported previously (Cullen et al.. 
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2001). The ERa primers bind to ER sequence. Under the specific condition 
adopted, specific ERa primers will anneal to and amplify the cDNA sequence 
corresponding to ERa. Any downregulation of ERa R N A transcription will give 
lesser amount of ERa cDNA sequence, thus less cDNA products are amplified and 
lower band intensity will be resulted. As seen in Fig 7.3, the band intensity of cDNA 
products treated with 2|LIM AS2O3 was lower than that of untreated control. This 
meant that ERa m R N A level was reduced upon 2jiM AS2O3 treatment. When 
stimulated with lOnM 17(3 estradiol, the m R N A level was also downregulated. It is 
due to the fact that estrogen is a ligand of ERa that will cause the inhibition of ER 
production. When AS2O3 was simultaneously incubated with 17p estradiol a further 
reduction in band intensity was observed. The result suggested that AS2O3 at 2|iM 
down-regulated the m R N A expression of ERa. 
In the first 24 hours treatment, lOnM 17p estradiol downregulated transcription 
level by 52% relative to control and further treatment to 48 hours downregulated the 
level by 72 %. 24 hours and 48 hours exposure to 2|LIM AS2O3 also induced a 
downregulation of ERa R N A transcription but to a lesser extent. When 2 ^ M 
AS2O3 were incubated with MCF-7 cells simultaneously with 17p estradiol, a 
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Fig 7.3 Regulation of ERa mRNA level in MCF-7 cells upon AS2O3 treatment. 
MCF-7 cells were treated with 2|aM AS2O3 alone and simulanteously with lOnM 17p 
estradiol for 24 and 48 hours. After treatment, total R N A was isolated, transferred 
to cDNA and amplified with ERa primers as described in Materials and Methods. 
A, Agarose gel of the RT PGR amplified G A D P H cDNA stained with ethidium 
bromide. G A D P H acts as internal control for normalization, its size is 400bp. B, 
Agarose gel of the RT PGR amplified ERa cDNA of size 490bp C. Densitometric 
analysis of the amplified ERa cDNA product levels after normalization with the 
GADPH. Data is a representative of three independent experiments. 
Page 158 
CHAPTER 1 
7 . 4 R e g u l a t i o n o f E s t r o g e n R e c e p t o r a ( E R a ) P r o t e i n L e v e l u p o n 
AS2O3 T r e a t m e n t 
In addition to the R N A level, it is necessary to examine the ERa protein level. 
It is well known that protein expression is a process after m R N A translation whereas 
m R N A is formed by R N A transcription when the corresponding gene is stimulated to 
express. Nevertheless, some studies suggesting that protein levels may not be 
correlated to its R N A level. It is possible by several mechanisms: 1. The inhibition of 
protein degradation; 2. the activation of protein turnover etc. Moreover, 
concentrations of ER proteins are the major factor governing the estrogen sensitivity 
of a target cell (Katzenellenbogen 1980). So, the effect of AS2O3 on ERa protein 
level was also examined by Western blot analysis, which will best correlate to its 
signaling transduction in MCF-7 cells. 
Within 48 hours treatment, there were 42 % and 22% drops in the ERa protein 
expression level upon lOnM 17(3 estradiol and 2[IM AS2O3 treatment when compared 
with control without treatment. Co-treatment of both resulted in a greater drop in 
protein expression level by 90%. This revealed that both lOnM 17p estradiol and 
2|iM AS2O3 downregulated ERa protein levels with greater effect induced by 17p 
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Fig 7.4 Regulation of ERa protein level in MCF-7 cells upon AS2O3 treatment 
for 48 hours. 
MCF-7 cells were treated with 2[IM AS2O3 alone and in combination with lOnM 
17(3 estradiol. After 48 hours, cellular proteins were extracted. Equal amounts of 
protein samples (30|j-g) were resolved by SDS-PAGE and probed with anti- ERa 
antibody (1:500). Figure A, a representative western blot of three independent 
experiments. Fig B, relative protein levels of different samples after quantification. 
Data are expressed as means 士 SD of three independent experiments and expressed 
relative to control that is 100 percent (* p<0.05 as relative to control while # p<0.05 
as relative to 17p estradiol). 
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7 . 5 R e g u l a t i o n o f E s t r o g e n R e c e p t o r a ( E R a ) T r a n s c r i p t i o n a l 
A c t i v i t y u p o n AS2O3 T r e a t m e n t 
Estrogens mediate effects on breast cancer cells by binding to its ERa. The 
Ei-ERa complex then translocates to the nucleus where it binds to its response 
element, estrogen response element (ERE), at the promoter region of target genes. 
The binding activates transcription of the target genes and in turn up-regulates their 
protein expressions. As a consequence, cellular responses such as proliferation and 
growth in normal human breast tissues and tumor cells are regulated (Sathya et al., 
1997, Driscoll et al., 1998, Boyer et al., 2000). In this section, the regulation of 
AS2O3 on the estrogen activated transcriptional activity was studied by examining the 
effect of AS2O3 on ERa binding to ERE. 
In the study, dual luciferase reporter system was adopted. Renilla luciferase 
control reporter vectors and pGL3 reporter vector were co-transfected to MCF-7 cells. 
pGL3 reporter vector was prepared by inserting ERE sequence into luciferase 
containing reporter molecule. The D N A plasmids containing this element was then 
introduced into MCF-7 cells. The transcriptional activity of ERa was determined 
by measuring luciferase activity after extraction by cell lysis. Luciferase activity 
was measured by conversion of substrate to product that emitted fluorescence at 
specific wavelength upon excitation. The fluorescence emitted by Renilla 
luciferase control reporter vectors in transfected MCF-7 cells was also measured in 
the same experiment, which acted as internal control for normalization as the 




Result was expressed as % activation. The normalized luciferase activity of 
lOnM 17(3 estradiol, AS2O3 at l^M and concentrations and AS2O3 
simultaneously added with 17p estradiol were shown in Fig 7.5. As expected, the 
luciferase activity was significantly enhanced by lOnM 17p estradiol to 3.5 fold as 
compared to control. Upon treatment with AS2O3, both IJ^M and 2|LIM, dose and 
time dependent reduction in % activity were observed. When expose to both 17p 
estradiol and 2|LIM AS2O3 over 72 hours, a reduction of % activity was also induced 
as compared to control. Although the % reduction (28.7%) was less significant 
when compared to those of treatments of IJIM AS2O3 (42.3%) or 2|LIM AS2O3 
(60.23%) alone over the same incubation period, the reduction was so significant that 
it could mask the activation induced by lOnM 17p estradiol alone. The results 
suggest that 2|LIM AS2O3 exerts inhibitory effect on ERa mediated luciferase 
activation over 48 and 72 hours treatment. In other words, AS2O3 at 2|LIM 
down-regulates the transcriptional activity of ERa. The most important is that it 
also counteracts the activated transcriptional activity of ER a induced by lOnM 17p 
estradiol (Fig 7.5). 
Page 162 
CHAPTER 1 
500 r - ^ ― - -
4 5 0 圓 48 hours 
J> : 4 0 0 I " 7 2 hours I 
1 1 350 P i  
g 8 300 
！ d 250 
I ! r ] - z ^ ^ ^ i z ^ 
1 1 1 5 � 1 I  
政 100 I 1 
50 - - t ^ __ -I m * 鬥 【 工 - � 
0 r k m\ I K m I k L I I k £ 1 I l U 
Control lOnM 1 |liM 2 |AM lOnM 17p 
17p AS2O3 AS2O3 Estradiol 
Estradiol + 2jLiM AS2O3 
* • wAtmexit 
Fig 7.5 Regulation of estrogen activated ERa transcriptional activity upon 
AS2O3 treatment for 48 and 72 hours. 
MCF-7 cells co-transfected with luciferase reporter plasmids were treated with 
various concentrations of AS2O3 alone, lOnM 17p estradiol alone and 2jLiM AS2O3 
simultaneously with lOnM 17p estradiol. Cells without any treatment (control) was 
prepared for comparison. During treatment, ERa-ligand complex bound to plasmid 
in cells at ERE sequence, which in turn activated expression of luciferase gene and 
emitted fluorescence upon assay. Each value was normalized by Renilla luciferase 
control vector. The luciferase activity is expressed as the percentage of untreated 
control that is 100 percent. The experiment was repeated for three times and a 
single representative experiment was shown. Error bars represent S.D. from four 
wells of each experiment. 
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7 . 6 R e g u l a t i o n o f E s t r o g e n T a r g e t G e n e , c - m y c . P r o t e i n L e v e l 
u p o n AS2O3 T r e a t m e n t 
A number of studies have searched for estrogen-regulated genes in human breast 
cancer cells in order to better understand the actions of estrogens. So far, the 
number of genes known to be directly activated by estrogen is quite small. Some of 
the target genes are summarized in Table 1.3. These genes may be ERE present or 
absent at the promoter regions. As AS2O3 is demonstrated to reduce D N A activation 
by ER at ERE sequence, it is reasonable to assume that AS2O3 will then alter the gene 
expression of target genes with ERE at their promoter regions. Finally, one or more 
transduction events are regulated to inhibit the survival and growth of MCF-7 cells. 
By western blot analysis, the protein expression of c-myc gene was studied. 
c-myc is a proto-oncogene. It is involved in the stimulation of cell proliferation, 
c-myc contains a half site ERE in its promoter region and its expression is 
upregulated by estrogen (Dubik et al., 1987，Shiu et al., 1993). It is possible that 
estrogens induce cell proliferation in breast cancer cells by regulating c-myc 
expression via ER signaling pathways. Some studies have revealed that the 
expression of c-myc is independent of ER status in tumor cells, suggesting that other 
factors or ER independent pathways are involved. 
The western blot analysis of c-myc protein level after treatment is shown in Fig 
7.6. As expected, 17(3 estradiol upregulated c-myc protein expression for 65% after 
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48 hours treatment with respect to untreated control. The upregulation was partially 
suppressed by 2[iM AS2O3 upon cotreatment in MCF-7 cells over same period of 
time, such that the protein level after co-treatment remained higher (131%) than that 
of control (100%). In the treatment of 2|liM AS2O3 alone, the protein level of c-myc 







S | 150 ^ 
1 2 3 4 
(B) Treatment 
Lane 1: lOnM 17p Estradiol Lane 3: lOnM 17p Estradiol + l^ iMAsiOa 
Lane 2: Untreated Control Lane 4: AS2O3 
Fig 7.6 Regulation of c-myc protein level in MCF-7 cells upon AS2O3 treatment 
for 48 hours. 
MCF-7 cells were treated with 2|LIM AS2O3 alone and in combination with LONM 
17P estradiol After 48 hours, total cellular proteins were extracted. Equal 
amount of protein samples (50|ag) were resolved by SDS-PAGE and probed with 
anti- c-myc antibody (1:500). Figure A, a representative western blot of two 




7 . 7 E f f e c t s o f AS2O3 o n C e l l C y c l e D i s t r i b u t i o n o f M C F - 7 C e l l s 
u n d e r E s t r o g e n s S t i m u l a t i o n 
The growth stimulatory effects of estrogens on human breast cancer are 
mediated by the shortening the length of Gi phase (Musgrove and Sutherland 1994). 
Studies in anti-estrogen treatment have indicated a reduction in S phase and increase 
in Gi phase. In this section, the effect of AS2O3 on cell cycle distribution of MCF-7 
cells was analyzed to investigate the possibility of involvement of cell cycle 
regulation in the ER signaling. 
Estrogens induce growth stimulatory effects by regulating target gene expression 
through ER signaling. These target genes produce protein products that regulate the 
cell cycle of cells. Aiming at elucidating the action mechanism on the growth 
inhibition of MCF-7 cells, the effect of AS2O3 on the cell cycle of MCF-7 cells was 
studied. MCF-7 cells were treated with 2|liPM AS2O3, 17p estradiol and 17p estradiol 
simultaneously with 2[iM AS2O3. Fig 7.7 A-D) shows the cell cycle distribution of 
MCF-7 cells over 48 hours treatment. Comparing with untreated control, a 48 
hours treatment with 2[iM AS2O3 markedly increased the proportion of cells in Gi 
phase by from 46.7% in control to 67.4% while reducing cell proportions in S phase 
and G2/M phase from 18.5% in control to 10.2% and 34.6% in control to 22.4% 
respectively. Consistent result was obtained over longer time treatment, 72 hours, 
with greater percentage changes in the phase distributions. Thus, AS2O3 induces Gi 




Upon incubation of same concentration of 17p estradiol alone with MCF-7 cells, 
a reduction of Gi phase by 35.5 % while increasing of G2/M phase and S phase cell 
populations by 9 % and 79.8 %. When incubating with AS2O3 together with 
17(3 estradiol, an increase of cell populations in Gi phases and a reduction of cell 
populations of G2/M phase and S-phase over same time treatment were also resulted. 
This implies that AS2O3 induces Gi phase growth arrest of MCF-7 cells stimulated by 
lOnM 17p estradiol. So, AS2O3 can block 17|3 estradiol induced cell cycle 
progression (Table 7.1 and Table 7.2). 
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Con't Fig 7.7 
Fig 7.7 Regulation of cell cycle distribution of MCF-7 cells upon treatment of 
2)iM AS2O3 and lOnM 17p estradiol. 
MCF-7 cells were treated with various concentration of AS2O3 alone or together with 
10 n M 17p estradiol for 48 and 72 hours. Cell cycle distribution of MCF-7 cells 
was studied by flow cytometry with propidium iodide (PI) staining. Y-axis 
represents the number of events (total:10,000) wheareas x-axis represents the 
fluorescence intensity of PI (FL-2). Fig A)-D) shows the distribution after 48 hours 
treatment Fig E)-H) show the distribution after 72 hours treatment. A)&E): 
Untreated control; B)&F): AS2O3； C)&G): lOnM 17p estradiol; E)&H): 2|iM 
AS2O3 and lOnM IVp estradiol. The data shown are obtained from a representative 
experiment of three independent experiments. 
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Table 7.1 Cell cycle distributions of M C F - 7 cells treated with 2|liM AS2O3 and 10 
nM 17p estradiol over 48 hours. 
After treatment of AS2O3 alone or simultaneously with lOnM 17p estradiol, % cell 
population of MCF-7 cells in Gi，S phase and G2/M phases were determined. + 
represents the presence of the indicated treatment while — represents the absence of 
the indicated treatment. 
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Table 7.2 Cell cycle distributions of MCF-7 cells treated with 2[iM AS2O3 and 
lOnM 17(3 estradiol over 72 hours. 
After treatment of AS2O3 alone or simultaneously with lOnM 17p estradiol, % cell 
population of MCF-7 cells in Gi，S phase and G2/M phases were determined. + 
represents the presence of the indicated treatment while — represents the absence of 
the indicated treatment. 
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7 . 8 S u m m a r y 
To sum up, AS2O3 in various concentrations do not bind to ERa binding site by 
competing with IVP estradiol for binding (Fig 7.2). However, 2[iM AS2O3 
suppressed the gene transcription and expression of ERa as it downrgulated its R N A 
and protein levels (Fig 7.3 and Fig 7.4). After 48 hours treatment, 2JLIM AS2O3 
suppressed ERa transcription activity and completely blocked 17p estradiol 
stimulated transcriptional activity (Fig. 7.5). Upon 2|liM AS2O3 treatment for 48 
hours, c-myc, an estrogen target gene, was inhibited in protein expression and the 
upregulation under 17P estradiol stimulation was completely blocked upon 48 hours 
treatment (Fig 7.6). 
Analysis of cell cycle distribution of MCF-7 cells treated with lOnM 17|3 
estradiol showed a stimulation of S phase progression upon AS2O3 treatment. 2|iM 
AS2O3 treatment induced cell cycle arrest at Gi phase while treatment in accompany 
with 17p estradiol showed a blockage of S phase progression but rather induced Gi 








8 . 1 T h e A n t i - T u m o r E f f e c t s o f AS2O3 o n M C F - 7 C e l l s 
Growing studies have revealed the effectiveness of AS2O3 in combating against 
solid tumors since its pilot treatment in APL patients. 
Breast cancers arouse increasing concerns recently. Studies in the anti-tumor 
effects of AS2O3 have been conducted on ovarian cancers, cervical cancers etc (Du and 
Ho, 2001). In view of the promising effectiveness of AS2O3 as chemotherapeutic drugs, 
the potential applications of AS2O3 in breast cancer treatments were explored in this 
study. 
8 . 2 C y t o t o x i c i t y o f AS2O3 o n M C F - 7 C e l l s 
In the studies of apoptotic mechanisms, estrogens deprived serum and medium 
was used in in vitro study. Since apoptosis can be induced by hormone withdrawal 
such as estrogens, culture condition in the absence of estrogens was used so as to 
ensure the apoptosis induction of AS2O3 was mainly due to the regulation of apoptotic 
downstream pathways instead of hormone withdrawal. 
The cytotoxicity of AS2O3 on MCF-7 cells was assessed by several parameters. 
Result of M T T assay (Fig 3.1) showed a dose and time dependent survival suppression 
of MCF-7 cells after AS2O3 treatment. The IC50 of AS2O3 were SpM, 1.8}aM, 1.2|iM, 
0.8^ IM and 0.5|liM in MCF-7 cells after 24 hours, 48 hours, 72 hours, 96 hours and 120 
hours treatments respectively. Compared with tamoxifen, lower concentrations of 
Page 175 
CHAPTER 1 
AS2O3 were found to induce same percentage survival inhibition, suggesting that 
AS2O3 were indeed more potent than tamoxifen in combating against MCF-7 cells (Fig 
3.5, Table 3.1). Consistent results were obtained when assessing viable cell number 
after treatment by trypan blue exclusion assay (Fig 3.2). An increased dead cell 
number with AS2O3 concentration and time treatment was shown. The trypan blue 
stained dead cells observed indicating the presence of dead cells after AS2O3 treatment, 
which was also increased with longer time treatment and higher dosage. Thus, 
cytotoxicity was elicited by AS2O3 in mediating anti-tumor effects on MCF-7 cells 
(Fig 3.3). 
Detailed mechanisms are unraveled in next section. 
8.2.1 Induction of Apoptosis in MCF-7 Cells upon AS2O3 Treatment 
As discussed in section 1.3.4.1 and 1.3.4, AS2O3 elicits apoptosis in mediating 
anti-tumor effects on APL cell lines and other solid tumors. Indeed, early studies have 
suggested that epithelial cells are resistant to apoptosis due to the absence of apoptotic 
features or regulators typically observed in apoptotic tumor cells. Little is known 
about the mechanisms in regulating apoptosis in epithelial cells. In recent years, 
studies of apoptosis mechanisms become a great interest for treatment strategy 
development in breast cancer. It may be due to increasing association of apoptotic 
related genes or proteins such as p53 and bcl-2 with breast cancer prognostic values 
and responsiveness to chemotherapy (Bonetti et al； 1998 and Lilling et al； 2000). 
In our studies, AS2O3 in concentrations between 0.5|_iM to 2\IM were found to 
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induce apoptosis in MCF-7 cells over 72 hours treatment in dose and time dependent 
manner. It was supported from the evidence that D N A fragmentation was detected in 
cytoplasm of MCF-7 cells after 1|LIM AS2O3 treatment for 72 hours (Fig 6.2). D N A 
fragments were also induced upon 48 hours treatment of 2|LIM AS2O3. It is widely 
accepted that D N A fragments of 180 bp detected in conventional agarose gel 
electrophoresis as D N A ladder is a hallmark feature of apoptosis (Wyllie, 1980). Our 
result did not indicate any D N A ladder formation after AS2O3 treatment (data not 
shown). The detection of D N A fragmentation is controversial. Some studies reported 
the absence of detectable intemucleosomes D N A in MCF-7 cells owning to initial 
cleavage of D N A fragments of approximately 300 kb and then 50kb in chromatin 
instead of typical 180 bp fragements observed as D N A ladder (Walker et al., 1991 and 
Oberhammer et al., 1993). A recent study showed the absence of D N A fragmentation 
and other typical biochemical features of apoptosis was due to the absence of 
functional caspase 3, which is responsible for intemucleosomal D N A fragmentation 
(Janicke et al., 1998 and Wolf et al., 1999). In contrary, some studies of cytotoxic 
agents induced apoptosis showed D N A fragments of 180kp detectable in agarose gel 
electrophoresis (Sokolova et al., 1995 and Kyprianou et al., 1991). This may be 
explained by strain-specific difference in MCF-7 cells (Gooch and Yee, 1999) and 
separate endonuclease activity responsible for high molecular and intemucleosomal 
D N A fragmentation (Pandey et al., 1994). So，in the present study, ELISA method 
was adopted in which D N A binding POD bound to D N A fragments of higher 
molecular weights to detect whether D N A fragments were produced after AS2O3 
treatment. D N A fragments were bound to D N A binding POD which in turn were 
detected by measuring intensity of colored product formed by enzymatic reaction of 
POD. This method is now widely adopted by studies of cytotoxic agent induced 
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apoptosis. The result was supported by the presence of sub-Gl peak in cell cycle 
analysis after (Fig 6.8). 
To further confirm the induction of apoptosis by AS2O3, we tested the 
extemalization of PS by flow cytometry with Annexin V-PI staining. PS 
extemalization was observed in majority of treated cells. Meanwhile, necrotic cells 
were also shown. However, it contributed to minority of cells as compared to the 
apoptotic cells (Fig 6.5). Also, apparent D N A fragments were detected in culture 
media showing necrotic cells were present in insignificant population after treatment 
(Fig 6.3). 
Together with the detection of sub-Gl peak in cell cycle analysis of MCF-7 cells 
after AS2O3 (Fig 6.8), it is obvious that 2\IM AS2O3 induces apoptosis in inhibiting the 
growth of MCF-7 cells. 
8.2.2 Action Mechanisms Underlying the Induction of Apoptosis by AS2O3 
Apoptosis is a complex process regulated by positive and negative regulators in 
coordinated manner. The downregulation or suppression of apoptotic inactivatior and 
upregulation or activation of apoptotic activator will trigger apoptosis. To clarify the 
downstream pathways proceeding to apoptosis induced by AS2O3 in MCF-7 cells, 
mitochondria was examined as it plays a critical role in apoptosis. Collapse of 
mitochondrial membrane potential was detected after 48 hours treatment with If^M 
AS2O3 treatment, further treatment with 2\iM AS2O3 induced a greater collapse as 
indicated by the shift of cell populations to right upon JC-1 staining (Fig 6.11). 
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Extensive studies have reported that upon stimuli, inner mitochondrial membrane 
undergoes conformational change that allowed discharge of membrane potential and 
pH gradient (Shimizu et al., 1999 and Hengartner, 2000). By then, mitochondrial 
permeability transition pore (PTP) locating in between the outer and inner 
mitochondrial membranes opens and complexes with bax, a member of bcl-2 family 
protein. Subsequently, it allows the release of cytochrome c from outer face of the 
inner mitochondrial membreane to the cytosol (Liu et al., 1996). Cytochrome c 
complexes with Apaf-1 and then procaspase 9 to form apoptosome which in turn 
activates caspase 3. The caspase activation cascade elicits D N A cleavage, nuclear 
condensation, cytoskeletal proteins cleavage or loss of cell adhesion and ultimately 
apoptosis (Mignotte and Vayssiere, 1998; Kam and Ferch, 2000; Hengartner, 2000 and 
Szewczyk and Wojtczak, 2002). 
It is widely accepted that the downstream pathway of mitochondria mediated 
apoptosis is caspase 3 dependent. In fact, MCF-7 cells are deficient of caspase 3 
(Janicke et al., 1998). Together with study indicating the requirement for caspase 3 to 
induce apoptosis by doxorubicin and etoposide in MCF-7 cells (Yang et al., 2001), one 
may think that it is impossible for AS2O3 to induce apoptosis through mitochondrial 
membrane potential disruption and ultimately bax elevation. Recent studies have 
indicated that TNF-a and paclitaxel induced cell death is possibly independent of 
caspase 3. Even caspase 3 was deficient, caspase 6 activation, PARP, procaspase 6， 
procaspase 8 and lamina cleavage also took place (Kagawa et al., 2001). This may be 
explained by the presence of some caspase like proteases, which participate in 
apoptosis execution in certain extent (Janicke et aL, 1998 and Kotte et al； 2002). So, 
AS2O3 may induce apoptosis through mitochondria pathway in the absence of caspase 
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3. However, in the present study, pathways downstream mitochondria are not 
addressed. Further studies on downstream pathways triggered by AS2O3 after PTP 
opening may shed light on the understanding of complete apoptotic pathway 
mediating AS2O3 induced apoptosis. 
Nevertheless, we have assessed the effects of AS2O3 on other apoptosis regulators. 
These findings will give us more understanding on the initiation and regulation of 
apoptosis by AS2O3. 
p53 is a tumor suppressor protein (Selvakumaran et al., 1994). It also acts as 
transcription factor in regulating target genes expression involving in apoptosis such 
as bcl-2 and bax (Miyashita et al., 1994 and Miyashita and Reed, 1995 and Zhao et al., 
2000). In the present study, p53 protein expression in MCF-7 cells was upregulated by 
2 folds after 48 hours treatment of 2\xM AS2O3. The elevation of p53 protein 
expression could be detected as early as treatment after 24 hours (Fig 6.15). This 
upregulation may enhance the bax protein expression and in turn facilitate the release 
of cytochrome c and apoptosis inducing factors to cytosol for downstream signal 
transduction of apoptosis. Meanwhile, bcl-2 protein expression was downregulated in 
MCF-7 cells by 25 % after 48 hours treatment of 2|jM AS2O3 (Fig 6.14). Bcl-2 acts as 
a negative regulator in mitochondrial mediated apoptosis. It counteracts the apoptosis 
stimulatory effect of bax and prevents the release of cytochrome c from mitochondria 
(Yang and Korsmeyer 1996 and Kluck et al., 1997). The suppression of bcl-2 protein 
expression by AS2O3 directly or through the upregulation of p53 will reduce the 
anti-apoptotic stimulus in MCF-7 cells and in turn enhance the induction of apoptosis. 
Some studies have indicated that downregulation of bcl-2 involved in apoptosis 
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induction and increased the sensitive of MCF-7 cells to cytotoxic induced drugs 
(Mandal and Kumar, 1996 and Piche et al., 1998). Further study of bax protein 
expression by western blot analysis is prompted to further elucidate the synergistic 
effects of p53 and bcl-2 on apoptosis induction. 
It has been demonstrated that reactive oxygen species (ROS) are mediators ofPTP 
opening. p53 transcript, PIG3 was shown to increase ROS production in mitochondria 
(Polyak et al., 1997). ROS production is enhanced as a result of early apoptotic 
processes. Moreover, bcl-2 is shown to protect cells from oxidative stress and deplete 
cellular GSH, which is important ROS scavenger (Hockenbery et al., 1993 and 
Femandez-Checa et al., 1998). The upregulation of p53 protein expression, 
mitochondria membrane potential disruption and downregulation of bcl-2 protein 
expression observed in our studies suggesting that ROS level may be elevated during 
AS2O3 treatment. In contrary, our study of the level of a ROS, namely superoxide, by 
flow cytometry with HE staining after AS2O3 treatment did not show any enhanced 
superoxide level (Fig 6.12). When incubating MCF-7 cells with AS2O3 and 
N-acetlycysteine (NAC) the survival inhibitory effect induced by AS2O3 on MCF-7 
cells was not suppressed (Fig 6.13). N A C is a thiol antioxidant that acts as cellular 
defender to reduce ROS in cells. The reduction of ROS in turn enhances apoptosis 
induction (Flora et al., 2001; Davis et al., 2001; Curtin et al., 2002 and Custodis et al., 
2002). Our observations suggest that ROS may not be responsible for AS2O3 induced 
apoptosis. Nevertheless, some studies found that ROS elevation is not an essential 
mediator for mitochondrial mediated apoptosis or it takes part in some forms of 
apoptosis. There is also evidence that inhibition of ROS production or activity do not 
mediate bcl-2 protein suppression on apoptosis (Jacobson and Raff, 1995 and Graeber 
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et al., 1996). 
At this stage, it is unreasonable to conclude whether ROS involved in AS2O3 
induced apoptosis or not. Further studies such as measurement of ROS related 
enzymes activity and detection of other ROS are awaited. 
8 . 3 G r o w t h I n h i b i t i o n o f AS2O3 o n M C F - 7 C e l l s 
Apart from apoptosis induction, AS2O3 was also shown to induce cell proliferation 
inhibition in MCF-7 cells over 72 hours treatment. In assessing new D N A synthesis of 
MCF-7 cells with [methyl- H] thymidine incorporation, an 50% inhibition of D N A 
synthesis was observed over 72 hours treatment with 2 |LIM AS2O3 (Fig 3 .4). As D N A 
synthesis is essential for cell division and proliferation, AS2O3 thus inhibits cell 
proliferation of MCF-7 cells. 
8.3.1 Cell Cycle Regulation of MCF-7 Cells upon AsiO^ Treatment 
Gi phase arrest is innate cell cycle in response to damage. In normal 
circumstances, cell cycle proceeds through Gi, S and G2/M phase. Upon damage, cell 
cycle will be suspended so as to allow time for D N A repair, undergo apoptosis or enter 
into a permanent Go state. Gi phase arrest induced by AS2O3 may prevent cells from 
proceeding to S phase for preparation of cell division such as D N A synthesis. This 
explains our finding of D N A synthesis reduction in MCF-7 cells upon AS2O3 treatment. 
By analyzing the cell cycle distribution of MCF-7 cells, AS2O3 was shown to alter the 
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cell cycle distribution. It is obvious that cell populations in Gi phase increased with 
the decrease of cell population in S phase and G2/M phase. In other words, 1 jiM and 
2 |iM AS2O3 induced cell cycle arrest in MCF-7 cells at Gi phase by blocking cells 
progress to S phase and then G2/M phase. The change in cell cycle distribution was 
dependent in dose and time incubation (Fig 6.8 and Fig 6.10). 
From our studies of p53 protein expression, the cell cycle arrest at Gi phase may 
be attribute to the upregulation of p53 protein expression. The upregulation was 
observed within 48 hours treatment (50% upregulation) and was further enhanced for 
72 hours treatment (90 % upregulation) (Fig 6.15). In addition to tumor suppressor 
protein, p53 acts as transcription factor to regulate target genes expressions involving 
in cell cycle regulation (Kem et al., 1991; Levine, 1997 and Zhao et al., 2000). Upon 
upregulation of p53 protein, protein expression is activated (el-Deiry et al., 
1994). p2ieipi induced will then bind directly to cyclin/Cdk complexes including 
cyclin D/Cdk4/6 and cyclin E /Cdk2. These complexes promote cell cycle progression 
from Gi phase to S phase by phosphorylating pRb corporately (Harper et al., 1993). 
As a consequence, downregulation or inhibition of both cyclin/cdk complexes will 
lead to accumulation of cells in Gi phase. So, AS2O3 may increase p53 protein level 
which in turn regulates cell cycle regulatory proteins and ultimately induces cell cycle 
arrest and reduce cell proliferation of MCF-7 cells. Studies of the effects of AS2O3 on 
cell cycle regulatory proteins will enhance the understanding of the mechanisms 
induced by AS2O3 in cell cycle regulation of MCF-7 cells. 
Taken together, 2 [iM AS2O3 treatment induced anti-tumor effects on MCF-7 cells 
through the induction of apoptosis and inhibition of cell proliferation. Our results 
Page 183 
CHAPTER 1 
suggest that the upregulation of p53 protein and disruption of mitochondrial 
membrane potential together with downregulation of apoptosis negative regulator, 
bcl-2 protein, elicits a mitochondrial mediated apoptosis which ultimately resulted in 
the hallmark features of apoptosis, D N A fragmentation and PS extemalization. 
Meanwhile, the upregulation of p53 prevents cell entry to S phase and induces cell 
cycle arrest at Gi phase as observed in cell cycle distribution analysis. By then, D N A 
synthesis is downregulated and cell proliferation was suppressed (Fig 8.1). 
Further studies are prompted. As AS2O3 seems to induce mitochondria mediated 
apoptosis, how does it bypass the signal transduction by caspase 3 downstream 
mitochondria? This suggests that there may be other pathways being activated to 
trigger apoptosis. 
Also, p53 elevation mediates both apoptosis induction and Gi cell cycle arrest. It 
is known that p53 overexpression is induced by D N A damage caused by UV, ionizing 
chemicals etc (Zhan et al., 1996). So, how does AS2O3 induce D N A damage? So far, 
there is only one study demonstrating that AS2O3 induced D N A methylation of p53 
gene promotor region in lung cancer cells. Whether AS2O3 initiates p53 gene 
transcription through D N A methylation in MCF-7 cells awaits further studies (Mass 
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Fig 8.1 Proposed mechanism of apoptosis induced by AS2O3 in MCF-7 cells. 
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8 . 4 G r o w t h I n h i b i t o r y E f f e c t s o f AS2O3 o n E s t r o g e n s S t i m u l a t e d 
M C F - 7 C e l l s 
It has been widely studied that estrogens exposure is a prominent risk factor of 
breast cancer. And estrogens' stimulatory effects can potentiate the growth of breast 
tumor cells (Henderson and Bernstein, 1988). In an attempt to treat breast cancer, 
estrogens withdrawal is one of the strategies. In fact, anti-hormone therapy basing on 
the principle of estrogens withdrawal is a promising treatment in breast cancer patients. 
To see whether AS2O3 is able to block estrogens stimulated cell growth in MCF-7 cells, 
the capability of AS2O3 in estrogens withdrawal was assessed. It will potentiate its 
effect in combating against breast cancer cells. 
In all the experiments, culture conditions in the absence of estrogens were 
maintained by using phenol red free culture medium supplemented with dextran 
coated charcoal fetal calf serum. Phenol red is a weak estrogensic substance that 
showed growth stimulatory effect on MCF-7 cells, which will mask the stimulatory 
effect of exogenous estrogens on MCF-7 cells (Berthois et al., 1986). Dextran coated 
charcoal absorbs endogenous hormones in the culture medium. Thereby, the effect of 
estrogens withdrawal of AS2O3 can be truly reflected by comparing to treatment with 
exogenous estrogens. 
Prior to the study, the growth stimulatory effect of estrogens was assessed in 
which lOnM 17(3 estradiol was found to be most dramatic in cell growth stimulation. 
Different concentrations of 17(3 estradiol has been used in the studies of ER regulated 
pathways or as model for anti-estrogenicity. The range of concentrations is within 
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O.lnM to lOOnM. Concentrations higher than this range will induce toxic effects. 
Here, we observed that InM 17(3 estradiol stimulated cell growth and maximum 
stimulation was achieved in concentration of lOnM. So, lOnM 17p estradiol was used 
in the following experiments as a positive control (Fig 4.1). 
With respect to the untreated control, the % survival of MCF-7 cells was reduced 
from 160% in lOnM 17(3 estradiol treatment alone to 50 % in co-treatment of 2[IM 
AS2O3 together with lOnM 17p estradiol (Fig 4.2). The viable cell number was also 
reduced upon co-treatment of AS2O3 and 17(3 estradiol (Fig 4.3). In addition, AS2O3 
was also found to suppress the cell proliferation stimulation of estradiol on MCF-7 
cells (Fig 4.4). 
MDA-MB-231 cell line is an estrogens independent cell line that does not depend 
on estrogens for growth and survival. It is estrogen receptor negative. AS2O3 in 
concentrations below 2|aM were also shown to suppress the survival of MDA-MB-231 
over 72 hours exposure. However, the 50% cell inhibition was achieved upon longer 
time treatment than those in MCF-7 cells (Fig 4.5). The lower sensitivity of 
MDA-MB-231 cells to AS2O3 suggested the association of estrogens receptor status 
with growth inhibitory potency. Together with the fact that estrogen receptors mediate 
estrogens' survival stimulatory actions in MCF-7 cells, ER may thus be mediators of 
AS2O3 induced estrogens withdrawal effect on breast cancer cells. For this reason, 
further studies were conducted to elucidate AsiOs's regulation on ER mediated action 
mechanisms. Moreover, AS2O3 elicited anti-tumor effects on MDA-MB-231 cells also 
suggested the involvement of other action mechanisms and signaling pathways 
independent or in coordinate with estrogens receptor mediated signaling pathways. 
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8.4.1 Regulation of Estrogen Receptor a (ERa) Signaling Pathway in 
MCF-7 cells upon AS2O3 Treatment 
The role of ERp plays in mediating breast cancer cells proliferation and survival 
remains unclear. Here, we only focus on ERa to elucidate estrogen withdrawal 
mechanisms induced by AS2O3 in inhibiting breast cancer cells survival. 
Anti-estrogens such as tamoxifen elicits estrogens withdrawal effect by mainly 
competitive binding to the hormone binding domain of ERa and subsequent alteration 
of conformations necessary for recruitment of transcription coactivators to 
transcription activation function 2 (AF2). Our study of the competitive binding ability 
of AS2O3 on MCF-7 cells indicated that AS2O3 did not compete with 17p estradiol for 
ER binding (Fig 7.2). The specific ERa binding requires hydrogen bonds formation 
between an aromatic ring in the ligands and residues in the domain and a water 
molecule. The remaining residues in the binding cavity interact with a variety of 
different hydrophobic groups of ligands (Brzozowski et al., 1997 and Pike et al” 2001). 
In view of the structure of AS2O3, the metal elements, arsenic and oxygen, are arranged 
in polar ring structure. It is believed that the incapability of AS2O3 in binding to ERa 
ligand binding site is attributed to its non-hydrophobic structure. 
By RT-PCR and western blot analysis, both ERa gene transcription and protein 
expression levels were downregulated upon lOnM 17(3 estradiol treatment (Fig 7.3 and 
Fig 7.4). Our results are consistent to other studies in which various concentrations of 
17P estradiol were used (Saceda et al., 1988; Read et al” 1989; Ree et al, 1989; 
Berthois et aL, 1990 and Aland et al., 1999). Although ER protein level was 
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downregulated but the remaining ERa protein can still mediate estrogens stimulatory 
cell growth. 
Some reports have indicated the association of ERa R N A level and protein level 
after 17p estradiol and other antiestrogen treatments (Ree et al； 1989; Saceda et al., 
1989 and Santagati et al., 1997). ERa protein degradation was reported to be 
dependent on estrogens induced proteasome mediated proteolysis instead of R N A 
transcription (Alarid et al., 1999). Here, we demonstrated the downregulation of ERa 
R N A level followed by the downregulation of ERa protein level over 48 hours 
treatment of AS2O3. The mechanism remains elusive but it is sure that upon 2[IM 
AS2O3 treatment together with lOnM 17p estradiol, both ER protein level and R N A 
level were further downregulated as compared with treatment of 17(3 estradiol alone 
(Fig 7.3 and Fig 7.4). The result might be responsible for the reduced estrogens 
stimulatory effect on MCF-7 cells by reducing the number of ERa available for 17p 
estradiol binding and subsequent activation of ERa signaling pathway. Yet, further 
studies are required for elucidation of mechanisms mediating downregulation of ER 
protein expression. 
After binding to ERa, estrogens-ERa complex will translocate to the target D N A 
binding site called estrogens responsive element (ERE) in the promoter region of 
target gene for gene transcription activation (Klinge, 2000). Here, we showed the 
suppressing effect of AS2O3 on lOnM 17p estradiol stimulated transcription activation 
by using luciferase reporter system containing ERE element. Upon lOnM 17p 
estradiol treatment, the activation was dramatically enhanced indicating lOnM 17p 
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estradiol's action on MCF-7 cells was mediated by estrogens-ERa complex binding to 
D N A and stimulation of target gene transcription. When treated with 2|aM AS2O3 
simultaneously with lOnM 17p estradiol, the transcription activation was not 
enhanced. Instead, it was suppressed by 2 folds and 5 folds over 48 and 72 hours 
treatment as compared to that of lOnM IVp estradiol treatment alone (Fig 7.5). Thus, 
AS2O3 at 2|iM suppressed 17p estradiol induced transcription of ERE bearing target 
genes. 
Now, we know that AS2O3 alters the ERa signaling pathway induced by 17p 
estradiol. Then how does the regulation of 17p estradiol activated ERa signaling 
results in suppression of 17p estradiol stimulated cell growth and even elicits a growth 
inhibition on MCF-7 cells? W e now look at the change in estrogens regulated gene 
expression. 
In the present study, c-myc protein expression was studied, c-myc is an oncogene 
responsible for cell growth (Kaczmarek et al., 1985; Escot et al., 1986 and Dang, 
1999). Previous studies had reported that c-myc expression was elevated in estrogens 
treated cells (Dubik et al； 1987 and Dubik et al., 1988). Moreover, downregulation of 
c-myc expression was sufficient to block 17(3 estradiol stimulated cell growth (Shiu et 
al., 1993). This result was also observed in our study as c-myc protein expression was 
enhanced by lOnM 17p estradiol after 48 hours treatment. At this time treatment, 
dramatic increase in % survival of MCF-7 cells upon 10 nM 17p estradiol treatment 
over 48 hours was observed (Fig 7.6). So, c-myc was responsible for the growth 
stimulation of MCF-7 cells as in previous study demonstrated. Upon exposure to 2\IM 
AS2O3 with lOnM 17p estradiol, the expression level of c-myc was reduced as 
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compared to that stimulated by lOnM 17p estradiol (Fig 7.6). From our study, survival 
of MCF-7 cells under same condition was reduced to 70% of control. Longer 
incubation to 72 hours, AS2O3 suppressed cell survival to 48% of control (Fig 4.2). So, 
it is possible that the blocking of 17|3 estradiol stimulated cell growth is associated 
with downregulation of c-myc protein expression. As the promoter region upstream of 
c-myc gene contains half ERE, the downregulation of c-myc protein expression may 
be attributed to the inhibition of ERa transcription activation. 
The growth inhibition induced by AS2O3 in MCF-7 cells was further explored by 
studying the effects of AS2O3 on estrogens regulated cell cycle. Similar to other 
studies, 17p estradiol stimulated cell growth by accelerating Gi-S phase progression 
and recruiting cells from Go phase to enter cell cycle (Sutherland et al； 1983). Here, 
we showed that the cell populations after lOnM 17p estradiol treatment increased in S 
phase and decreased in Gi phase, i.e. the stimulatory cell cycle progression on MCF-7 
cells (Fig 7.7). When co-treated with 2|LIM AS2O3 and 17p estradiol, the cell 
population accumulated in Gi phase, indicating that 2\\M AS2O3 opposed 17p estradiol 
induced cell cycle progression to S phase in MCF-7 cells (Table 7.1 and Table 7.2). 
The opposition may be due to the regulation of cell cycle proteins in Gi phase and Gi/S 
phase such as downregulation of cyclin D1 R N A and protein expression, as 
upregulation of cyclin D1 levels were shown to be responsible for 17p estradiol 
stimulated cell cycle progression (Watts et cd., 1994; Foster and Wimalasena et al., 
1996; Prall et al., 1997 and Charpentier et al., 2000). By cDNA microarray analysis, 
cyclin D1 gene was found to be regulated by estrogens with ERE sequence in the 
promote regions (Gruvberger et al., 2001). So, AS2O3 induced cell growth inhibition 
on MCF-7 cells by Gi phase arrest in MCF-7 cells and this may be related to cyclin Dl, 
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that awaits for further studies. 
Taken together, upon treatment with 2jLiM AS2O3, the transcription activity of 
17(3 estradiol-ERa complex was markedly reduced. The reduction of transcription 
activation may be attributed to the downregulation of ERa R N A transcription and 
protein expression. However, it was independent of competitive binding to ERa. The 
inhibition of 17p estradiol-ERa complex binding to D N A results in the reduced 
transcription of estrogens target gene, c-myc, which is responsible for estrogens 
stimulated cell cycle progression. The ultimate Gi phase arrest and prevention of cell 
cycle progression to S phase and G2/M phase led to the inhibition of estrogens 
stimulated cell growth on MCF-7 cells. Thereby, AS2O3 is capable of blocking MCF-7 
cells from estrogen's growth stimulation through the regulation of ERa mediated 
signaling pathway and ultimately cell cycle progression of MCF-7 cells (Fig 8.2). 
Studies of ligands induced conformational change on ERa binding have showed 
that ERa is phosphorylated on tyrosine residue upon estrogens treatment (Migliaccio 
et al., 1989). The phosphorylation enhances the binding of ERa-ligand complex to 
D N A sequence and modulates ERa transcription activity (Denton et aL, 1992; Le 
Goff et al., 1994 and Tzeng and Klinge, 1996). Studies have revealed that the precise 
D N A binding and gene transcription activation requires recruitment of coactivators at 
ligand specific peptide binding surfaces of ERa (Paige et al., 1999). In view of 
suppression of 17(3 estradiol enhanced ERa transcription by AS2O3 without any 
alteration of 17(3 estradiol binding to ERa, AS2O3 may inactivate the ERa signaling 
after 17p estradiol-ERa complex formation. This may be possible by prevention of 
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phoiphorylation through the functional inhibition of protein kinase A and/ protein 
kinase C. Studies have emphasized their synergistic transcription activation in breast 
cancer cell lines including MCF-7 cells (Katzenellenbogen and Norman, 1990 and 
Cho and Katzenellenbogen, 1993). Meanwhile, AS2O3 may alter the assemble of 
transcription activator responsible for 17p estradiol-ERa complex activation on target 
gene transcription due to the ability of AS2O3 in modulating activities of sulfhydryl 
rich proteins such as protein tyrosine phosphorylations (Cavigelli et al., 1996). 
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8 . 5 C r o s s T a l k o f E R a S i g n a l i n g P a t h w a y a n d A p o p t o s i s i n 
M e d i a t i n g t h e A n t i - T u m o r E f f e c t s o f AS2O3 o n M C F - 7 C e l l s 
Previous sections have demonstrated that AS2O3 in concentrations below 2 |iM 
elicited anti-tumor effects on MCF-7 cells by inducing cytotoxicity and growth 
inhibition. Cytotoxicity was triggered by induction of mitochondrial mediated 
apoptosis while growth inhibition was elicited by cell cycle regulation through ERa 
mediated protooncogene expression. The initiations of both pathways are regulated by 
activation of certain protein expressions. These factors may interplay in these 
mechanisms and ultimately induce the anti-tumor effect on MCF-7 cells. It leads to 
the hypothesis that AS2O3 probably induces apoptosis and estrogens withdrawal 
simultaneously in combating against MCF-7 cells. 
In the study of apoptosis induction by AS2O3, bcl-2 protein expression was 
downregulated upon AS2O3 treatment in a time dependent manner. Recently, bcl-2 
was shown to be overexpressed in tumors including breast cancer cells. Moreover, the 
sensitivity of breast cancer towards chemotherapeutic treatment was related to bcl-2 
expression (Piche et al., 1998). Here, we have demonstrated that the downregulation 
of bcl-2 protein expression upon 48 hours treatment with 2 |iM AS2O3 (Fig 6.14). As 
previous study showed that estrogens upregulated of bcl-2 gene transcription in 
MCF-7 cells and also promoted the drug resistance of MCF-7 cells towards 
adriamycin (Teixeira et al., 1995), AS2O3 induced blocking of estrogens stimulatory 
effect on MCF-7 cells may be mediated through the downregulation of bcl-2 
expression which ultimately induced growth inhibitory effect on estrogens stimulated 
MCF-7 cells. In fact, bcl-2 was found to be activated by 17(3 estradiol independent of 
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ERa complex binding to D N A sequence (Dong et al., 1999). In addition to 
eliminating anti-apoptotic effect, AS2O3 may suppress estrogen's growth stimulation 
on MCF-7 cells through reduction of bcl-2 expression. 
The presence of regulatory factors on both pathways enables AS2O3 to exert both 
effects. Thereby, AS2O3 can continue to combat against breast cancer cells at estrogens 
dependent stage to estrogens independent stage through the contribution of different 
mechanisms on different stages. 
It has been discussed that p53 initiates mitochondrial mediated apoptosis. p53 is 
a transcription factor which activates various downstream target genes such as 
p21/waf involving in cell growth and division (Levine, 1997; Zhao et al” 2000 and W u 
and Deng, 2002). Here we showed the upregulation of p53 expression after 2jaM 
AS2O3 treatment over 48 hours (Fig 6 .15). Over the same time treatment, 2|LIM AS2O3 
suppressed the growth stimulation of 17|3 estradiol on MCF-7 cells through cell cycle 
regulation mediated by repression of ER transcription activity (Fig 4.2, Fig 4.3 and Fig 
4.4). As p53 is the regulator in cell cycle progression through the regulation of cell 
cycle proteins such as p21/waf (Gartel and Tyner, 1999). Previous findings also 
demonstrated the repression of ERa mediated transcriptional activity by p53 (Yu et al； 
1997 and Liu et al.’ 1999). It is possible that the AS2O3 induced p53 protein 
upregulation may involve in ERa signaling suppression and consequently growth 
inhibition of MCF-7 cells. 
So, it is possible that AS2O3 elevated p53 gene expression which in turn initiated 
mitochondrial mediated apoptosis by activating the transcription of bax and 
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attenuating the suppression of ERa signaling pathway to inhibit estrogens stimulated 
gene transcriptions involving in cell proliferation. Thereby, both apoptosis and cell 
proliferation inhibition were triggered to execute the anti-tumor effects of AS2O3 on 
MCF-7 cells. 
As discussed before, AS2O3 was shown to induce cell survival inhibition on both 
MCF-7 cells and MDA-MB-231 cells (Fig 3.1, Fig 4.5). These results prompt to the 
hypothesis of presence of other mechanisms mediating anti-tumor effect on breast 
cancer cells. So, whether the induction of apoptosis exists together with growth 
inhibition or co-existence of both pathway? Here, it is possible that AS2O3 regulates 
apoptosis and ERa signaling pathway together. Although we have not studied the 
direct relationship between apoptotic regulatory proteins and either action 
mechanisms, it is speculated that AS2O3 triggered both mechanisms in inducing 
anti-tumor effects on MCF-7 cells. 
8.6 T o x i c i t y o f AS2O3 t o w a r d s N o r m a l T i s s u e s 
For many years, AS2O3 has been shown to induce paradoxical properties. Acute 
exposure of high dose of AS2O3 environmentally or occupationally induces toxic 
effects resulting in a numerous human diseases such as peripheral vascular disorders, 
liver injury and even cancers in lung and other organs. Meanwhile, low dose of AS2O3 
in clinical managing prescription is effective in treating syphilis, leukemia and other 
solid tumors. The mechanisms underlying this biphasic property are remaining 
unresolved. Nevertheless, low dose AS2O3 was shown to be non-toxic on normal 
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tissues both clinically, in vitro and in vivo studies, in the development of 
chemotherapeutic agents, toxicity to normal cells is a great concern. The potential of 
clinical application will be lower if the agents are cytotoxic to both tumor and normal 
cells. Because other secondary diseases or cancers will be raised after treatment of 
primary cancers. The process will recycle without endless. This is also a reason why 
continuous drug development is urged as accumulating commonly prescribed 
chemotherapeutic agents such as doxorubicin are found to be toxic to normal organs in 
the body. Therefore, assessment of toxicity to normal tissues is a must for all the 
chemotherapeutic drugs. 
In this study, 2|aM AS2O3 was shown to induce anti-tumor effects on MCF-7 cells 
through initiations of apoptosis and inhibition of cell proliferation. Moreover, AS2O3 
at this concentration did not show any cell survival inhibitory effects on human 
fibroblasts, Hs 68 cells (Fig 5.1). Hs 68 is a fibroblast cell line. Although it is not 
epithelial cell line, the unaffected cell survival of this normal cell line after AS2O3 
treatment leads to the speculation of unaffected cell survival in other cell lines by 
AS2O3. In addition, we have assessed the effect of AS2O3 on normal tissues. After 
successive intravenous administration of 5mg/kg AS2O3 to nude mice, no significant 
elevation of enzyme activity was detected. These tissue specific enzymes locate in 
large proportion in liver and heart. Elevation of alanine transaminase and aspartate 
transaminase activities reflects liver damage while elevation of creatine kinase and 
lactate dehydrogenase activities indicates the damage of heart tissue (Fig 5.2，Fig 5.3, 
Fig 5.4, and Fig 5.5). Our study demonstrated the non-cytotoxic effect of AS2O3 
towards both organs at a dosage higher than that in in vitro studies, i.e. 2 fj,M. So, in 
vivo study provides a toxicity assessment of AS2O3. For clinical trial, AS2O3 was 
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shown to induce clinically manageable symptoms in APL patients, which later 
approved as chemotherapeutic agent for treating APL patients, by FDA. In regards to 
clinical applications of AS2O3 in treating breast cancer cells, clinical trials are 








9 . 1 C o n c l u s i o n s 
As a whole, AS2O3 was shown to induce anti-tumor effect on breast cancer 
adenocarcinoma cell line, MCF-7 cell line. The effect was triggered by the induction 
of cell death and growth inhibition on MCF-7 cells. Evidence presented in this study 
suggests that 2|iM AS2O3 treatment induce mitochondrial mediated apoptosis and cell 
cycle arrest at Gi phase. 
Moreover, AS2O3 is capable of suppressing estrogens stimulated cell growth in 
MCF-7 cells. It is mediated through negative regulation of estrogens activated ERa 
signaling pathway. Consequently, estrogens stimulated cell cycle progression is 
suppressed. 
Comparing with tamoxifen, the most common prescribed therapeutic drugs for 
breast cancer patients, AS2O3 is more potent in growth inhibition of MCF-7 cells. 
Together with AsiOs's anti-tumor effect in a more aggressive breast cancer cells, 
MDA-MB-231 cells, it is therefore speculated that AS2O3 can provide another 
promising alternative for the prevention and treatment of breast cancers at early stage 
and advanced stage. 
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9.2 F u t u r e P e r s p e c t i v e s 
Although our studies have provided evidences of the anti-tumor properties of 
AS2O3 on MCF-7 cells, certain aspects are remained elusive. 
Regarding to apoptosis, the pathway downstream mitochondria is still elusive. It 
is predicted that AS2O3 induces apoptosis may be independent of caspase 3 and free 
radicals production. In view of AS2O3 ‘s effects on other cancer cell lines, these two 
mediators are usually involved. It will be of great significance to elucidate other 
apoptotic pathways involved in AsiOs's anti-tumor effects and anti-tumor mechanism 
of MCF-7 cells. 
Moreover, there are other pathways mediating the estrogens's action on breast 
cancers such as ERa independent pathways, ERE independent pathways. Growing 
interest is now focused on the cross talk between ERa signaling pathway and growth 
factor signaling pathways such as EGF. To fully explore the action mechanisms of 
AS2O3 in suppressing estrogens' growth stimulation on breast cancer cells, these topics 
also await further studies. 
Last but not the least, we have demonstrated that AS2O3 regulates certain protein 
expressions in inducing apoptosis and growth inhibition. Cell survival is the balance 
between cell death and cell proliferation, it is sure that AS2O3 may also regulate other 





Adams,J.M. & Cory,S. (1998) The Bcl-2 protein family: arbiters of cell survival. 
Science, 281, 1322-1326. 
Akao,Y., Mizoguchi,H., Kojima,S., Naoe,T., Ohishi,N. & Yagi,K. (1998) Arsenic 
induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases 
and down-regulation of Bcl-2 protein. Br. J.Haematol., 102, 1055-1060. 
Alarid, E.T., Bakopoulos,N & Solodin,N. (1999) Proteasone-mediated proteolysis of 
estrogen receptor: a novel component in autologous down-regulation. Mol 
Endo., 13’ 1522-1534. 
Altucci, L. & Gronemeyer, H. (2001) Nuclear receptors in cell life and death. Trends in 
Endo & Meta., 12, 460-468. 
Antman,K.H. (2001) Introduction: the history of arsenic trioxide in cancer therapy. 
Oncologist., 6 Suppl 2, 1-2. 
Aronson,S.M. (1994) Arsenic and old myths. R.I.Med., 77, 233-234. 
Ausbuel,F.M., et a/ (1990) Current protocols in molecular biology. Vol 2. Greene 
Publishing Assoc. and Wiley-Interscience, New York, p.A.1.5. 
Avvisati,G., Mele,A., Stazi,M.A., Vegna,]VLL., Pasquini,P. & Mandelli,F. (1991) 
Epidemiology of acute promyelocytic leukemia in Italy. APL Collaborating 
Group. Ann.Oncol.，2, 405-408. 
Barchowsky,A., Roussel,R.R., Klei,L.R., James,P.E., Ganju,N., Smith,K.R. & 
Dudek,EJ. (1999) Low levels of arsenic trioxide stimulate proliferative signals 
in primary vascular cells without activating stress effector pathways. 
Toxicol.Appl.Pharmacol., 159, 65-75. 
Bennett,J.M., Catovsky,D.，Daniel,M.T., Flandrin,G., Galton,D.A., Gralnick,H.R. & 
Sultan,C. (1976) Proposals for the classification of the acute leukaemias. French-
American-British (FAB) co-operative group. Br.J.Haematol., 33, 451-458. 
Bernard,!., Weil,M., Boiron,M., Jacquillat,C., Flandrin,G. & Gemon,M.F. (1973) Acute 
promyelocytic leukemia: results of treatment by daunombicin. Blood, 41, 
489-496. 
Berthois,Y., Katzenellenbogen,J.A. & K:atzeiidleiibogeii,:B.S. (1986) Phenol red in 
tissue culture media is a weak estrogen: implications concerning the study of 
estrogen-responsive cells in culture. Proc.Natl.Acad.Sci.U.S.A, 83, 2496-2500. 
Page 203 
BJKEEJREIS.CES.  
Berthoix,Y., Dong,X.F., Roux-Dossetto,M. & Martin,P.M. (1990) Expression of estrogen 
receptor and its messenger ribonucleic acid in the MCF-7 cell line: 
multiparametric analysis of its processing and regulation by estrogen. Mol Cell 
Endocrinol, 74,11-20. 
Bertrand,R., Sarang,M, Jenkin,J, Kerrigan,D. & Pommier，Y. (1991) Differential 
induction of secondary D N A fragmentation by topoisomerase II inhibitors in 
human tumor cell lines with amplified c-myc expression. Cancer Res., 51, 
6280-6285. 
Bevan,C. & Parker,M. (1999) The role of coactivators in steroid hormone action. 
‘Exp.Cell Res., 253, 349-356. 
Bonetti,A., Zaninelli,M, Leone,R.，Cetto,aL., Pelosi,G., Biolo,S., Menghi,A., 
Manfrin，E.，Bonetti,F. & Piubello,Q. (1998) bcl-2 but not p53 expression is 
associated with resistance to chemotherapy in advanced breast cancer. 
Clin.Cancer Res., 4, 2331-2336. 
Borrow,J.，Goddard,A.D., Sheer,D. & Solomon,E. (1990) Molecular analysis of acute 
promyelocytic leukemia breakpoint cluster region on chromosome 17. Science, 
249, 1577-1580. 
Boyer，M., Poujol,N., Margeat,E. & Royer,C.A. (2000) Quantitative characterization of 
the interaction between purified human estrogen receptor aand D N A using 
fluorescence anisotropy. Nucl. Acids. Res., 28, 2494-2502. 
Braimsberg，H.A., Coldham,N.G. & Wong,W. (1986) Hormonal therapies for breast 
cancer: can progestogens stimulate growth? Cancer Lett., 30, 213-218. 
Bmiiner,N., Bronzert,D., Vindelov,:LL.， Rygaard,K., Spang-Thomsen,M. & 
Lippman,M.E. (1989) Effect on growth and cell cycle kinetics of estradiol and 
tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. 
Cancer Res., 49，1515-1520. 
Brzozowski,A.M., Pike,AC., Dauter,Z., Hubbard,R.E., Bonn,!., Engstrom,0., 
Ohman,L., Greene,G.L., Gustafsson,J.A. & Carlquist,M. (1997) Molecular basis 
of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-758. 
Cai,X., Shen,Y 丄.，Zhu,Q., Jia,P.M., Yu,Y., Zhou,L., Huang,Y., Zhang,J.W., 
Xiong,S.M., Chen,S.J., Wang,Z.Y., Chen,Z. & aien,G.Q. (2000) Arsenic 
trioxide-induced apoptosis and differentiation are associated respectively with 
mitochondrial transmembrane potential collapse and retinoic acid signaling 
pathways in acute promyelocytic leukemia. Leukemia, 14, 262-270. 
Castaigne,S., Chomienne,C., Daniel,M.T., Ballerini,P., Berger,R., Fenaux,P. & Degos,L. 
(1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic 
leukemia. 1. Clinical results. Blood, 76, 1704-1709. 
Page 204 
HjKEEJREiN.CES.  
Cavigelli,M.，Li,W.W” Lin,A” Su,B” Yoshioka,K. & Karin,M. (1996) The tumor 
promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. 
E M B O J., 15,6269-6279. 
Charpentier,A.H., Bednarek,A.K., Daniel,R.L., Hawkins,K.A., Laflin,K.J” Gaddis,S., 
MacLeod,M.C. & Aldaz,C.M. (2000) Effects of estrogen on global gene 
expression: identification of novel targets of estrogen action. Cancer Res., 60, 
5977-5983. 
Chen,G.Q., Shi,X.G., Tang,W., Xiong,S.M., Zhu,J., Cai,X.，Han,Z.G., Ni,J.H., Shi,G.Y., 
Jia,P.M., Liu,M.M., He,K.L., Niu,C., Ma,J., Zhang,P., Zhang,T.D., Paul,P., 
Naoe,T., Kitamura,K., Miller,W., Waxman,S., Wang,Z.Y., de The,H., Chen,S.J. 
& Chen,Z. (1997) Use of arsenic trioxide (AS2O3) in the treatment of acute 
promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on 
APL cells. Blood, 89, 3345-3353. 
Chen,G.Q., Zhu,J., Shi，X.G., Ni,J.H.，Zhong,H.J., Si,G.Y., Jin,XL., Tang,W., Li,X.S., 
Xong,S.M., Shen,Z.X., Sun,G.L, Ma,J., Zhang,P., Zhang,T.D., Gazin,C., 
Naoe,T., Chen,S.J, Wang,Z.Y. & Chen,Z. (1996) In vitro studies on cellular and 
molecular mechanisms of arsenic trioxide (AS2O3) in the treatment of acute 
promyelocytic leukemia: As203 induces NB4 cell apoptosis with 
downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML 
proteins. Blood, 88, 1052-1061. 
Chen,Y.C., Lin-Shiau,S.Y. & Lin,J.K. (1998) Involvement of reactive oxygen species 
and caspase 3 activation in arsenite-induced apoptosis. J.Cell Physiol, 177, 
324-333. 
Chen,Z., Wang,Z.Y. & Chen,S.J. (1997) Acute promyelocytic leukemia: cellular and 
molecular basis of differentiation and apoptosis. Pharmacol.Ther., 76, 141-149. 
Cho,H. & Katzenellenbogen，B.S. (1993) Synergistic activation of estrogen 
receptor-mediated transcription by estradiol and protein kinase activators. 
Mol.EndocrinoL, 7, 441-52. 
Clarke,R.，Leonessa,F.，Welch,J.N. & Skaar,T.C. (2001) Cellular and molecular 
pharmacology of antiestrogen action and resistance. Pharmacol.Rev., 53, 25-71. 
Clarke,R.B., Howell,A., Potten,C.S. & Anderson,E. (1997) Dissociation between steroid 
receptor expression and cell proliferation in the human breast. Cancer Res., 57, 
4987-4991. 
Cohen,M.H., Hirschfeld,S., Flamm,H.S.，Ibrahim, A-, Johnson, J.R., 0’Leary,J.J., 
White,R.M., Williams,G.A. & Pazdur,R. (2001) Drug approval summaries: 
arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. 
Oncologist., 6, 4-11. 
Page 205 
RKKERMCE^S  
Cullen,R., Maguire,T.M., McDermott,E.W, Hill,AD-, 0'Higgins,NJ. & Duffy,M.J. 
(2001) Studies on oestrogen receptor-alpha and -beta m R N A in breast cancer. 
EurJ.Cancer, 37, 1118-1122. 
Curtin,J.F., Donovan,M. & Cotter,T.G. (2002) Regulation and measrurement of 
oxidative stress in apoptosis. J Immunol.Methods, 265，49-72. 
CustodioJ.B.A., Cardoso,C.M.P. & Almeida,L.M. (2002) Thiol protecting agents and 
antioxidants inhibit the mitochondrial permeability transition promoted by 
etoposide: implications in the prevention of ectoposide-induced apoptosis. 
Chemico-Biol.Interactions, 140，169-184. 
Dai,J., Weinberg,R.S., Waxman,S. & Jing，Y. (1999) Malignant cells can be sensitized to 
undergo growth inhibition and apoptosis by arsenic trioxide through modulation 
of the glutathione redox system. Blood, 93, 268-277. 
Danforth,D.N., Jr. & Sgagias,M.K. (1991) Interleukin 1 alpha blocks 
estradiol-stimulated growth and down- regulates the estrogen receptor in MCF-7 
breast cancer cells in vitro. Cancer Res., 51, 1488-1493. 
Dang，C.V. (1999) c-Myc target genes involved in cell growth, apoptosis, and 
metabolism. MoLCell.Biol., 19, 1-11. 
Davis,W. Jr., Ronai,Z. & Tew,K.D. (2001) Cellular thiols and reactive oxygen species in 
drug-induced apoptosis. J Pharmol.Exp.Ther., 296, 1-6. 
de The,H. & Chelbi-Alix,M.K. (2001) APL, a model disease for cancer therapies? 
Oncogene, 20, 7136-7139. 
Degos,L. & Wang,Z.Y. (2001) All trans retinoic acid in acute promyelocytic leukemia. 
Oncogene, 20，7140-7145. 
Deiss,L.P, Galinka,H, Berissi,H, Cohen,O. & Kimchi,A. (1996) Cathepsin D protease 
mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and 
TNF-alpha. E M B O J., 15, 3861-3870. 
Deng,G., Chen,L.C., Schott,D.R., Thor,A., Bhargava,V., Ljimg,B.M., Chew,K. & 
Smith,H.S. (1994) Loss of heterozygosity and p53 gene mutations in breast 
cancer. Cancer Res., 54, 499-505. 
Denton,R.R., Koszewski,N.J. & Notides,A.C. (1992) Estrogen receptor phosphorylation. 
Hormonal dependence and consequence on specific D N A binding. J.Biol.Chem., 
267，7263-7268. 




Dong,L.，Wang,W, Wang，F.，Stoner,M, ReedJ.C., Harigai,M, Samudio,!., 
Kladde,M.P., Vyhlidal,C. & Safe，S. (1999) Mechanisms of transcriptional 
activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. 
J.Biol.Chem., 274, 32099-32107. 
Douer,D., Preston-Martin,S, Chang,E., Nichols,P.W., Watkins,K.J. & Levine,A.M. 
(1996) High frequency of acute promyelocytic leukemia among Latinos with 
acute myeloid leukemia. Blood, 87, 308-313. 
Driscoll，M.D., Sathya,G., Muyan,M.，Klinge,C.M., Hilf,R. & Bambara，R.A. (1998) 
Sequence requirements for estrogen receptor binding to estrogen response 
elements. J.Biol.Chem., 273, 29321-29330. 
DU,Y.H. & Ho,P.C. (2001) Arsenic compounds induce cytotoxicity and apoptosis in 
cisplatin- sensitive and -resistant gynecological cancer cell lines. Cancer 
Chemother.Pharmacol., 47，481-490. 
Dubik,D. & Shiu,R.P. (1988) Transcriptional regulation of c-myc oncogene expression 
by estrogen in hormone-responsive human breast cancer cells. J.Biol.Chem., 263, 
12705-12708. 
Dubik,D. & Shiu,R.P. (1992) Mechanism of estrogen activation of c-myc oncogene 
expression. Oncogene, 7, 1587-1594. 
Dubik,D., Dembinski,T.C. & Shiu,R.P. (1987) Stimulation of c-myc oncogene 
expression associated with estrogen- induced proliferation of human breast 
cancer cells. Cancer Res., 47, 6517-6521. 
Dyck,J.A., Maul,G.G., Miller,W.H., Jr., ChenJ.D., Kakizuka,A- & Evans，R.M. (1994) 
A novel macromolecular structure is a target of the promyelocyte- retinoic acid 
receptor oncoprotein. Cell, 76, 333-343. 
el Deiry,W.S., Harper,J.W., O'Connor,P.M., Velculescu,V.E., Canman,C.E., JackmanJ., 
Pietenpol,J.A., BuiTell,M., Hill,D.E., Wang,Y. & • (1994) WAFl/CIPl is 
induced in p53-mediated GI arrest and apoptosis. Cancer Res., 54, 1169-1174. 
Ellis,P.A., Saccani-Jotti,G., Clarke,R., Johnston, S.R., Anderson,E., Howell,A., 
A'Hem,R., Salter,】.，Detre,S., Nicholson,R., Robertson,；., Smith,I.E. & 
Dowsett,M. (1997) Induction of apoptosis by tamoxifen and ICI 182780 in 
primary breast cancer. Int.J.Cancer, 72, 608-613. 
Escot,C., Theillet,C., Lidereau，R., Spyratos,F., Champeme,M.H., Gest’J. & Callahan,R. 
(1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary 
breast carcinomas. Proc. Natl. Acad. Sci. U. S. A, 83, 4834-4838. 
Fabian,C.J., Kimler,B.F., McKittrick,R., Park,C.H., Lin,F., Krishnan,L., Jewell,W.R., 
Osborne,C.K., Martino,S.’ Hutchins,L.F. & . (1994) Recruitment with high 
physiological doses of estradiol preceding chemotherapy: flow cytometric and 
Page 207 
J^EFEREIS.CE.S.  
therapeutic results in women with locally advanced breast cancers--a Southwest 
Oncology Group study. Cancer Res., 54, 5357-5362. 
Fadok’V.A.，Voelker, D.R, Campbell,RA” Cohen,JJ., Bratton.D.L. & Henson,RM. 
(1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes 
triggers specific recognition and removal by macrophages. J Immunol, 148, 
2207-16. 
Femandez-ChecaJC., Garcia-Ruiz,C, Colell,A., Morales,A., Mari，M.，Miranda,M. & 
Ardite,E. (1998) Oxidative stress: role of mitochondria and protection by 
glutathione. Biofactors, 8, 7-11. 
Flora,S.D., Izzotti,A., Agostini,F.D. & Banlanskey,R.M. (2001) Mechanisms of 
N-acetycysteine in the prevention of D N A damage and cancer, with special 
reference to smoking-related end-points. Carcinogenesis, 22, 999-1013. 
Fomari,F.A., Jr., Jarvis,D.W, Grant,S, Orr,M.S., Randolph,J.K., White,F.K. & 
Gewirtz,D.A. (1996) Growth arrest and non-apoptotic cell death associated with 
the suppression of c-myc expression in MCF-7 breast tumor cells following acute 
exposure to doxorubicin. Biochem.PharmacoL, 51, 931-940. 
Fomari,F.A, Jr., Jarvis,D.W, Grant,S, Orr,M.S, Randolph,!.K, White,F.K. & 
Gewirtz,D.A. (1996) Growth arrest and non-apoptotic cell death associated with 
the suppression of c-myc expression in MCF-7 breast tumor cells following acute 
exposure to doxorubicin. Biochem. Pharmacol., 51, 931-940. 
Foster, J.S. &Wimalasena, J. (1996) Estrogen regulates activity of cyclin-dependent 
kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol 
Endocrinol., 10, 488-498. 
Gartel,A.L. & Tyner,A丄.(1999) Transcriptional regulation of the p21(WAFl/CIPl) 
gene. Exp.Cell Res., 246, 280-289. 
Godfrey,S.M., McAuliffe,C.A., Mackie,A.G. and Pritchard,R.G. (1998) Inorganic 
Derivatives of the Elements In: Chemistry of Arsenic, Antimony and Bismuth, 
London. New York: Blackie Academic and Professional. 
GoochJ.L. & Yee,D. (1999) Strain-specific differences in formation of apoptotic D N A 
ladders in MCF-7 breast cancer cells. Cancer Lett., 144, 31-37. 
Gorby,M.S. (1994) Arsenic in human medicine. In: Nriagu,J.O. eds. Arseinc in the 
Environment Part II: Human Health and Ecosystem Effects. John Wiley & Sons, 
Inc. pp. 1-16. 
Gottardis，M.M. & Jordan,V.C. (1988) Development of tamoxifen-stimulated growth of 
MCF-7 tumors in athymic mice after long-term antiestrogen administration. 
Cancer Res., 48, 5183-5187. 
Page 208 
EEI^ EREJ^ CEJS  
Graeber,T.G., Osmanian,C., Jacks,!., Housman,D.E.，Koch，CJ., Lowe,S.W. & 
Giaccia,A.J. (1996) Hypoxia-mediated selection of cells with diminished 
apoptotic potential in solid tumours. Nature, 379, 88-91. 
Green,D.R. & Reed,J.C. (1998) Mitochondria and apoptosis. Science, 281, 1309-1312. 
Grignani,F., Fermcci,P.F.，Testa,U., Talamo，G., Fagioli,M., Alcalay,M.，Mencarelli,A., 
Grignani,F., Peschle,C. & NicolettiJ. (1993) The acute promyelocytic 
leukemia-specific PML-RAR alpha fiision protein inhibits differentiation and 
promotes survival of myeloid precursor cells. Cell, 74，423-431. 
Gruvberger,S., Ringner,M., Chen，Y.，Panavally,S., Saal,L.H., Borg,A., Femo,M., 
Peterson,C. & Meltzer,P.S. (2001) Estrogen receptor status in breast cancer is 
associated with remarkably distinct gene expression patterns. Cancer Res., 61, 
5979-5984. 
Guo,W., Zhu,J. & Wang,H. (1999) [Effects of all-trans retinoic acid, arsenic trioxide and 
daunombicin on tissue factor expression in NB4 cells]. Zhonghua 
Xue.Ye.Xue.Za Zhi., 20, 453-455. 
Hall,J.M., Couse,J.F. & Korach,K.S. (2001) The multifaceted mechanisms of estradiol 
and estrogen receptor signaling. J. Biol. Chem., 276, 36869-36872. 
Harper,J.W., Adami,G.R., Wei,N., Keyomarsi,K. & Elledge,S.J. (1993) The p21 
Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin- dependent 
kinases. Cell, 75,805-816. 
Henderson,B.E., Ross,R. & Bernstein,L. (1988) Estrogens as a cause of human cancer: 
the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res., 48, 
246-253. 
Henderson,B.E., Ross,R.K.，Pike,M.C. & CasagrandeJ.T. (1982) Endogenous hormones 
as a major factor in human cancer. Cancer Res., 42, 3232-3239. 
Hengartner,M.O. (2000) The biochemistry of apoptosis. Nature, 407, 770-776. 
Hockenbery,D.M., 01tvai,Z.N., Yin,X.M., Milliman,C.L. & Korsmeyer,S.J. (1993) 
Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75, 
241-251. 
Hollstein,M., Sidransky,D., Vogelstein,B. & Harris,C.C. (1991) p53 mutations in human 
cancers. Science, 253, 49-53. 
Huang,M.E., Ye,Y.C.’ Chen,S.R., ChaiJ.R., LuJ.X.，Zhoa,L., Gu,L.J. & Wang,Z.Y. 
(1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic 
leukemia. Blood, 72, 567-572. 
Page 209 
MEEREJS.CEJS  
Huang,X. (1999) Regulation of arsenic trioxide-inducing apoptosis. Zhonghua 
Xue.Ye.Xue.Za Zhi., 20, 258-260. 
Huseby,R.A, Maloney,T.M. & McGrath,C.M. (1984) Evidence for a direct 
growth-stimulating effect of estradiol on human MCF-7 cells in vivo. Cancer 
Res., 44, 2654-2659. 
Iacobelli,S., Scambia,G., Natoli，V., Natoli,C. & Sica,G. (1984) Estrogen stimulates cell 
proliferation and the increase of a 52,000 dalton glycoprotein in human breast 
cancer cells. J.Steroid Biochem.，20, 747-752. 
Ioakim-Liossi,A., Karakitsos，P., Markopoulos,C., Aroni,K., Athanassiadou,P., 
Delivelioti,K., Athanassiades,P. & Vaiopoulos,G. (2001) p53 protein expression 
and oestrogen and progesterone receptor status in invasive ductal breast 
carcinomas. Cytopathology, 12, 197-202. 
Iwama,K., Nakajo,S., Aiuchi,T. & Nakaya,K. (2001) Apoptosis induced by arsenic 
trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of 
ERK and the Ca2+- dependent production of superoxide. Int.J.Cancer, 92, 
518-526. 
Jabara,A.G., Toyne,P.H. & Harcourt,A.G. (1973) Effects of time and duration of 
progesterone administration on mammary tumours induced by 
7,12-dimethylbenz(a)anthracene in Sprague-Dawley rats. Br.J.Cancer, 27, 63-71. 
Jacobson,M.D. & Raff,M.C. (1995) Programmed cell death and Bcl-2 protection in very 
low oxygen. Nature, 374, 814-816。 
Janicke,R.U., Sprengart,M.L., Wati,M.R. & Porter,A.G. (1998) Caspase-3 is required for 
D N A fragmentation and morphological changes associated with apoptosis. J. 
Biol. Chem, 273, 9357-9360. 
Jiang,X.H., Wong,B.C., Yuen,ST., Jiang,S.H., Cho,C.H., Lai,K.C., Lin,M.C., 
Kung,H.F., Lam,S.K. & amn-Yu，W.B. (2001) Arsenic trioxide induces 
apoptosis in human gastric cancer cells through up-regulation of p53 and 
activation of caspase-3. Int.J.Cancer, 91, 173-179. 
Kaczmarek,L., Hyland,J.K., Watt,R., Rosenberg,M. & Baserga,R. (1985) Microinjected 
c-myc as a competence factor. Science, 228, 1313-1315. 
Kagawa,S., Gu,J., Honda,T., McDonnell,TJ., Swisher,S.G., RothJ.A. & Fang,B. (2001) 
Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear 
fragmentation but not cell death. Clin.Cancer Res., 7, 1474-1480. 
Kam,P.C. & Ferch,N.L (2000) Apoptosis: mechanisms and clinical implications. 
Anaesthesia, 55, 1081-1093. 
Page 210 
•REKERE.N.CES  
Kane,D.J., Sarafian,T.A., Anton,R., Hahn，H., Gralla，E.B., Valentine,!.S., Ord,T. & 
Bredesen，D.E. (1993) Bcl-2 inhibition of neural death: decreased generation of 
reactive oxygen species. Science, 262, 1274-1277. 
Kato,S., Kitamoto，T., Masuhiro,Y. & YanagisawaJ. (1998) Molecular mechanism of a 
cross-talk between estrogen and growth-factor signaling pathways. Oncology, 55 
Suppl 1,5-10. 
Katzenellenbogen,B.S. & Korach,K.S. (1997) A new actor in the estrogen receptor 
drama-enter ER-beta. Endocrinology, 138, 861-862. 
Katzenellenbogen,B.S. & Nonnan，M.J. (1990) Multihormonal regulation of the 
progesterone receptor in MCF-7 human breast cancer cells: interrelationships 
among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology, 
126, 891-898. 
Katzenellenbogen,B.S. (1980) Dynamics of steroid hormone receptor action. 
Annu.Rev.Physiol, 42, 17-35. 
Katzenellenbogen,B.S., Choi,L, Delage-Mourroux,R., Ediger,T.R., Martini,P.G.V., 
Montano,M., Sun,J., Weis,K. and Katzenellenbogen,J.A. (2000) Molecular 
mechanisms of estrogen action: selective ligands and receptor pharmacology. 
J.Steroid Biochem. & Mol.Biol.，74, 279-285. 
Kem,S.E., Kinzler,K.W., Bmskin,A., Jarosz,D., Frideman,P., Prives,C. & Vogelstein,B. 
(1991) Identification of p53 as a sequence-specific DNA-binding protein. 
Science, 252, 1708-1711。 
Kitamura,K., Minami,Y., Yamamoto,K., Akao,Y., Kiyoi,H., Saito,H. & Naoe,T. (2000) 
Involvement of CD9 5-independent caspase 8 activation in arsenic 
trioxide-induced apoptosis. Leukemia, 14, 1743-1750. 
Klinge,C.M. (2000) Estrogen receptor interaction with co-activators and co-repressors. 
Steroids, 65, 227-251. 
Klinge,C.M., Peale,F.V.，Jr., Hilf,R., Bambara,R.A. & Zain,S. (1992) Cooperative 
estrogen receptor interaction with consensus or variant estrogen responsive 
elements in vitro. Cancer Res., 52, 1073-1081. 
Kluck,R.M., Bossy-Wetzel,E., Green,D.R. & Newmeyer,D.D. (1997) The release of 
cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. 
Science, 275, 1132-1136. 
Koken,M.H., Linares-Cruz,G., Quignon,F., Viron,A., Chelbi-Alix,M.K., 
Sobczak-Thepot,J., Juhlin,L., Degos,L., Calvo,F. & de The,H. (1995) The PML 




Koken’M.H.’ Puvion-Dutilleul,F., Guillemin,M.C., Viron，A., Linares-Cruz,G., 
Stuurman,N., de Jong，L.，Szostecki,C.，Calvo,F., Chomienne,C. & . (1994) The 
t(15;17) translocation alters a nuclear body in a retinoic acid- reversible fashion. 
E M B O J., 13, 1073-1083. 
Koopman,G., Reutelingsperger,C.P., Kuijten,G.A.’ Keehnen,R.M., Pals,S.T. & van 
Oers,M.H. (1994) Annexin V for flow cytometric detection of phosphatidylserine 
expression on B cells undergoing apoptosis. Blood, 84, 1415-1420. 
Kotten，T.J., Blajeski,A.L., Meng,X.W.’ Svingen,P.A., Ruchaud,S., Mesner,P.W. Jr., 
Boemer，S.A., Samejiman,K.，Henriquez,N.V., Chilcote,TJ., Lord,J., Salmon,M., 
Eamshaw,W.C. & Kaufmami,S.H. (2002) Lack of correlation between caspase 
activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer 
cells. J Biol.Chem., 277, 804-815. 
Kousteni,S., BellidoJ.’ Plotkin,L.I, O'Brien,C.A., Bodenner,D丄.，Han,L., Han’K., 
DiGregorio,G.B., Katzenellenbogen,J.A.，Katzenellenbogen,B.S., Roberson,P.K.， 
Weinstein,R.S., Jilka，R.L. & Manolagas,S.C. (2001) Nongenotropic, 
sex-nonspecific signaling through the estrogen or androgen receptors: 
dissociation from transcriptional activity. Cell, 104, 719-730. 
Kuiper,G.G., Enmark，E., Pelto-Hmkko,M., Nilsson,S. & Gustafsson,J.A. (1996) Cloning 
of a novel receptor expressed in rat prostate and ovary. Proc.Natl.Acad.Sci.U.S.A, 
93, 5925-5930. 
Kushner, P.J., Agard, D.A, Green, G.L, Scanlan, T.S., Shiau, A.K., Uht, R.M. & Webb, 
P. (2000) Estrogen receptor pathways to AP-1. J of Steriod Biochem & Mol 
BioL, 74, 311-317. 
Kwong，Y.L. & Todd,D. (1997) Delicious poison: arsenic trioxide for the treatment of 
leukemia. Blood, 89, 3487-3488. 
Kyprianou,N., English,H.F., Davidson,N.E. & Isaacs,J.T. (1991) Programmed cell death 
during regression of the MCF-7 human breast cancer following estrogen ablation. 
Cancer Res., 51, 162-166. 
Labrecque,!., Allan,D.，Chambon,P., Iscove,N.N., Lohnes,D. & Hoang,T. (1998) 
Impaired granulocytic differentiation in vitro in hematopoietic cells lacking 
retinoic acid receptors alpha 1 and gamma. Blood, 92, 607-615. 
Lacroix,M., Querton,G., Hennebert,P., Larsimont,D. & Leclercq,G. (2001) Estrogen 
receptor analysis in primary breast tumors by ligand-binding assay, 
immunocytochemical assay, and northern blot: a comparison. Breast Cancer 
Res.Treat., 67, 263-271. 
Lanotte,M., Martin-Thouvenin,V., Najman,S., Balerini,P., Valensi,F. & Berger,R. (1991) 
NB4, a maturation inducible cell line with t(15;17) marker isolated from a human 
acute promyelocytic leukemia (M3). Blood, 77, 1080-1086. 
Page 212 
BEEEREI^CEJS  
Le Goff,P., Montano，M.M., Schodin,D.J. & Katzenellenbogen,B.S. (1994) 
Phosphorylation of the human estrogen receptor. Identification of 
hormone-regulated sites and examination of their influence on transcriptional 
activity. J.Biol.Chem., 269, 4458-4466. 
Le，X.F., Vallian,S., Mu,Z.M., Himg,M.C. & Chang,K.S. (1998) Recombinant P M L 
adenovirus suppresses growth and tumorigenicity of human breast cancer cells 
by inducing GI cell cycle arrest and apoptosis. Oncogene, 16, 1839-1849. 
Lehmann,S, Bengtzen,S., Paul,A., Christensson,B. & Paul,C. (2001) Effects of arsenic 
trioxide (As203) on leukemic cells from patients with non-M3 acute 
myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of 
resistance. Eur.J.Haematol., 66，357-364. 
Levenson，A.S. & Jordan,V.C. (1999) Selective oestrogen receptor modulation: 
molecular pharmacology for the millennium. EurJ.Cancer, 35, 1628-1639. 
Levine,A.J. (1997) p53, the cellular and gatekeeper for growth and division. Cell, 88, 
323-331. 
Lining,G., Hacohen,H., Nordenberg,J., Livnat,T., Rotter,V. & Sidi,Y. (2000) 
Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory 
agents: possible relation to high bcl-2/bax ratio? Cancer Lett., 161, 27-34. 
Lippman,M., Bolan,G. & Hiiff，K. (1976) The effects of estrogens and antiestrogens on 
hormone-responsive human breast cancer in long-term tissue culture. Cancer 
Res., 36, 4595-4601. 
Liu,G., Schwartz,J.A. & Brooks,S.C. (1999) p53 down-regulates ER-responsive genes 
by interfering with the binding of ER to ERE. Biochem.Biophys.Res.Commun., 
264, 359-364. 
Liu,X., Kim,C.N., Yang,J., Jemmerson,R. & Wang,X. (1996) Induction of apoptotic 
program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86, 
147-157. 
MacGregorJ.L & Jordan，V.C. (1998) Basic guide to the mechanisms of antiestrogen 
action. Pharmacol.Rev., 50, 151-196. 
Mahieux,R., Pise-Masison,C., Gessain,A., Brady,J.N., Olivier,R., Perret,E., Misteli,T. & 
Nicot,C. (2001) Arsenic trioxide induces apoptosis in human T-cell leukemia 
virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism 
involving Bcl-2 cleavage. Blood, 98, 3762-3769. 
Mahony,S.M. & Tisdale,M.J. (1989) Reversal of weight loss induced by tumour necrosis 
factor-alpha. Cancer Lett., 45, 167-172. 
Page 213 
M^KEKEiS.CE^.  
Makin, G. and Dive, C. (2001) Apoptosis and cancer chemotherapy. Trends in Cell Biol., 
11,S22-S26. 
Mandal，M. & Kumar,R. (1996) Bcl-2 expression regulates sodium butyrate-induced 
apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ., 7, 311-318. 
Mass,M.J. & Wang，L. (1997) Arsenic alters cytosine methylation patterns of the 
promoter of the tumor suppressor gene p53 in human lung cells: a model for a 
mechanism of carcinogenesis. Mutat Res., 386，263-77. 
Migliaccio,A.’ Di,D.M., Green,S., de Falco,A., Kajtaniak,E丄.，Blasi’F., Chambon,P. & 
Auricchio,R (1989) Phosphorylation on tyrosine of in vitro synthesized human 
estrogen receptor activates its hormone binding. Mol Endocrinol., 3, 1061-9. 
Mignotte,B. & Vayssiere,J.L. (1998) Mitochondria and apoptosis. Eur. J. Biochem., 252, 
1-15. 
Miyashita,T. & ReedJ.C. (1995) Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene. Cell, 80, 293-299. 
Miyashita,T” Krajewski,S., Kragewska,M., Wang,H.G., Lin,H.K., Liebermarm,D.A. 
Hoffman,B. & Reed,J.C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and 
bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805. 
MolinoloA.A., Lanari,C., Charreau,E.H., Sanjuan，N. & Pasqualini,C.D. (1987) Mouse 
mammary tumors induced by medroxyprogesterone acetate: 
immunohistochemistry and hormonal receptors. J.Natl.Cancer Inst, 79, 
1341-1350. 
Mu,Z.M., Chin,K.V., Liu,J.H., Lozano,G. & Chang，K.S. (1994) PML, a growth 
suppressor disrupted in acute promyelocytic leukemia. Mol.Cell Biol., 14, 
6858-6867. 
Muller,M., Wilder,S., Bannasch,D., Israeli,D., Lehlbach,K., Li-Weber,M., 
Friedman,SI., Galle,P.R., Stremmel,W., Oren,M. & Krammer,P.H. (1998) p53 
activates the CD95 (APO-l/Fas) gene in response to D N A damage by anticancer 
drugs. J.Exp.Med., 188, 2033-2045. 
Murgo, A.J. (2001) Clincial trails of arsenic trioxide in hematologic and solid tumors: 
Overview of the National Cancer Institute Cooperative Research and 
development studies. The Oncologist., 6 Suppl 2:22-28. 
MusgroveJE.A. & Sutherland,R丄.(1994) Cell cycle control by steroid hormones. Semin 
Cancer Biol., 5, 381-9. 
Nandi,S., Guzman,R.C. & Yang,J. (1995) Hormones and mammary carcinogenesis in 




Naqve S.M.，Vaishnave, C and Singh, H. (1994) Arsenic in human medicine. In: Arseinc 
in the Environment Part II: Human Health and Ecosystem Effects. Nriagu, J.O. 
John Wiley & Sons，Inc. pp55-92. 
Nicholson,D.W. (2000) From bench to clinic with apoptosis-based therapeutic agents. 
Nature, 407, 810-816. 
Oberhammer,F., Wilson,J.W., Dive,C., Morris,LD., Hickman,J.A., Wakeling,A.E., 
Walker,P.R. & Sikorska，M. (1993) Apoptotic death in epithelial cells: cleavage 
of D N A to 300 and/or 50 kb fragments prior to or in the absence of 
intemucleosomal fragmentation. E M B O J., 12, 3679-3684. 
Oberhammer,F., Wilson,J.W., Dive,C.’ Morris,LD., Hickman,J.A., Wakeling,A.E.， 
Walker,P.R. & Sikorska,M. (1993) Apoptotic death in epithelial cells: cleavage 
of D N A to 300 and/or 50 kb fragments prior to or in the absence of 
intemucleosomal fragmentation. E M B O J., 12, 3679-3684. 
01efsky,J.M. (2001) Nuclear receptor minireview series. J.Biol.Chem., 276’ 
36863-36864. 
Osborne,C.K. (1998) Tamoxifen in the treatment of breast cancer. N.EnglJ.Med., 339, 
1609-1618. 
Osborne,C.K., Hobbs，K. & Clark,G.M. (1985) Effect of estrogens and antiestrogens on 
growth of human breast cancer cells in athymic nude mice. Cancer Res., 45, 
584-590. 
Paige,L.A., Christensen,DJ., Gron，H., Norris,J.D., Gottlin,E.B., Padilla,K.M, 
Chang,CY., Ballas,L.M., Hamilton,P.T., McDonnell,D.P. & Fowlkes,D.M. 
(1999) Estrogen receptor (ER) modulators each induce distinct conformational 
changes in ER alpha and ER beta. Proc.Natl.Acad.Sci.U.S.A , 96, 3999-4004. 
Pandey,S., Walker,P.R. & Sikorska,M. (1994) Separate pools of endonuclease activity 
are responsible for intemucleosomal and high molecular mass D N A 
fragmentation during apoptosis. Biochem.Cell Biol” 72, 625-629. 
Park,J.W., Choi,Y.J., Jang,M.A., Baek,S.H., Lim,J.H., Passaniti,T. & Kwon,T.K. (2001) 
Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase- 3 
activation and bcl-2 phosphorylation in promonocytic U937 cells. 
Biochem.Biophys.Res.Commun., 286, 726-734. 
Parton,M., Dowsett,M. & Smith,1. (2001) Studies of apoptosis in breast cancer. BMJ., 
322, 1528-1532. 
Piazza,F., Gumeri,C. & Pandolfi,P.P. (2001) The theory of APL. Oncogene, 20, 
7216-7222. 
Page 215 
Piche,A.，Grim,J., Rancourt,C, Gomez-Navarro,J., ReedJ.C. & Curiel，D.T. (1998) 
Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain 
antibody increases drug-induced cytotoxicity in the breast cancer cell line 
MCF-7. Cancer Res, 58, 2134-2140. 
Pike,AC., Brzozowski,A.M., Walton,J., Hubbard,R.E., Thorsell,A.G.，Li，Y.L.， 
Gustafsson,J.A. & Carlquist，M. (2001) Structural insights into the mode of action 
of a pure antiestrogen. Stmcture.(Camb.), 9, 145-153. 
Polyak,K., Xia,Y.，Zweier,J.L., Kinzler,K.W. & Vogelstein,B. (1997) A model for 
p53-induced apoptosis. Nature, 389, 300-5. 
Prall，O.W., Sarcevic，B., Musgrove,E. A., Watts,C.K. & Sutherland，R.L. (1997) 
Estrogen-induced activation of Cdk4 and Cdk2 during Gl-S phase progression is 
accompanied by increased cyclin D1 expression and decreased cyclin-dependent 
kinase inhibitor association with cyclin E- Cdk2. J.Biol.Chem., 272, 
10882-10894. 
Purohit’A., Flanagan,A.M. & Reed,M.J. (1992) Estrogen synthesis by osteoblast cell 
lines. Endocrinology, 131, 2027-2029. 
Raelson,J.V.，Nervi,C., Rosenauer,A., Benedetti，L.， Monczak,Y., Pearson,M., 
Pelicci,P.G. & Miller,W.H., Jr. (1996) The PML/RAR alpha oncoprotein is a 
direct molecular target of retinoic acid in acute promyelocytic leukemia cells. 
Blood, 88, 2826-2832. 
Read,L.D, Greene,GI. & Katzenellenbogen,B.S. (1989) Regulation of estrogen 
receptor messenger ribonucleic acid and protein levels in human breast cancer 
cell lines by sex steroid hormones, their antagonists, and growth factors. Mol 
Endocrinol, 2, 295-304. 
Ree,a h., Landmark,B.F., Eskild,W., Levy,F.O., Lahooti,H., Jahnsen,T., Aakvaag,A. & 
Hansson,V. (1989) Autologous down-regulation of messenger ribonucleic acid 
and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to 
progesterone receptor levels. Endocrinology, 124, 2577-2583. 
Robinson,MJ. & Cobb,M.H. (1997) Mitogen-activated protein kinase pathways. 
Curr.Opin.Cell Biol, 9, 180-186. 
Rosenberg,M.J., Landrigan,P.J. & Crowley,S. (1980) Low-level arsenic exposure in 
wood processing plants. AmJ.Ind.Med., 1, 99-107. 
Roy,B., Beamon,J., Balint,E. & Reisman,D. (1994) Transactivation of the human p53 
tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 




& Martin，M.B. (1988) Regulation of the estrogen receptor in MCF-7 cells by 
estradiol. Mol.Endocrinol., 2, 1157-62. 
Saeki，T” Cristiano,A., Lynch,MJ., Brattain,M., Kim,N., Normanno,N., Kenney,N.， 
Ciardiello,F. & Salomon,D.S. (1991) Regulation by estrogen through the 
5'-flanking region of the transforming growth factor alpha gene. Mol.Endocrinol., 
5， 1955-1963. 
Santagati,S., Gianazza,E., AgratiJP.，Vegeto,E., Patrone,C.，Pollio,G. & Maggi,A. (1997) 
Oligonucletoides squelching reveals the mechanism of estrogen receptor 
autologous down-regulation. Mol.Endocrinol., 11, 938-949. 
Sathya,G., Li,W., Klinge,C.M” Anolik,J.H.，Hif’R. & Bambara,R.A. (1997) Effects of 
multiple estrogen responsive elements, their spacing and location on estrogen 
response of reporter genes. Mol.Endocrinol., 11, 1994-2003. 
Schedin,P.J.，Thackray,L.B., Malone,P., Fontaine,S。C., Friis,R.R. & Strange,R. (1996) 
Programmed cell death and mammary neoplasia. Cancer Treat.Res., 83, 3-22. 
Schuchard,M., Landers,J.P., Sandhu,N.P. & Spelsberg,T.C. (1993) Steroid hormone 
regulation of nuclear proto-oncogenes. Endocr.Rev., 14, 659-669. 
Selvakumaran,M., Lin,H.K., Miyashita,T” Wang,H.G., Krajewski，S., Reed,J.C., 
Hoffman,B. & Liebennann,D. (1994) Immediate early up-regulation of bax 
expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic 
pathways. Oncogene, 9, 1791-1798. 
Seol,J.G.，Park,W.H., Kim,E.S., Jung,C.W.，Hyun,J.M.，Kim,B.K. & Lee,Y.Y. (1999) 
Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line 
PCI-1. Biochem.Biophys.Res.Commun., 265, 400-404. 
Shafie,S.M. & Grantham,F.H. (1981) Role of hormones in the growth and regression of 
human breast cancer cells (MCF-7) transplanted into athymic nude mice. 
J.Natl.Cancer Inst, 67, 51-56. 
Shao，W., Fanelli,M., Ferrara,F.F., Riccioni,R., Rosenauer,A-, Davison,K., Lamph,W.W., 
Waxman,S., Pelicci,P.G., Lo,C.F, Avvisati,G., Testa,U., Peschle,C., 
Gambacorti-Passerini,C, Nervi，C. & Miller,W.H., Jr. (1998) Arsenic trioxide as 
an inducer of apoptosis and loss of PML/RAR alpha protein in acute 
promyelocytic leukemia cells. J.Natl.Cancer Inst., 90, 124-133. 
Shen,Z.X., Chen，G.Q., Ni,J.H., Li,X.S., Xiong,S.M., Qiu,Q.Y., Zhu,J., Tang,W., 
Siin,G.L.，Yang，K.Q., Chen,Y., Zhou,L., Fang,Z.W., Wang,Y.T., Ma,J., 
Zhang,P., Zhang,T.D., Chen,SJ., Chen,Z. & Wang,Z.Y. (1997) Use of arsenic 
trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): 11. 




Shimizu,S., Narita，M. & Tsujimoto，Y. (1999) Bcl-2 family proteins regulate the release 
ofapoptogenic cytochrome c by the mitochondrial channel VDAC. Nature, 399, 
483-487. 
Shiu,R.P., Watson,P.H. & Dubik,D. (1993) c-myc oncogene expression in 
estrogen-dependent and -independent breast cancer. Clin.Chem., 39, 353-355. 
Sm,K.P., Chan,J.Y. & Fung,K.P. (2002) Effect of arsenic trioxide on human 
hepatocellular carcinoma HepG2 cells: Inhibition of proliferation and induction 
of apoptosis. Life Sci., 71, 275-285. 
Soignet，S 丄” Frankel,S.R., Doner,D.’ Tallman,M.S., Kantarjian,H.， Calleja,E.， 
Stone,R.M.，Kalaycio,M” Scheinberg,D.A.，Steinherz，P.，Sievers,E.L., Coutre,S.， 
Dahlberg,S, Ellison,R. & Warrell,R.P., Jr. (2001) United States multicenter 
study of arsenic trioxide in relapsed acute promyelocytic leukemia. J.Clin.Oncol., 
19, 3852-3860. 
Soignet,S.L.，Maslak,P, Wang,Z.G, Jhanwar,S., Calleja,E., Dardashti,L.J., Corso,D” 
DeBlasioA., Gabrilove,J., Scheinberg,D.A, Pandolfi,P.P. & Warrell,R.P., Jr. 
(1998) Complete remission after treatment of acute promyelocytic leukemia with 
arsenic trioxide. N.EnglJ.Med., 339, 1341-1348. 
SokolovaJ.A., Cowan,K.H. & Schneider,E. (1995) Ca2+/Mg(2+)-dependent 
endonuclease activation is an early event in VP- 16-induced apoptosis of human 
breast cancer MCF7 cells in vitro. Biochim.Biophys.Acta, 1266, 135-142. 
SokolovaJA, Cowan,K.H. & Schneider，E. (1995) Ca^VMg^"" - dependent endonuclease 
activation is an early event in VP-16-induced apoptosis of human breast cancer 
MCF7 cells in vitro. Biochimica et Biophysica Acta, 1266, 135-142. 
Soule,H.D. & McGrath,C.M. (1980) Estrogen responsive proliferation of clonal human 
breast carcinoma cells in athymic mice. Cancer Lett., 10, 177-189. 
Sun, G., Porter, W . & Safe, S. (1998) Estrogen-induced retinoic acid receptor a 1 gene 
expression: role of estrogen receptor-Spl complex. Mol.Endocrinol., 12, 
882-890. 
Sutherland,EX., Reddel,R.R. & Green,M.D. (1983) Effects of oestrogens on cell 
proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of 
antioestrogens. EurJ.Cancer Clin.Oncol., 19, 307-318. 
Szewczyk,A. & Wojtczak,L. (2002) Mitochondria as a pharmacological target. 
PharmacoLRev., 54, 101-127. 
Teixeira,C., Reed,J.C. & Pratt,M.A. (1995) Estrogen promotes chemotherapeutic drug 
resistance by a mechanism involving Bcl-2 proto-oncogene expression in human 
breast cancer cells. Cancer Res., 55, 3902-3907. 
Page 218 
•RE-I^ EiREN.CE.S.  
Thompson,CB. (1995) Apoptosis in the pathogenesis and treatment of disease. Science, 
267, 1456-146 
Tsai，S. & Collins,S.J. (1993) A dominant negative retinoic acid receptor blocks 
neutrophil differentiation at the promyelocyte stage. Proc.Natl.Acad.Sci.U.S.A, 
90,7153-7157. 
Tzeng,D.Z. & Klinge,C.M. (1996) Phosphorylation of purified estradiol-liganded 
estrogen receptor by casein kinase II increases estrogen response element 
binding but does not alter ligand stability. Biochem.Biophys.Res.Commun., 223, 
554-560. 
Umans,R.S., Weichselbaum,R.R., Johnson,C.M. & Little,J.B. (1984) Effects of estradiol 
concentration on levels of nuclear estrogen receptors in MCF-7 breast tumor 
cells. J Steroid Biochem., 20, 605-609. 
Veis,D.J., Sorenson,C.M., Shutter,J.R. & Korsmeyer,S.J. (1993) Bcl-2-deficient mice 
demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and 
hypopigmented hair. Cell, 75, 229-240. 
Walker,P.R., Smith,C., Youdale,T., Leblanc,J, Whitfield,；.F. & Sikorska’M. (1991) 
Topoisomerase Il-reactive chemotherapeutic drugs induce apoptosis in 
thymocytes. Cancer Res., 51, 1078-1085. 
WangJ.T. & Phang,J.M. (1995) Effects of estrogen on apoptotic pathways in human 
breast cancer cell line MCF-7. Cancer Res, 55, 2487-2489. 
Wang,Z.Y. (2001) Arsenic compounds as anticancer agents. Cancer 
Chemothr.PharmacoL, 48 Supl 1, 72-76. 
WaiTell,R.P., Jr., de The,H., Wang,Z.Y. & Degos,L. (1993) Acute promyelocytic 
leukemia. N.Engl.J.Med., 329, 177-189. 
Warri,A.M., Huovinen,R.L., Laine,A.M., Martikainen,P.M. & Harkonen,P.L. (1993) 
Apoptosis in toremifene-induced growth inhibition of human breast cancer cells 
in vivo and in vitro. J.Natl.Cancer Inst., 85, 1412-1418. 
Watson,P.H., Pon,R.T. & Shiu,R.P. (1991) Inhibition of c-myc expression by 
phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in 
the growth of human breast cancer. Cancer Res., 51, 3996-4000. 
Watts,C.K., Sweeney,K.J., Warlters,A., Musgrove,E.A. & Sutherland,R丄.(1994) 
Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression 
in MCF-7 human breast cancer cells. Breast Cancer Res.Treat., 31, 95-105. 
Weis，K., Rambaud,S., Lavau，C.，JansenJ., CarvalhoJ., Carmo-Fonseca,M., Lamond,A. 
& Dejean,A. (1994) Retinoic acid regulates aberrant nuclear localization of 
PML-RAR alpha in acute promyelocytic leukemia cells. Cell, 76, 345-356. 
Page 219 
MFERMCEJS  
Welsch,C.W. (1985) Host factors affecting the growth of carcinogen-induced rat 
mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer 
Res., 45, 3415-3443. 
Willingham，M.C. (1999) Cytochemical methods for the detection of apoptosis. J 
Histochem.Cytochem. ,47,1101-10109. 
Wolf,B.B.，Schuler,M., Echeverri,F. & Green,D.R. (1999) Caspase-3 is the primary 
activator of apoptotic D N A fragmentation via D N A fragmentation 
factor-45/inhibitor of caspase-activated DNase inactivation. J.Biol.Chem., 274, 
30651-30656. 
Wu，X. & Deng,Y. (2002) Bax and BH3-domain-only proteins in p53-mediated apoptosis. 
Front.Biosci., 7, 151-6. 
Wyllie,A.H. (1980) Glucocorticoid-induced thymocyte apoptosis is associated with 
endogenous endonuclease activation. Nature, 284, 555-556. 
Yang,E. & Korsmeyer,S.J. (1996) Molecular thanatopsis: a discourse on the BCL2 
femily and cell death. Blood, 88, 386-401. 
Yang,X.H.，Sladek,T丄.，Liu,X., Butler,B.R., Froelich,CJ. & Thor,A.D. (2001) 
Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin-
and etoposide-induced apoptosis. Cancer Res., 61，348-354. 
Yoshida，H., Kitamura,K., Tanaka,K., Omura,S.，Miyazaki,T., Hachiya,T., Ohno,R. & 
Naoe,T. (1996) Accelerated degradation of PML-retinoic acid receptor alpha 
(PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic 
leukemia: possible role of the proteasome pathway. Cancer Res., 56, 2945-2948. 
YU,C.L., Driggers,P., Barrera-Hemandez,G., Nunez,S.B., Segars,J.H. & Cheng,S. (1997) 
The tumor suppressor p53 is a negative regulator of estrogen receptor signaling 
pathways. Biochem.Biophys.Res.Commun., 239, 617-620. 
Zhan,Q.，Alamo,I., Yu,K., Boise,L.H., Chemey,B., Tosato,G.，O'Connor,P.M. & 
Fomace,A.J., Jr. (1996) The apoptosis-associated gamma-ray response of 
BCL-X(L) depends on normal p53 function. Oncogene, 13, 2287-2293. 
Zhang,T.D., Chen,G.Q., Wang,Z.G., Wang,Z.Y., Chen,S.J. & Chen,Z. (2001) Arsenic 
trioxide, a therapeutic agent for APL. Oncogene, 20, 7146-7153. 
Zhang,Y. & Nie，L. (2001) Studies of apoptosis of malignant lymphoma cells induced by 
arsenic trioxide. Cell Biol.Int, 25, 1003-1006. 
Zhao，C.Q.’ Young,M.R.，Diwan,B.A., Coogan，T.P. & Waalkes,M.P. (1997) Association 
of arsenic-induced malignant transformation with D N A hypomethylation and 
aberrant gene expression. Proc.Natl.Acad.Sci.U.S.A , 94, 10907-10912. 
Page 220 
J^EIFEREJS.CE^   
Zhao，R.，Gish,K, Murphy,M., Yin,Y., Nottennan,D, Hoffman,W.H., Tom,E., Mack,D.H. 
& Levine,A.J. (2000) Analysis of p53-regulated gene expression patterns using 
oligonucleotide arrays. Genes Develop., 14，981-993. 
Zhu,J, Koken，M.H., Quignon,F., Chelbi-Alix,M.K., Degos,L, Wang,Z.Y, Chen,Z. & 
de The，H. (1997) Arsenic-induced P M L targeting onto nuclear bodies: 
implications for the treatment of acute promyelocytic leukemia. 
Proc.Natl.Acad.Sci.U.S.A, 94, 3978-3983. 
Zhu，X.H.，Shen，Y丄•，Jing，Y.K.，Cai,X.，Jia,P.M., Huang,Y., Tang,W., Shi,G.Y., 
Sun,Y.P., Day., Wang,Z.Y.，Chen,S.J.，Zhang,T.D., Waxman,S., Chen,Z. & 
Chen,G.Q. (1999) Apoptosis and growth inhibition in malignant lymphocytes 
after treatment with arsenic trioxide at clinically achievable concentrations. 







CUHK L i b r a r i e s 
_•國 lillll 
••3TSS7Sfl 
